0000899923-21-000063.txt : 20210804 0000899923-21-000063.hdr.sgml : 20210804 20210804160634 ACCESSION NUMBER: 0000899923-21-000063 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210804 DATE AS OF CHANGE: 20210804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYRIAD GENETICS INC CENTRAL INDEX KEY: 0000899923 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 870494517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26642 FILM NUMBER: 211144012 BUSINESS ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 BUSINESS PHONE: 801-584-3600 MAIL ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 10-Q 1 mygn-20210630.htm 10-Q mygn-20210630
false000089992312/312021Q200008999232021-01-012021-06-30xbrli:shares00008999232021-07-28iso4217:USD00008999232021-06-3000008999232020-12-310000899923mygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTestingMember2020-01-012020-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923mygn:PharmaceuticalAndClinicalServicesMember2020-01-012020-06-3000008999232021-04-012021-06-3000008999232020-04-012020-06-3000008999232020-01-012020-06-30iso4217:USDxbrli:shares0000899923us-gaap:CommonStockMember2019-12-310000899923us-gaap:AdditionalPaidInCapitalMember2019-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000899923us-gaap:RetainedEarningsMember2019-12-310000899923us-gaap:NoncontrollingInterestMember2019-12-3100008999232019-12-310000899923us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100008999232020-01-012020-03-310000899923us-gaap:NoncontrollingInterestMember2020-01-012020-03-310000899923us-gaap:RetainedEarningsMember2020-01-012020-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310000899923us-gaap:CommonStockMember2020-03-310000899923us-gaap:AdditionalPaidInCapitalMember2020-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310000899923us-gaap:RetainedEarningsMember2020-03-310000899923us-gaap:NoncontrollingInterestMember2020-03-3100008999232020-03-310000899923us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300000899923us-gaap:RetainedEarningsMember2020-04-012020-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300000899923us-gaap:CommonStockMember2020-06-300000899923us-gaap:AdditionalPaidInCapitalMember2020-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000899923us-gaap:RetainedEarningsMember2020-06-300000899923us-gaap:NoncontrollingInterestMember2020-06-3000008999232020-06-300000899923us-gaap:CommonStockMember2020-12-310000899923us-gaap:AdditionalPaidInCapitalMember2020-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000899923us-gaap:RetainedEarningsMember2020-12-310000899923us-gaap:NoncontrollingInterestMember2020-12-310000899923us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100008999232021-01-012021-03-310000899923us-gaap:RetainedEarningsMember2021-01-012021-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310000899923us-gaap:CommonStockMember2021-03-310000899923us-gaap:AdditionalPaidInCapitalMember2021-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000899923us-gaap:RetainedEarningsMember2021-03-310000899923us-gaap:NoncontrollingInterestMember2021-03-3100008999232021-03-310000899923us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000899923us-gaap:NoncontrollingInterestMember2021-04-012021-06-300000899923us-gaap:RetainedEarningsMember2021-04-012021-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000899923us-gaap:CommonStockMember2021-06-300000899923us-gaap:AdditionalPaidInCapitalMember2021-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000899923us-gaap:RetainedEarningsMember2021-06-300000899923us-gaap:NoncontrollingInterestMember2021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2020-04-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2020-04-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2021-04-012021-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2020-04-012020-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2020-04-012020-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923country:US2021-04-012021-06-300000899923us-gaap:NonUsMember2021-04-012021-06-300000899923country:US2020-04-012020-06-300000899923us-gaap:NonUsMember2020-04-012020-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticHereditaryCancerTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMemberus-gaap:NonUsMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticHereditaryCancerTestingMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticTumorProfilingMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticTumorProfilingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticTumorProfilingMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticPrenatalTestingMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticPrenatalTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticPrenatalTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMembercountry:US2020-01-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMemberus-gaap:NonUsMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticPharmacogenomicsMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticAutoimmuneMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:MolecularDiagnosticAutoimmuneMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticAutoimmuneMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticOtherTestingMembercountry:US2020-01-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMemberus-gaap:NonUsMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticOtherTestingMember2020-01-012020-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2021-01-012021-06-300000899923country:USmygn:MolecularDiagnosticTestingMember2020-01-012020-06-300000899923mygn:MolecularDiagnosticTestingMemberus-gaap:NonUsMember2020-01-012020-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923country:USmygn:PharmaceuticalAndClinicalServicesMember2020-01-012020-06-300000899923us-gaap:NonUsMembermygn:PharmaceuticalAndClinicalServicesMember2020-01-012020-06-300000899923country:US2021-01-012021-06-300000899923us-gaap:NonUsMember2021-01-012021-06-300000899923country:US2020-01-012020-06-300000899923us-gaap:NonUsMember2020-01-012020-06-3000008999232019-07-012020-06-300000899923mygn:PerformanceObligationEstimatedTransactionPriceMember2021-01-012021-06-300000899923mygn:PerformanceObligationEstimatedTransactionPriceMember2021-04-012021-06-30xbrli:pure0000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-04-012021-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-04-012020-06-300000899923mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300000899923mygn:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-06-300000899923us-gaap:CashMember2021-06-300000899923us-gaap:CashEquivalentsMember2021-06-300000899923us-gaap:CorporateDebtSecuritiesMember2021-06-300000899923us-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:USTreasuryAndGovernmentMember2021-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000899923us-gaap:CashMember2020-12-310000899923us-gaap:CashEquivalentsMember2020-12-310000899923us-gaap:CorporateDebtSecuritiesMember2020-12-310000899923us-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:USTreasuryAndGovernmentMember2020-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-31mygn:security0000899923us-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueInputsLevel3Member2021-01-012021-06-300000899923us-gaap:FairValueInputsLevel3Member2021-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2021-06-300000899923us-gaap:MoneyMarketFundsMember2021-06-300000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2021-06-300000899923us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2021-06-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMember2021-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2021-06-300000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2021-06-300000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000899923us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-06-300000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Membermygn:ContingentConsiderationMember2021-06-300000899923us-gaap:FairValueInputsLevel3Membermygn:ContingentConsiderationMember2021-06-300000899923mygn:ContingentConsiderationMember2021-06-300000899923us-gaap:FairValueInputsLevel1Member2021-06-300000899923us-gaap:FairValueInputsLevel2Member2021-06-300000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310000899923us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2020-12-310000899923us-gaap:MoneyMarketFundsMember2020-12-310000899923us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2020-12-310000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMember2020-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2020-12-310000899923us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel3Member2020-12-310000899923us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-12-310000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Membermygn:ContingentConsiderationMember2020-12-310000899923us-gaap:FairValueInputsLevel3Membermygn:ContingentConsiderationMember2020-12-310000899923mygn:ContingentConsiderationMember2020-12-310000899923us-gaap:FairValueInputsLevel1Member2020-12-310000899923us-gaap:FairValueInputsLevel2Member2020-12-310000899923us-gaap:FairValueInputsLevel3Member2020-12-310000899923mygn:MyriadAutoimmuneAssetsAndMyriadRBMIncMember2021-04-012021-06-300000899923us-gaap:LeaseholdImprovementsMember2021-06-300000899923us-gaap:LeaseholdImprovementsMember2020-12-310000899923us-gaap:EquipmentMember2021-06-300000899923us-gaap:EquipmentMember2020-12-310000899923mygn:DiagnosticsMember2020-12-310000899923us-gaap:AllOtherSegmentsMember2020-12-310000899923mygn:DiagnosticsMember2021-01-012021-06-300000899923us-gaap:AllOtherSegmentsMember2021-01-012021-06-300000899923mygn:DiagnosticsMember2021-06-300000899923us-gaap:AllOtherSegmentsMember2021-06-300000899923mygn:PurchasedLicensesAndTechnologiesMember2021-06-300000899923us-gaap:CustomerRelationshipsMember2021-06-300000899923us-gaap:TrademarksMember2021-06-300000899923mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember2021-06-300000899923mygn:PurchasedLicensesAndTechnologiesMember2020-12-310000899923us-gaap:CustomerRelationshipsMember2020-12-310000899923us-gaap:TrademarksMember2020-12-310000899923mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember2020-12-310000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2018-07-312018-07-310000899923us-gaap:RevolvingCreditFacilityMember2016-12-230000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2018-07-310000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2020-12-310000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2021-02-210000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMember2021-09-300000899923us-gaap:RevolvingCreditFacilityMembermygn:AmendmentToCreditAgreementMember2021-06-300000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2020-04-012022-06-300000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMember2020-04-012022-06-300000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembersrt:MinimumMembermygn:AmendmentToCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-07-012022-07-010000899923srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-07-012022-07-010000899923us-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembersrt:MinimumMembermygn:AmendmentToCreditAgreementMember2022-07-012022-07-010000899923srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembersrt:ScenarioForecastMembermygn:AmendmentToCreditAgreementMember2022-07-012022-07-010000899923us-gaap:RevolvingCreditFacilityMember2021-01-012021-06-300000899923us-gaap:RevolvingCreditFacilityMember2020-07-012020-12-310000899923mygn:EighthShareRepurchaseProgramMember2016-06-300000899923mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember2021-06-300000899923us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300000899923mygn:NonEmployeeDirectorMembermygn:OptionsAndRestrictedStockUnitsMember2021-01-012021-06-300000899923us-gaap:EmployeeStockOptionMember2021-01-012021-06-300000899923mygn:OptionsGrantedAfterDecemberFiveTwentyTwelveMemberus-gaap:EmployeeStockOptionMember2021-01-012021-06-300000899923us-gaap:EmployeeStockOptionMembermygn:OptionsGrantedPriorToDecemberFiveTwentyTwelveMember2021-01-012021-06-300000899923us-gaap:RestrictedStockUnitsRSUMember2020-12-310000899923us-gaap:RestrictedStockUnitsRSUMember2021-06-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2021-04-012021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2020-04-012020-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2021-01-012021-06-300000899923mygn:CostOfMolecularDiagnosticTestingMember2020-01-012020-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2021-04-012021-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2020-04-012020-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2021-01-012021-06-300000899923mygn:CostOfPharmaceuticalAndClinicalServicesMember2020-01-012020-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2020-04-012020-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-04-012021-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-04-012020-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-06-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300000899923us-gaap:EarliestTaxYearMemberus-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2021-01-012021-06-300000899923us-gaap:LatestTaxYearMemberus-gaap:StateAndLocalJurisdictionMemberus-gaap:CaliforniaFranchiseTaxBoardMember2021-01-012021-06-300000899923us-gaap:EarliestTaxYearMemberus-gaap:NewJerseyDivisionOfTaxationMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:LatestTaxYearMemberus-gaap:NewJerseyDivisionOfTaxationMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:EarliestTaxYearMemberus-gaap:NewYorkStateDivisionOfTaxationAndFinanceMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:LatestTaxYearMemberus-gaap:NewYorkStateDivisionOfTaxationAndFinanceMemberus-gaap:StateAndLocalJurisdictionMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMemberus-gaap:EarliestTaxYearMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:FederalMinistryOfFinanceGermanyMemberus-gaap:LatestTaxYearMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:EarliestTaxYearMemberus-gaap:SwissFederalTaxAdministrationFTAMember2021-01-012021-06-300000899923us-gaap:ForeignCountryMemberus-gaap:LatestTaxYearMemberus-gaap:SwissFederalTaxAdministrationFTAMember2021-01-012021-06-30mygn:segment0000899923mygn:DiagnosticsMember2021-04-012021-06-300000899923us-gaap:AllOtherSegmentsMember2021-04-012021-06-300000899923mygn:DiagnosticsMember2020-04-012020-06-300000899923us-gaap:AllOtherSegmentsMember2020-04-012020-06-300000899923mygn:DiagnosticsMember2020-01-012020-06-300000899923us-gaap:AllOtherSegmentsMember2020-01-012020-06-300000899923mygn:MyriadMyPathLLCLaboratoryMember2021-05-282021-05-280000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermygn:MyriadAutoimmuneAssetsMember2021-05-010000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermygn:MyriadRBMIncMember2021-05-210000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-04-012021-06-300000899923us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-06-300000899923us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMembermygn:MyriadRBMIncMemberus-gaap:SubsequentEventMember2021-07-010000899923us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMember2021-07-010000899923us-gaap:SubsequentEventMember2021-07-312021-07-310000899923us-gaap:RevolvingCreditFacilityMemberus-gaap:SubsequentEventMembermygn:AmendmentToCreditAgreementMember2021-08-04

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________
FORM 10-Q
_________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to           
Commission file number:  0-26642
_________________________________________
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
_________________________________________
Delaware
(State or other jurisdiction
of incorporation or organization)
320 Wakara Way, Salt Lake City, UT
(Address of principal executive offices)
87-0494517
(I.R.S. Employer Identification No.)

84108
(Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
_________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par valueMYGNNasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerxAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  x
As of July 28, 2021, the registrant had 78,055,365 shares of $0.01 par value common stock outstanding.




MYRIAD GENETICS, INC.
INDEX TO FORM 10-Q
Page

3



MYRIAD GENETICS, INC.
Condensed Consolidated Balance Sheets
(in millions)
June 30,
2021
December 31,
2020
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents$118.4 $117.0 
Marketable investment securities46.0 33.7 
Trade accounts receivable94.8 89.5 
Inventory17.7 27.1 
Assets held for sale225.7  
Prepaid taxes18.6 108.4 
Prepaid expenses and other current assets17.7 13.7 
Total current assets538.9 389.4 
Operating lease right-of-use assets86.6 59.7 
Long-term marketable investment securities19.9 21.0 
Property, plant, and equipment, net43.2 40.7 
Intangibles, net426.8 576.5 
Goodwill240.1 329.2 
Other assets4.8 2.3 
Total assets$1,360.3 $1,418.8 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$28.5 $20.5 
Accrued liabilities90.9 79.1 
Current maturities of operating lease liabilities12.7 13.6 
Deferred revenues22.6 32.7 
Liabilities held for sale12.2  
Current portion of long-term debt104.1  
Total current liabilities271.0 145.9 
Unrecognized tax benefits31.0 30.5 
Long-term deferred taxes58.2 71.3 
Noncurrent operating lease liabilities83.9 50.6 
Long-term debt 224.8 
Other long-term liabilities13.8 14.7 
Total liabilities457.9 537.8 
Commitments and contingencies
Stockholders’ equity:
Common stock, 77.7 million and 75.4 million shares outstanding at June 30,
2021 and December 31, 2020, respectively
0.8 0.8 
Additional paid-in capital1,176.9 1,109.5 
Accumulated other comprehensive loss(4.0)(2.3)
Accumulated deficit(271.2)(227.0)
Total Myriad Genetics, Inc. stockholders’ equity902.5 881.0 
Non-controlling interest(0.1) 
Total stockholders' equity902.4 881.0 
Total liabilities and stockholders’ equity$1,360.3 $1,418.8 
See accompanying notes to Condensed Consolidated Financial Statements.
4

MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Operations (unaudited)
(in millions, except per share amounts)
Three months ended
June 30,
Six months ended
June 30,
2021202020212020
Revenues:
Molecular diagnostic testing$178.7 $83.3 $338.3 $233.8 
Pharmaceutical and clinical services10.7 9.9 24.2 23.4 
Total revenue189.4 93.2 362.5 257.2 
Costs and expenses:
Cost of molecular diagnostic testing48.0 32.2 92.1 75.3 
Cost of pharmaceutical and clinical services5.7 4.5 11.9 11.5 
Research and development expense19.5 17.4 42.6 37.1 
Selling, general, and administrative expense134.8 107.4 280.3 240.3 
Change in the fair value of contingent consideration0.4  1.3 (3.4)
Goodwill and long-lived asset impairment charges1.8  1.8 98.4 
Total costs and expenses210.2 161.5 430.0 459.2 
Operating loss(20.8)(68.3)(67.5)(202.0)
Other income (expense):
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Total other income, net17.0 9.8 14.1 12.4 
Loss before income tax(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest (0.1) (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)
Net loss per share:
Basic and diluted$(0.06)$(0.74)$(0.58)$(2.29)
Weighted average shares outstanding:
Basic and diluted77.2 74.6 76.6 74.6 
See accompanying notes to Condensed Consolidated Financial Statements.
5

MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Comprehensive Loss (unaudited)
(in millions)
Three months ended
June 30,
Six months ended
June 30,
2021202020212020
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)
Unrealized loss on available-for-sale debt securities, net of tax(0.1)0.8 (0.3)0.7 
Change in foreign currency translation adjustment, net of tax(0.3)1.8 (1.4)(0.7)
Comprehensive loss(5.1)(52.8)(45.9)(170.6)
Comprehensive loss attributable to non-controlling interest    
Comprehensive loss attributable to Myriad Genetics, Inc. stockholders$(5.1)$(52.8)$(45.9)$(170.6)
See accompanying notes to Condensed Consolidated Financial Statements.
6

MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Stockholders’ Equity
(in millions)
Common
stock
Additional
paid-in
capital
Accumulated
other
comprehensive
loss
Accumulated
deficit
Non-controlling interestTotal
stockholders’
equity
BALANCES AT DECEMBER 31, 2019$0.7 $1,085.1 $(5.3)$(3.3)$0.1 $1,077.3 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 0.2 — — — 0.2 
Stock-based payment expense— 7.5 — — — 7.5 
Non-controlling interest— — — — (0.1)(0.1)
Net loss— — — (115.2)— (115.2)
Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary— — 0.1 — — 0.1 
Other comprehensive loss, net of tax— — (2.6)— — (2.6)
BALANCES AT MARCH 31, 2020$0.7 $1,092.8 $(7.8)$(118.5)$ $967.2 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 1.9 — — — 1.9 
Stock-based payment expense— 1.9 — — — 1.9 
Net loss— — — (55.4)— (55.4)
Other comprehensive income, net of tax— — 2.6 — — 2.6 
BALANCES AT JUNE 30, 2020$0.7 $1,096.6 $(5.2)$(173.9)$ $918.2 
BALANCES AT DECEMBER 31, 2020$0.8 $1,109.5 $(2.3)$(227.0)$ $881.0 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 26.0 — — — 26.0 
Stock-based payment expense— 9.0 — — — 9.0 
Net loss— — — (39.5)— (39.5)
Other comprehensive loss, net of tax— — (1.3)— — (1.3)
BALANCES AT MARCH 31, 2021$0.8 $1,144.5 $(3.6)$(266.5)$ $875.2 
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax— 23.5 — — — 23.5 
Stock-based payment expense— 8.9 — — — 8.9 
Non-controlling interest— — — — (0.1)(0.1)
Net loss— — — (4.7)— (4.7)
Other comprehensive loss, net of tax— — (0.4)— — (0.4)
BALANCES AT JUNE 30, 2021$0.8 $1,176.9 $(4.0)$(271.2)$(0.1)$902.4 
See accompanying notes to Condensed Consolidated Financial Statements.
7

MYRIAD GENETICS, INC.
Condensed Consolidated Statements of Cash Flows (unaudited)
(in millions)
Six months ended
June 30,
20212020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to Myriad Genetics, Inc. stockholders$(44.2)$(170.6)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization35.3 35.6 
Non-cash interest expense0.8 0.3 
Non-cash lease expense6.8 6.3 
Stock-based compensation expense17.9 9.4 
Deferred income taxes(11.5)(49.0)
Unrecognized tax benefits0.4 1.0 
Change in fair value of contingent consideration1.3 (3.4)
Loss on inventory6.6  
Impairment of goodwill and long-lived assets1.8 98.4 
Gain on deconsolidation of subsidiary (1.0)
Gain on sale of assets(32.4) 
Changes in assets and liabilities:
Prepaid expenses(4.7)2.4 
Trade accounts receivable(12.3)50.3 
Other receivables0.3 0.9 
Inventory(0.8)(0.9)
Prepaid taxes89.8 24.7 
Other assets(2.7) 
Accounts payable8.1 0.6 
Accrued liabilities16.1 12.7 
Deferred revenue(9.2)29.1 
Net cash provided by operating activities67.4 46.8 
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures(11.6)(5.3)
Proceeds from sale of subsidiary 21.3 
Proceeds from sale of assets32.5  
Purchases of marketable investment securities(36.6)(15.8)
Proceeds from maturities and sales of marketable investment securities25.0 33.4 
Net cash provided by investing activities9.3 33.6 
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans50.1 2.2 
Payment of tax withheld for common stock issued under stock-based compensation plans(0.6)(0.1)
Payment of contingent consideration recognized at acquisition(3.3) 
Fees associated with refinancing of revolving credit facility(1.2)(1.0)
Repayment of revolving credit facility(120.0) 
Net cash provided by (used in) financing activities(75.0)1.1 
Effect of foreign exchange rates on cash and cash equivalents(0.3)(0.5)
Change in cash and cash equivalents classified as held for sale 1.5 
Net increase in cash and cash equivalents1.4 82.5 
Cash and cash equivalents at beginning of the period117.0 81.2 
Cash and cash equivalents at end of the period$118.4 $163.7 
See accompanying notes to Condensed Consolidated Financial Statements.
8

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1.BASIS OF PRESENTATION
Myriad Genetics, Inc. and subsidiaries (collectively, the “Company” or “Myriad”) discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empowering every individual by revealing the answers inside each of us. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah.
The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period ended December 31, 2020 (the “Transition Report on Form 10-K”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30. Additionally, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible.
Due to the COVID-19 global pandemic (“COVID-19”), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company’s year over year results may not be comparable. Management continues to monitor the impacts of COVID-19, including variants of COVID-19, on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. The Company is not able to estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.
Held for Sale Policy
Net assets held for sale represent property, plant, and equipment, intangibles, and other assets and liabilities that have met the criteria of "held for sale" accounting, as specified by ASC 360, Property, Plant, and Equipment, and are recorded at the lower of carrying value or fair value less costs to sell. Fair value is based on the estimated proceeds from the sale of the net assets utilizing recent purchase agreements and costs to sell include direct costs that are estimable and probable. The Company expects to complete the sale of these net assets within twelve months following their initial classification as held for sale. See Note 16 for additional information regarding assets and liabilities held for sale.
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.

Recent Accounting Pronouncements
Recently Adopted Standards
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted with no material impact to the Company's Condensed Consolidated Financial Statements.
9

2.REVENUE
Myriad generates revenue by performing molecular diagnostic testing and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Autoimmune (Vectra), and Other. The Company previously provided clinical services until selling Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 as described in Note 16, Myriad myPath revenue was included in Other within molecular diagnostic revenues. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.
The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):
Three months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$73.8 $12.2 $86.0 $34.9 $5.0 $39.9 
Tumor Profiling18.1 11.1 29.2 8.6 1.9 10.5 
Prenatal29.2 0.2 29.4 16.5 0.1 16.6 
Pharmacogenomics22.6  22.6 8.5  8.5 
Autoimmune10.2  10.2 7.3  7.3 
Other0.2 1.1 1.3 0.5  0.5 
Total molecular diagnostic revenue154.1 24.6 178.7 76.3 7.0 83.3 
Pharmaceutical and clinical service revenue10.7  10.7 9.9  9.9 
Total revenue$164.8 $24.6 $189.4 $86.2 $7.0 $93.2 
Six months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$138.9 $23.2 $162.1 $116.2 $8.9 $125.1 
Tumor Profiling42.3 17.9 60.2 19.3 4.9 24.2 
Prenatal52.8 0.3 53.1 36.7 0.2 36.9 
Pharmacogenomics40.2  40.2 28.9  28.9 
Autoimmune20.9  20.9 17.7  17.7 
Other0.2 1.6 1.8 1.0  1.0 
Total molecular diagnostic revenue295.3 43.0 338.3 219.8 14.0 233.8 
Pharmaceutical and clinical service revenue24.2  24.2 19.5 3.9 23.4 
Total revenue$319.5 $43.0 $362.5 $239.3 $17.9 $257.2 
The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
10

Six months ended
June 30,
(in millions)20212020
Deferred revenue - beginning balance$32.7 $3.6 
Revenue recognized(15.5)(6.1)
Prepayments6.3 35.3 
Held for sale reclassification(0.9) 
Deferred revenue - ending balance$22.6 $32.8 
In accordance with ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical services that may have terms longer than one year and include multiple performance obligations. As of June 30, 2021, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $6.7 million. 

11

In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices.

The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and six months ended June 30, 2021, the Company recognized $13.3 million and $13.2 million in revenue, respectively, which resulted in a $0.13 impact to earnings per share to each period for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $6.8 million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period.
The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 16% and 18% of total revenue for the three and six months ended June 30, 2021, respectively, and 12% and 15% of total revenue for the three and six months ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. Medicare accounted for 11% of accounts receivable at June 30, 2021. No payor accounted for more than 10% of accounts receivable at December 31, 2020. The Company does not require collateral from its customers.

12

3.MARKETABLE INVESTMENT SECURITIES
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
June 30, 2021
Cash and cash equivalents:
Cash$60.4 $— $— $60.4 
Cash equivalents58.0 — — 58.0 
Total cash and cash equivalents118.4 — — 118.4 
Available-for-sale:
Corporate bonds and notes46.1 0.3  46.4 
Municipal bonds13.2 0.1  13.3 
Federal agency issues2.5   2.5 
US government securities3.7   3.7 
Total$183.9 $0.4 $ $184.3 
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
December 31, 2020:
Cash and cash equivalents:
Cash$47.9 $— $— $47.9 
Cash equivalents69.1 — — 69.1 
Total cash and cash equivalents117.0 — — 117.0 
Available-for-sale:
Corporate bonds and notes28.8 0.5  29.3 
Municipal bonds9.4 0.2  9.6 
Federal agency issues4.0   4.0 
US government securities11.7 0.1  11.8 
Total$170.9 $0.8 $ $171.7 

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2021:
(in millions)Amortized
cost
Estimated
fair value
Cash$60.4 $60.4 
Cash equivalents58.0 58.0 
Available-for-sale:
Due within one year45.8 46.0 
Due after one year through five years19.7 19.9 
Due after five years  
Total$183.9 $184.3 

There were no debt securities classified as available-for-sale in a gross unrealized loss position as of June 30, 2021 or December 31, 2020.

Additional information relating to fair value of marketable investment securities can be found in Note 4.


13

4.FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
Level 3—unobservable inputs.
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 14.0 years, utilizing various potential pay-out scenarios.  Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.  Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.
The fair value of the Company’s long-term debt, which it considers a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements.  The fair value of the Company's long-term debt is estimated to be $106.0 million at June 30, 2021. As of June 30, 2021, the Company intended to pay off the remaining balance of debt during the quarter ended September 30, 2021. As such, long-term debt was reclassified to Current portion of long-term debt in the Company's Condensed Consolidated Balance Sheets as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility (as defined in Note 8) on July 30, 2021, which is described in Note 17.
The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions)Level 1Level 2Level 3Total
June 30, 2021
Money market funds (a)$58.0 $ $ $58.0 
Corporate bonds and notes 46.4  46.4 
Municipal bonds 13.3  13.3 
Federal agency issues 2.5  2.5 
US government securities 3.7  3.7 
Contingent consideration  (8.5)(8.5)
Total$58.0 $65.9 $(8.5)$115.4 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

14

(in millions)Level 1Level 2Level 3Total
December 31, 2020
Money market funds (a)$69.1 $ $ $69.1 
Corporate bonds and notes 29.3  29.3 
Municipal bonds 9.6  9.6 
Federal agency issues 4.0  4.0 
US government securities 11.8  11.8 
Contingent consideration  (10.9)(10.9)
Total$69.1 $54.7 $(10.9)$112.9 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

Nonrecurring Fair Value Measurements
In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company's assets and liabilities are also subject to nonrecurring fair value measurements.

As a result of the approval of the Company's Board of Directors to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit during the quarter ended June 30, 2021, the Company performed an interim impairment analysis for the assets held for sale. The Company did not recognize any impairment charges on the asset groups classified as held for sale. The fair value used in the analysis, which the Company considers a Level 2 measurement, was based on the sale prices of Myriad RBM, Inc. and the Myriad Autoimmune assets.

The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions)Carrying
Amount
Balance December 31, 2020$10.9 
Payment of contingent consideration(3.3)
Change in fair value recognized in the income statement1.3 
Translation adjustments recognized in other comprehensive loss(0.4)
Ending balance June 30, 2021$8.5 

5.PROPERTY, PLANT AND EQUIPMENT, NET
(in millions)June 30,
2021
December 31,
2020
Leasehold improvements$36.5 $35.7 
Equipment109.6 117.9 
Property, plant and equipment, gross146.1 153.6 
Less accumulated depreciation(102.9)(112.9)
Property, plant and equipment, net$43.2 $40.7 

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Depreciation expense$3.4 $2.5 $6.3 $5.1 


15

6.GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the six months ended June 30, 2021:
(in millions)DiagnosticOtherTotal
Beginning balance$272.3 $56.9 $329.2 
Goodwill held for sale reclassification(31.6)(56.9)(88.5)
Translation adjustments(0.6) (0.6)
Ending balance$240.1 $ $240.1 

In connection with the Company's entry into definitive agreements to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit, the Company classified a portion of goodwill as assets held for sale. See Note 16 for further discussion.

Intangible Assets
Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At June 30, 2021:
Purchased licenses and technologies$817.1 $(276.6)$540.5 
Customer relationships4.7 (4.7) 
Trademarks3.0 (1.6)1.4 
Total amortized intangible assets824.8 (282.9)541.9 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Less: intangible assets held for sale$(211.5)$91.6 $(119.9)
Total intangible assets$618.1 $(191.3)$426.8 
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At December 31, 2020:
Purchased licenses and technologies$818.2 $(248.2)$570.0 
Customer relationships4.7 (4.5)0.2 
Trademarks3.0 (1.5)1.5 
Total amortized intangible assets825.9 (254.2)571.7 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Total intangible assets$830.7 $(254.2)$576.5 

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Amortization of intangible assets$13.5 $15.2 $29.0 $30.5 
16

7.ACCRUED LIABILITIES
(in millions)June 30,
2021
December 31,
2020
Employee compensation and benefits$50.7 $48.9 
Accrued taxes payable3.7 4.3 
Recoupments payable and reserves8.1 9.3 
Short-term contingent consideration 3.4 
Accrued royalties5.0 3.8 
Purchase commitment5.9  
Other accrued liabilities17.5 9.4 
Total accrued liabilities$90.9 $79.1 

8.LONG-TERM DEBT
On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) by and among Myriad, as borrower, and the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 which effected an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million. On May 1, 2020, the Company entered into Amendment No. 2, which waived the Company’s compliance with certain financial covenants, amended compliance with certain operating covenants, and modified the interest rate and other terms during a modification period from March 31, 2020 through June 30, 2021 (the “Modification Period”). On February 22, 2021, the Company entered into Amendment No. 3 (the “Amended Facility”), which, among other things, decreased the maximum aggregate principal commitment from $350.0 million to $300.0 million, with a further reduction in the maximum aggregate principal commitment from $300.0 million to $250.0 million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company’s compliance with certain financial covenants through the quarter ending March 31, 2022, extended the Modification Period for an additional year, through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. There are no scheduled principal payments of the Amended Facility prior to its maturity date.
The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balance and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. The interest rate as of June 30, 2021 was 4.5%.
Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. A minimum liquidity covenant was added for the period beginning May 1, 2020 until March 31, 2021, and a minimum EBITDA covenant was added for the quarters ended December 31, 2020 and March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ending March 31, 2022 and also lowered the minimum liquidity covenant applicable through such quarter. Amendment No. 3 also removed the minimum EBITDA covenant and restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0 million, unless such borrowings are in connection with acquisitions. The Company was in compliance with all applicable financial covenants at June 30, 2021.
During the six months ended June 30, 2021, the Company made principal repayments totaling $120.0 million on the Amended Facility. During the transition period ended December 31, 2020, the Company did not make any principal repayments.
17

The Amended Facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries and each such domestic subsidiary of Myriad has guaranteed the repayment of the Amended Facility. As of June 30, 2021, the Company intended to use the proceeds from the sale of Myriad RBM, Inc. to make a voluntary repayment in full on the Amended Facility during the quarter ended September 30, 2021. As a result, the Company classified the entire outstanding balance as current in its Condensed Consolidated Financial Statements as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility on July 30, 2021, which is described in Note 17. Also, see Note 17 for information on the sale of Myriad RBM, Inc. Amounts outstanding under the Amended Facility were as follows:
(in millions)June 30,
2021
December 31,
2020
Long-term debt$ $226.7 
Long-term debt discount (1.9)
Long-term debt, net 224.8 
Current portion of long-term debt106.4  
Current portion of long-term debt discount(2.3) 
Debt, net$104.1 $224.8 

9.OTHER LONG-TERM LIABILITIES
(in millions)June 30,
2021
December 31,
2020
Contingent consideration$8.5 $7.4 
Other5.3 7.3 
Total other long-term liabilities$13.8 $14.7 

The Company's balance of other long-term liabilities as of June 30, 2021 and December 31, 2020 consists of the Company’s portion of social security taxes that have been deferred under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) that do not have to be remitted until December 2022.
10.PREFERRED AND COMMON STOCKHOLDERS' EQUITY
The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at June 30, 2021.
The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 77.7 million shares issued and outstanding at June 30, 2021.
Common shares issued and outstanding
Six months ended
June 30,
(in millions)20212020
Beginning common stock issued and outstanding75.4 74.5 
Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan2.3 0.2 
Common stock issued and outstanding at end of period77.7 74.7 
Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.  Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.  In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.
18

The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Denominator:
Weighted-average shares outstanding used to compute basic EPS77.2 74.6 76.6 74.6 
Effect of dilutive shares    
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS77.2 74.6 76.6 74.6 
Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
June 30,
(in millions)20212020
Anti-dilutive options and RSUs excluded from EPS computation7.0 7.1 
Stock Repurchase Program
In June 2016, the Company’s Board of Directors authorized a share repurchase program of $200.0 million of the Company’s outstanding common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.  As of June 30, 2021, the Company is authorized to repurchase up to $110.7 million of shares under this authorization. No shares were repurchased during the six months ended June 30, 2021 or 2020.
11.STOCK-BASED COMPENSATION
On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of June 30, 2021, the Company has 3.6 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan.
The number of shares, terms, and vesting periods are generally determined by the Company’s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to non-employee directors vest in full upon completion of one year of service on the anniversary following the date of the grant. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant.


19

Stock Options
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20205.2 $23.24 
Options granted $ 
Less:
Options exercised(2.1)$22.93 
Options canceled or expired(0.1)$24.81 
Options outstanding at June 30, 20213.0 $23.42 
Options exercisable at June 30, 20212.4 $26.25 
As of June 30, 2021, there was $3.4 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 2.1 years.
Restricted Stock Units
A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20203.2 $20.56 
RSUs granted1.5 $29.89 
Less:
RSUs vested(0.1)$18.88 
RSUs canceled(0.6)$24.54 
RSUs outstanding at June 30, 20214.0 $23.72 
As of June 30, 2021, there was $74.5 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.5 years. 
Employee Stock Purchase Plan
The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the “2012 Purchase Plan”), under which 2.0 million shares of common stock have been authorized.  Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.  As of June 30, 2021, approximately 0.1 million shares of common stock are available for issuance under the 2012 Purchase Plan.
Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Cost of molecular diagnostic testing$0.4 $0.3 $0.7 $0.7 
Cost of pharmaceutical and clinical services 0.1 0.1 0.2 
Research and development expense1.0 1.2 2.5 2.3 
Selling, general, and administrative expense7.5 0.3 14.6 6.2 
     Total stock-based compensation expense$8.9 $1.9 $17.9 $9.4 
20

12.INCOME TAXES
In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.
Income tax expense for the three months ended June 30, 2021 was $0.9 million, or approximately (23.7)% of pre-tax loss compared to an income tax benefit of $3.0 million, or approximately 5.1% of pre-tax loss, for the three months ended June 30, 2020.  Income tax expense for the three months ended June 30, 2021 is based on the Company’s estimated annualized effective tax rate for the fiscal year ending December 31, 2021, adjusted for discrete items recognized during the period.  For the three months ended June 30, 2021, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, carrying back net operating losses under the provisions of the CARES Act, and release of a valuation allowance.
The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.  The Company is currently under audit by the State of California for the fiscal years June 30, 2017-2018, the State of New Jersey for the fiscal years June 30, 2013-2017; the State of New York for the fiscal years June 30, 2016-2018; Germany for the fiscal years June 30, 2013-2015; and Switzerland for the fiscal years June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.
13.COMMITMENTS AND CONTINGENCIES
The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of June 30, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.
From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.
14.SEGMENT AND RELATED INFORMATION
The Company’s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.


21

Segment revenue and operating income (loss) were as follows during the periods presented:
(in millions)DiagnosticsOtherTotal
Three months ended June 30, 2021
Revenues$177.1 $12.3 $189.4 
Depreciation and amortization15.7 1.2 16.9 
Segment operating income (loss)37.5 (58.3)(20.8)
Three months ended June 30, 2020
Revenues$81.0 $12.2 $93.2 
Depreciation and amortization16.7 1.0 17.7 
Segment operating loss(33.8)(34.5)(68.3)
Six months ended June 30, 2021
Revenues$334.9 $27.6 $362.5 
Depreciation and amortization32.7 2.6 35.3 
Segment operating income (loss)48.0 (115.5)(67.5)
Six months ended June 30, 2020
Revenues$231.5 $25.7 $257.2 
Depreciation and amortization33.5 2.1 35.6 
Segment operating loss(127.4)(74.6)(202.0)

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Total operating loss for reportable segments$(20.8)$(68.3)$(67.5)$(202.0)
Unallocated amounts:
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Loss from operations before income taxes(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest (0.1) (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)

15.SUPPLEMENTAL CASH FLOW INFORMATION
Six months ended
June 30,
(in millions)20212020
Cash paid during the period for income taxes$1.7 $1.0 
Cash paid for interest1.7 4.3 
Cash received for income tax receivables89.9  
Fair value adjustment on marketable investment securities recorded to stockholders' equity(0.3)0.7
Establishment of operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets$40.5 $ 
Operating lease liabilities46.7  

22

16.DIVESTITURES
On April 26, 2021, the Company entered into a definitive agreement with Castle Biosciences, Inc. for the sale of the Myriad myPath, LLC laboratory, which is the laboratory that offers the myPath Melanoma test. The transaction subsequently closed on May 28, 2021, and the Myriad myPath, LLC laboratory was sold for total cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a net gain of $31.2 million, in Other income on the Company’s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company’s diagnostics reporting segment.
Held for Sale
On May 1, 2021, the Company entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit (the "Autoimmune Business Transaction") to Laboratory Corporation of America Holdings for total cash consideration of $150.0 million. The Autoimmune Business Transaction is expected to close during the quarter ending September 30, 2021.
On May 21, 2021, the Company entered into a definitive agreement to sell Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. This transaction closed on July 1, 2021.
The Company measured these businesses at the lower of their carrying value or fair value less any costs to sell. No impairment was recognized on the held for sale assets during the quarter ended June 30, 2021.

The operating results of these businesses do not qualify for reporting as discontinued operations. The operations of the Myriad Autoimmune business and Myriad RBM, Inc. are included in the Company's diagnostics reporting segment and other reporting segment, respectively. The following table presents information related to the assets and liabilities classified as held for sale at June 30, 2021:
(in millions)Total
Assets
Inventory$3.4 
Intangibles, net119.9 
Goodwill88.5 
Other assets13.9 
Total assets held for sale$225.7 
Liabilities
Accrued liabilities$5.8 
Noncurrent operating lease liabilities3.1 
Other liabilities3.3 
Total liabilities held for sale$12.2 
Total net assets held for sale$213.5 
Inventory
In connection with the divestiture transactions, the Company recognized losses of $5.9 million and $6.6 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the quarter ended June 30, 2021, as the Company will no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the quarter ended June 30, 2021.
23

17.SUBSEQUENT EVENTS
On July 1, 2021, the Company completed its sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. As the sale qualified as a specified asset sale as defined under the Amended Facility, as of July 1, 2021, the Company's maximum aggregate principal commitment on its Amended Facility decreased from $300.0 million to $263.5 million.
On July 30, 2021, the Company made a voluntary principal payment of $106.4 million to pay off the remaining outstanding balances on the Amended Facility and a $0.4 million interest payment incurred on the Amended Facility. As a result, the Company has no outstanding balances under the Amended Facility as of the date of this filing.

24


Item 2.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
(Dollars and shares in millions, except per share data)

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the transition period ended December 31, 2020 included in our Transition Report on Form 10-K filed with the SEC, on March 16, 2021. “We,” “us,” “our,” “Myriad” and the “Company” as used in this Quarterly Report on Form 10‑Q refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.
Cautionary Statement Regarding Forward-Looking Statements
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10‑Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes,” “seek,” “could,” “continue,” “likely,” “will,” “strategy” and “goal” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to:

uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services;
risks related to our ability to efficiently and flexibly manage our business amid uncertainties associated with COVID-19;
the risk that sales and profit margins of our existing molecular diagnostic tests may decline or that we may not be able to operate our business on a profitable basis;
risks related to our ability to generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests;
risks related to changes in governmental or private insurers’ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests;
risks related to increased competition and the development of new competing tests and services;
the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests in a timely manner, or at all;
the risk that we may not successfully develop new markets for our molecular diagnostic tests, including our ability to successfully generate revenue outside the United States;
the risk that licenses to the technology underlying our molecular diagnostic tests and any future tests are terminated or cannot be maintained on satisfactory terms;
risks related to delays or other problems with operating our laboratory testing facilities;
risks related to public concern over genetic testing in general or our tests in particular;
risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems;
risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all;
risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire;
risks related to our projections about the potential market opportunity for our products;
the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests;
25

the risk of patent-infringement claims or challenges to the validity of our patents;
risks related to changes in intellectual property laws covering our molecular diagnostic tests, or patents or enforcement, in the United States and foreign countries;
risks of new, changing and competitive technologies and regulations in the United States and internationally;
the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; and
the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements in this Quarterly Report attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

General
We discover and commercialize genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. Since our founding in 1992, we have performed tests for approximately five million patients. Our mission and purpose is to advance health and well-being for all, empowering every individual by revealing the answers inside each of us.
We are currently developing and executing upon a strategic transformation plan that is focused on the following strategic priorities: (1) put patients and customers first; (2) build new tech-enabled commercial capabilities; (3) elevate core products to their full potential; and (4) create new avenues for growth. In connection with these strategic priorities, we are focusing our efforts on our Hereditary Cancer, Tumor Profiling, Prenatal and Pharmacogenomics products and, as described below, have divested, or are in the process of divesting, certain non-core assets and businesses. We intend to execute on our transformation plan by prioritizing product innovation, research and technology initiatives, strategic collaborations and investments, and defining and deploying a customer-centric technology-enabled commercial model. We believe that by focusing on these strategic priorities, we will be able to reduce complexity and cost, improve our financial performance, build a more effective and cost-efficient sales model, and enhance our reimbursement and revenue cycle capabilities. In addition, we believe we can accelerate growth as we invest in innovation, research and partnership, develop capabilities to support our sales team with new digital tools and add more direct-to-consumer engagement, and build commercial capabilities to support new products and acquisitions.
Business Updates

During the quarter ended June 30, 2021, we continued to see improvement in business fundamentals for our diagnostic products which have been affected by the COVID-19 pandemic. We have also made the following recent announcements:

On May 1, 2021, we entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit (the "Autoimmune Business Transaction") to Laboratory Corporation of America Holdings for total cash consideration of $150.0 million.

On May 21, 2021, we entered into a definitive agreement to sell Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness and transaction costs which adjustment amounts are estimated to be $(3.9) million in the aggregate. This transaction was completed on July 1, 2021.

On May 28, 2021, we completed the sale of the Myriad myPath, LLC laboratory to Castle Biosciences, Inc. for cash consideration of $32.5 million.

We announced the appointments of Thomas P. Slavin, M.D., as Chief Medical Officer of Myriad Genetic Laboratories, and Melissa Gonzales, as President of Myriad Women's Health.

26

We presented the results from a study with more than 275,000 women, which validated the use of a new method for polygenic breast cancer risk assessments in women of all ancestries, to leading collaborators on June 4, 2021 at the 2021 American Society of Clinical Oncology Annual Meeting.

On July 30, 2021, we made a voluntary principal payment of $106.4 million and paid off the remaining outstanding balance on our Amended Facility.

Results of Operations for the Three Months Ended June 30, 2021 and 2020

The results of operations for the three months ended June 30, 2021 and 2020 are discussed below. See Note 14 “Segment and Related Information” in the notes to our Condensed Consolidated Financial Statements for information regarding our operating segments.

Revenue
Three months ended June 30,Change% of Total Revenue
(in millions)20212020202120212020
Molecular diagnostic revenues:
Hereditary Cancer$86.0 $39.9 $46.1 45%43%
Tumor Profiling29.2 10.5 18.7 15%11%
Prenatal29.4 16.6 12.8 16%17%
Pharmacogenomics22.6 8.5 14.1 12%9%
Autoimmune10.2 7.3 2.9 5%8%
Other1.3 0.5 0.8 1%1%
Total molecular diagnostic revenue178.7 83.3 95.4 
Pharmaceutical and clinical service revenue10.7 9.9 0.8 6%11%
Total revenue$189.4 $93.2 $96.2 100%100%

Molecular diagnostic revenues increased $95.4 million for the three months ended June 30, 2021 compared to the same period in the prior year. Revenue for the three months ended June 30, 2020 was negatively impacted by the pandemic as patients incurred significant obstacles to access health care professionals. Hereditary Cancer revenues increased $46.1 million compared to the same period in the prior year due primarily to a 100% increase in volume. Tumor profiling revenues increased $18.7 million compared to the same period in the prior year due primarily to expanded coverage in Japan, a 41% increase in volume, and a 17% increase in average reimbursement per test. Revenue from Pharmacogenomics increased $14.1 million compared to the same period in the prior year due primarily to a 161% increase in volume. Prenatal revenues increased $12.8 million compared to the same period in the prior year due primarily to a 36% increase in average reimbursement per test.
Pharmaceutical and clinical service revenue increased slightly for the three months ended June 30, 2021 compared to the same period in the prior year due to increases in volume of services compared to the same period in the prior year.

Cost of Sales
Three months ended June 30,
(in millions)20212020Change
Cost of molecular diagnostic testing$48.0 $32.2 $15.8
Cost of molecular diagnostic testing as a % of revenue26.9 %38.7 %
Cost of pharmaceutical and clinical services$5.7 $4.5 $1.2
Cost of pharmaceutical and clinical services as a % of revenue53.3 %45.5 %

27

The Cost of molecular diagnostic testing as a percentage of revenue decreased from 38.7% to 26.9% during the three months ended June 30, 2021 compared to the same period in the prior year. The decrease was primarily driven by the increase in revenue from higher test volumes during the period as the same period from the prior year was impacted by COVID-19; thus, costs decreased as a percentage of revenues as revenues from increases in test volumes outpaced personnel and materials costs to perform the tests.
The Cost of pharmaceutical and clinical services as a percentage of revenue increased from 45.5% to 53.3% during the three months ended June 30, 2021 compared to the same period in the prior year due to the change in mix of services provided.
Research and Development Expense
Three months ended June 30,
(in millions)20212020Change
R&D expense$19.5 $17.4 $2.1
R&D expense as a % of total revenue10.3 %18.7 % 

Research and development expense for the three months ended June 30, 2021 increased compared to the same period in the prior year primarily due to increases in compensation costs as a result of employee bonus reductions in the prior period stemming from the significant impact of COVID-19 on the Company's financial results, and increases in costs incurred in the current period as part of the Company’s strategic transformation initiatives.
Selling, General and Administrative Expense
Three months ended June 30,
(in millions)20212020Change
Selling, general and administrative expense$134.8 $107.4 $27.4
Selling, general and administrative expense as a % of total revenue71.2 %115.2 %
Selling, general and administrative expense increased for the three months ended June 30, 2021 compared to the same period in the prior year primarily due to a $7.3 million increase in stock-based compensation due to lower stock-based compensation in the prior period as a result of adjustments to stock-based compensation related to the departure of our former Chief Executive Officer, a $6.4 million increase in bonus expense as a result of employee bonus reductions in the prior period stemming from the significant impact of COVID-19 on the Company's financial results, a $4.6 million increase in commissions due to increases in sales, a $3.3 million increase in legal expenses, and $2.3 million in costs incurred in the current period as part of the Company's strategic transformation initiative.

Change in the Fair Value of Contingent Consideration
Three months ended June 30,
(in millions)20212020Change
Change in the fair value of contingent consideration$0.4 $— $0.4
Change in the fair value of contingent consideration as a % of total revenue0.2 %— % 
The fair value of contingent consideration for the three months ended June 30, 2021 increased compared to the same period in the prior year due to changes in timing of expected cash payments associated with the contingent consideration related to the Sividon Diagnostics GmbH acquisition in fiscal year 2016.  

28

Goodwill and long-lived asset impairment charges
Three months ended June 30,
(in millions)20212020Change
Goodwill and long-lived asset impairment charges$1.8 $— $1.8
Goodwill and long-lived asset impairment charges as a % of total revenue1.0 %— %
Goodwill and long-lived asset impairment charges increased for the three months ended June 30, 2021 compared to the same period in the prior year primarily due to the Company recognizing a $1.8 million impairment to right-of-use assets as a result of the voluntary early termination of certain lease agreements to consolidate space during the current period. There were no impairments recognized in the prior period.
Other Income (Expense), Net
Three months ended June 30,
(in millions)20212020Change
Other income (expense), net$17.0 $9.8 $7.2

Other income (expense), net increased for the three months ended June 30, 2021 compared to the same period in the prior year due primarily to the $31.2 million net gain recognized on the sale of the Myriad myPath, LLC laboratory in the current period, partially offset by charges in the current period, including losses of $5.9 million and $6.6 million for a non-cancelable purchase commitment and inventory, respectively, recognized in connection with the divestiture transactions. Increases were also partially offset by the receipt of $14.6 million in stimulus funds from the CARES Act in the prior period.
Income Tax Expense (Benefit)
Three months ended June 30,
(in millions)20212020Change
Income tax expense (benefit)$0.9 $(3.0)$3.9
Effective tax rate(23.7)%5.1 % 
Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.

Income tax expense (benefit) for the three months ended June 30, 2021 was $0.9 million, and our effective tax rate was (23.7)%.  The decrease in the effective rate for the three months ended June 30, 2021 as compared to the same period in the prior year is primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, the tax impact of the CARES Act, and release of a valuation allowance.



29

Results of Operations for the Six Months Ended June 30, 2021 and 2020

The results of operations for the six months ended June 30, 2021 and 2020 are discussed below. See Note 14 “Segment and Related Information” in the notes to our Condensed Consolidated Financial Statements for information regarding our operating segments.

Revenue
Six months ended June 30,Change% of Total Revenue
(in millions)20212020202120212020
Molecular diagnostic revenues:
Hereditary Cancer$162.1 $125.1 $37.0 45%49%
Tumor Profiling60.2 24.2 36.0 17%10%
Prenatal53.1 36.9 16.2 14%14%
Pharmacogenomics
40.2 28.9 11.3 11%11%
Autoimmune20.9 17.7 3.2 6%7%
Other1.8 1.0 0.8 —%—%
Total molecular diagnostic revenue338.3 233.8 104.5 
Pharmaceutical and clinical service revenue24.2 23.4 0.8 7%9%
Total revenue$362.5 $257.2 $105.3 100%100%

Molecular diagnostic revenue for the six months ended June 30, 2021 increased $104.5 million compared to the same period in the prior year. Revenue for the six months ended June 30, 2020 was negatively impacted by the pandemic as patients incurred significant obstacles to access health care professionals. Hereditary Cancer revenues increased $37.0 million compared to the same period in the prior year due primarily to a 30% increase in volume. Tumor Profiling revenues increased $36.0 million compared to the same period in the prior year due to a 30% increase in volume, expanded coverage, including in Japan, and the submission of claims for previously performed tests that were pending clarification of the coverage policy. Prenatal revenues increased $16.2 million compared to the same period in the prior year due primarily to an increase of 21% in the average reimbursement per test and a 19% increase in volume. Revenue from Pharmacogenomics increased $11.3 million compared to the same period in the prior year due primarily to a 49% increase in volume.
Pharmaceutical and clinical service revenue increased slightly for the six months ended June 30, 2021 compared to the same period in the prior year due to $2.9 million generated from processing COVID-19 tests in the current period and also to a $1.7 million increase in revenue from pharmaceutical services for the six months ended June 30, 2021 compared to the same period in the prior year. Increases were partially offset by decreased revenue attributable to the sale of the Clinic, an internal medicine emergency hospital, which was sold in February 2020 and generated $3.9 million in revenue during the prior period.

Cost of Sales
Six months ended June 30,
(in millions)20212020Change
Cost of molecular diagnostic testing$92.1 $75.3 $16.8
Cost of molecular diagnostic testing as a % of revenue27.2 %32.2 %
Cost of pharmaceutical and clinical services$11.9 $11.5 $0.4
Cost of pharmaceutical and clinical services as a % of revenue49.2 %49.1 %
The Cost of molecular diagnostic testing as a percentage of revenue decreased from 32.2% to 27.2% during the six months ended June 30, 2021 compared to the same period in the prior year. The decrease was primarily driven by the increase in revenue from higher test volumes during the period as the same period from the prior year was impacted by COVID-19; thus, costs decreased as a percentage of revenue as revenue from increases in test volumes outpaced personnel and materials costs to perform the tests.
30

The cost of pharmaceutical and clinical services as a percentage of revenue decreased slightly from 49.1% to 49.2% during the six months ended June 30, 2021 compared to the same period in the prior year due to the change in mix of services provided.
Research and Development Expense
Six months ended June 30,
(in millions)20212020Change
R&D expense$42.6 $37.1 $5.5
R&D expense as a % of total revenue11.8 %14.4 %

Research and development expense for the six months ended June 30, 2021 increased compared to the same period in the prior year primarily due to increases in costs incurred in the current period as part of the Company’s strategic transformation initiatives and increases in compensation costs as a result of employee bonus reductions in the prior period stemming from the significant impact of COVID-19 on the Company's financial results.
Selling, General and Administrative Expense
Six months ended June 30,
(in millions)20212020Change
Selling, general and administrative expense$280.3 $240.3 $40.0
Selling, general and administrative expense as a % of total revenue77.3 %93.4 %
Selling, general and administrative expense increased for the six months ended June 30, 2021 compared to the same period in the prior year primarily due to $15.3 million in costs incurred in the current period as part of the Company's strategic transformation initiative, an $8.3 million increase in stock-based compensation due to lower stock-based compensation in the prior period as a result of adjustments to stock-based compensation related to the departure of our former Chief Executive Officer, a $7.4 million increase in bonus expense as a result of employee bonus reductions in the prior year stemming from the significant impact of COVID-19 on the Company's financial results, a $5.1 million increase in commissions due to increases in sales, and a $4.2 million increase in legal expenses. Increases were partially offset by a decrease in sales and marketing expenses of $5.4 million due primarily to fewer in-person sales and marketing events and travel-related expenses.

Change in the Fair Value of Contingent Consideration
Six months ended June 30,
(in millions)20212020Change
Change in the fair value of contingent consideration$1.3 $(3.4)$4.7
Change in the fair value of contingent consideration as a % of total revenue0.4 %(1.3)%
The fair value of contingent consideration for the six months ended June 30, 2021 increased compared to the same period in the prior year due to changes in timing of expected cash payments associated with the contingent consideration related to the Sividon Diagnostics GmbH acquisition in fiscal year 2016.  
Goodwill and long-lived asset impairment charges
Six months ended June 30,
(in millions)20212020Change
Goodwill and long-lived asset impairment charges$1.8 $98.4 $(96.6)
Goodwill and long-lived asset impairment charges as a % of total revenue0.5 %38.3 %
Goodwill and long-lived asset impairment charges decreased for the six months ended June 30, 2021 compared to the same period in the prior year primarily due to the Company recognizing goodwill impairment charges in the prior period related to the Myriad Autoimmune reporting unit, as well as additional charges related to the abandonment of an in-process research and development intangible asset during the prior period.
31

Other Income (Expense), Net
Six months ended June 30,
(in millions)20212020Change
Other income (expense), net$14.1 $12.4 $1.7

Other income (expense), net increased for the six months ended June 30, 2021 compared to the same period in the prior year due primarily to the $31.2 million net gain recognized on the sale of the Myriad myPath, LLC laboratory in the current period, partially offset by charges in the current period, including losses of $5.9 million and $6.6 million for a non-cancelable purchase commitment and inventory, respectively, recognized in connection with the divestiture transactions. Increases were also partially offset by the receipt of $14.6 million in stimulus funds from the CARES Act in the prior period.
Income Tax Expense (Benefit)
Six months ended June 30,
(in millions)20212020Change
Income tax benefit$(9.2)$(18.9)$9.7
Effective tax rate17.2 %10.0 %
Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.

Income tax benefit for the six months ended June 30, 2021 was $9.2 million, and our effective tax rate was 17.2%.  The increase in the effective rate for the six months ended June 30, 2021 as compared to the same period in the prior year is primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, the tax impact of the CARES Act, and release of a valuation allowance.
Liquidity and Capital Resources
Our primary sources of liquidity are our cash, cash equivalents and marketable investment securities, our cash flows from operations, our cash flows from investing activities, and amounts available for borrowing under our Amended Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development, debt repayment, and acquisitions. We believe that investing organically through research and development and acquisitively to support business strategy provides the best return on invested capital. In the second quarter ended June 30, 2021, we entered into separate definitive agreements for the sale of the Myriad myPath, LLC laboratory; the sale of select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit; and the sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company. On May 28, 2021, we completed the sale of the Myriad myPath, LLC laboratory for total cash consideration of $32.5 million, and on July 1, 2021, we completed the sale of Myriad RBM, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. We expect to close the Autoimmune Business Transaction for total cash consideration of $150.0 million during the third quarter of 2021, generating proceeds that are expected to provide additional liquidity.
We believe that our existing capital resources and the cash to be generated from the Autoimmune Business Transaction will be sufficient to meet our current and projected operating requirements for the foreseeable future. In addition, our capital resources and cash on hand may be used for acquisitions or other strategic investments.
All remaining borrowings under our Amended Facility, which matures on July 31, 2023, were repaid on July 30, 2021 using cash generated from our recent divestitures. Our available capital resources, however, may be consumed more rapidly than currently expected, and we may need or want to raise additional financing. We may not be able to secure such financing in a timely manner or on favorable terms, if at all. In addition, we are subject to financial covenants as part of our outstanding Amended Facility that could limit our ability to incur additional indebtedness. Without additional funds, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations, and potentially delay development of our diagnostic tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.
32

The Amended Facility restricts our ability to make future borrowings if unrestricted cash, cash equivalents and marketable securities exceed $150.0 million, unless such borrowings are used in connection with certain permitted acquisitions. Amendment No. 3 to the Amended Facility also included an immediate reduction in our revolving commitment to $300.0 million, with a further reduction to $250.0 million by the earlier of September 30, 2021 or the receipt of certain specified asset sales proceeds, and provided for further reductions to our revolving commitment, or mandatory prepayments of revolving loans, in the event of certain asset sales, which could limit our borrowing capacity, or reduce liquidity, in future periods. The Amended Facility allows us to keep the net cash proceeds of material asset sales received above certain dollar thresholds without corresponding mandatory prepayments or commitment reductions. In connection with the consummation of the sale of the Myriad myPath, LLC laboratory and Myriad RBM, Inc., we received certain specified asset sales proceeds as defined in Amendment No. 3 to the Amended Facility. Accordingly, on July 1, 2021, our revolving commitment amount was reduced from $300.0 million to $263.5 million and it will be reduced further to $250.0 million by the earlier of September 30, 2021 or the receipt of additional specified asset sales proceeds.
In 2019, we entered into a non-cancelable operating lease for our new corporate headquarters in Salt Lake City, Utah, which commenced April 2021 with a lease term of 15 years and total future lease payments of approximately $69.1 million.
Due to the continuing evolving global situation from the COVID-19 pandemic, including the emergence of the more highly transmissible Delta coronavirus variant and its impact on the ongoing recovery from the COVID-19 pandemic in the quarter ended June 30, 2021, it is not possible to predict whether unanticipated consequences of the pandemic are reasonably likely to materially affect our liquidity and capital resources in the future. Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified management, scientific, and technical personnel. Competition and compensation for such personnel and other qualified personnel rose as employment vacancies surged in the first half of 2021, and job applicants are often seeking a more flexible work arrangement over the long term as a condition of employment. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our research and development programs and molecular diagnostic services business. Disruptions to our supply chain as a result of COVID-19 and ongoing responses to it could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, inflation arising from the recovery from the COVID-19 pandemic, led by federal stimulus funding, increases to household savings, and the sudden macroeconomic shift in activity levels arising from the loosening or removal of many government restrictions and the broader availability of COVID-19 vaccines in the United States in the second quarter of 2021, may have an ongoing impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies.

The following table represents the balances of cash, cash equivalents and marketable investment securities: 
(in millions)June 30,
2021
December 31,
2020
Change
Cash and cash equivalents$118.4 $117.0 $1.4 
Marketable investment securities46.0 33.7 12.3 
Long-term marketable investment securities19.9 21.0 (1.1)
Cash, cash equivalents and marketable investment securities$184.3 $171.7 $12.6 
The increase in cash, cash equivalents, and marketable investment securities was primarily driven by the change in the balance of prepaid taxes due to the receipt of an $89.6 million U.S. federal tax refund in the quarter ended March 31, 2021, $32.5 million in total cash consideration from the sale of the Myriad myPath, LLC laboratory and proceeds of $50.1 million from the exercise of stock options, partially offset by a $120.0 million repayment of the Company's revolving credit facility during the six months ended June 30, 2021 and by cash used in operating activities as part of our normal course of business.
33

The following table represents the Condensed Consolidated Cash Flow Statement:
Six Months Ended June 30,
(in millions)20212020Change
Cash flows from operating activities$67.4 $46.8 $20.6 
Cash flows from investing activities9.3 33.6 (24.3)
Cash flows from financing activities(75.0)1.1 (76.1)
Effect of foreign exchange rates on cash and cash equivalents(0.3)(0.5)0.2 
Change in cash and cash equivalents classified as held for sale— 1.5 (1.5)
Net increase in cash and cash equivalents1.4 82.5 (81.1)
Cash and cash equivalents at the beginning of the period117.0 81.2 35.8 
Cash and cash equivalents at the end of the period$118.4 $163.7 $(45.3)
Cash Flows from Operating Activities
The increase in cash flows from operating activities for the six months ended June 30, 2021, compared to the same period in the prior year, was primarily due to the change in the balance of prepaid taxes due to the receipt of an $89.6 million U.S. federal tax refund, partially offset by a decrease in cash flows from operating activities primarily driven by a $62.6 million change in trade accounts receivable in the current period compared to the prior period due to the change in sales volumes and cash collections as a result of the significant impact of COVID-19 on the Company's financial results during the prior period.
Cash Flows from Investing Activities
The decrease in cash flows from investing activities for the six months ended June 30, 2021, compared to the same period in the prior year, was primarily due to a $29.2 million change in mix of purchases of and proceeds from marketable investment securities, partially offset by incremental cash proceeds of $11.2 million from divestitures due to the sale of the Myriad myPath, LLC laboratory in May 2021 for total cash consideration of $32.5 million, which exceeded cash proceeds from the sale of the Clinic of $21.3 million in February 2020.
Cash Flows from Financing Activities
The decrease in cash flows from financing activities for the six months ended June 30, 2021, compared to the same period in the prior year, was primarily due to the use of $120.0 million in cash for repayments of the Amended Facility during the six months ended June 30, 2021. The decrease was partially offset by an increase of $47.4 million in proceeds from the exercise of stock options, net of shares exchanged for payroll withholding tax, for the six months ended June 30, 2021 compared to the same period in the prior year.
Effects of Inflation
We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented. However, inflation caused by the acute shift brought on by the global recovery from the COVID-19 pandemic may have an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce diagnostic testing results, and costs of lab supplies in future periods. Inflationary costs may impact our profitability and could adversely affect our business, financial condition and results of operations.
Share Repurchase Program
Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock. We may repurchase our common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by our management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.  As of June 30, 2021, we are authorized to repurchase up to $110.7 million under our current share repurchase authorization.  See “Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds – Issuer Purchases of Equity Securities” below.


34

Critical Accounting Policies
Critical accounting policies are those policies which are both important to the presentation of a company’s financial condition and results and require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a further discussion of our critical accounting policies, see our Transition Report on Form 10-K. Other than the policy on held for sale assets and liabilities described in Note 1, no significant changes to our accounting policies took place during the period presented.
Item 3.    Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in our market risk during the six months ended June 30, 2021 compared to the disclosures in Part II, Item 7A of our Transition Report on Form 10-K, which are incorporated by reference herein.
Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures.  
We maintain disclosure controls and procedures (“Disclosure Controls”) within the meaning of Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.
As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2021, our Disclosure Controls are effective and the prior period material weakness in the Company's internal control over financial reporting as disclosed below has been remediated.
In connection with the preparation of our Consolidated Financial Statements as of and for the transition period ended December 31, 2020, we identified a material weakness in controls over the accounting for intercompany transactions, foreign currency exchanges and foreign currency translation related to our international subsidiaries. Specifically, as part of our financial statement close process, certain of our control activities were not sufficiently designed or operating effectively to ensure all of our policies were in compliance with generally accepted accounting principles, consistent in their application, retained in appropriate documentation and communicated to relevant parties. As a result of the material weakness, we recorded certain immaterial corrections to intercompany accounts, as well as foreign currency exchange and translation gains and losses, in our Consolidated Financial Statements for the transition period ended December 31, 2020. Management has completed its remediation of the material weakness as described below.
Remediation of Material Weakness
We have implemented control measures to improve our internal control over financial reporting and remediated the material weakness identified above. We took the following actions to remediate the material weakness:

We designed additional control and review procedures needed to provide more robust and comprehensive internal controls over financial reporting that address the risks of material misstatement related to the accounting for intercompany transactions, foreign currency exchanges and foreign currency translation within our business processes.
We implemented additional application controls in our financial systems, implemented formal review procedures, and formally documented our newly designed processes for the identified areas.
We subjected the additional controls implemented to testing and concluded that the controls are operating effectively.


35


Changes in Internal Controls  
The Company is in the midst of a multi-year transformation project to achieve better analytics and process efficiencies through the use of Oracle Fusion Cloud Services System, which will be substantially completed in the fourth quarter. Emphasis will continue to be placed on the maintenance of effective internal controls and assessment of the design and operating effectiveness of key control activities throughout development and deployment of each phase.
Other than as described above, there were no changes in our internal control over financial reporting that occurred during the three months ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
36

PART II - Other Information
Item 1.    Legal Proceedings.

Qui Tam Lawsuit

In June 2016, our wholly owned subsidiary, Crescendo Bioscience, Inc. (“CBI”), received a subpoena from the Office of Inspector General of the Department of Health and Human Services requesting that CBI produce documents relating to entities that received payment from CBI for the collection and processing of blood specimens for testing, including a named unrelated company, healthcare providers and other third party entities. The Office of Inspector General subsequently requested additional documentation in December 2017. CBI provided to the Office of Inspector General the documents requested. On January 30, 2020, the United States District Court for the Northern District of California unsealed a qui tam complaint, filed on April 16, 2016 against CBI and the Company, alleging violations of the Federal and California False Claims Acts and the California Insurance Fraud Prevention Act. On January 22, 2020, after a multi-year investigation into CBI’s and the Company’s alleged conduct, the United States declined to intervene. On January 27, 2020, the State of California likewise filed its notice of declination. The Company was not aware of the complaint until after it was unsealed. On May 23, 2020, the court denied CBI and the Company’s motion to dismiss. The Company intends to continue to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.

Purported Securities Class Action

On September 27, 2019, a purported class action complaint was filed in the United States District Court for the District of Utah, against the Company, its former President and Chief Executive Officer, Mark C. Capone, and its Interim President and Chief Executive Officer, Executive Vice President and Chief Financial Officer, R. Bryan Riggsbee (“Defendants”). On February 21, 2020, the plaintiff filed an amended class action complaint, which added the Company’s Executive Vice President of Clinical Development, Bryan M. Dechairo, as an additional Defendant. This action, captioned In re Myriad Genetics, Inc. Securities Litigation (No. 2:19-cv-00707-DBB), is premised upon allegations that the Defendants made false and misleading statements regarding our business, operations, and acquisitions. The lead plaintiff seeks the payment of damages allegedly sustained by it and the purported class by reason of the allegations set forth in the amended complaint, plus interest, and legal and other costs and fees. On March 16, 2021, the United States District Court for the District of Utah denied the Company’s motion to dismiss. The Company intends to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome or an estimate of the amount or range of potential loss, if any.

Other Legal Proceedings

On August 24, 2018, our wholly owned subsidiary, Assurex Health, Inc. (“Assurex”), was served with an Amended Complaint which had been filed in the Circuit Court of Cook County, Illinois, County Department, Law Division, Civil Action No. 2018 L 004972, by Pipe Trades Services MN Welfare Plan (“Pipe Trades”), as a qui tam relator, on behalf of the State of Illinois, Pipe Trades, and all others similarly situated, purportedly arising from Assurex’s alleged violations of the Illinois Insurance Claims Fraud Prevention Act and other causes of action. Pipe Trades seeks certification of a putative class, certification as the purported class representative, and the payment of treble damages allegedly sustained by Pipe Trades and the purported class by reason of the allegations set forth in the amended complaint, plus statutory damages and penalties, plus interest, and legal and other costs and fees. The State of Illinois and Cook County, Illinois, have declined to intervene in the matter. On February 19, 2021, the court granted Assurex’s motion to dismiss the complaint, without prejudice and with leave for Pipe Trades to file an amended complaint, for failure to state a claim on which relief can be granted. On March 19, 2021, Pipe Trades filed an amended complaint. We intend to continue to vigorously defend against this action. Due to the nature of this matter and inherent uncertainties, it is not possible to provide an evaluation of the likelihood of an unfavorable outcome, but the Company does not expect this matter to have a material impact on our business, financial position or results of operations.

Other than as set forth above, we are not a party to any legal proceedings that we believe will have a material impact on our business, financial position or results of operations.
37

Item 1A.    Risk Factors.
In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading “Item 1A. Risk Factors” included in the Transition Report on Form 10-K, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in the Transition Report on Form 10-K other than the updates to the risk factors set forth below. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC.
Our financial condition and results of operations could be further adversely affected by the ongoing coronavirus pandemic.
Any outbreaks of COVID-19 (including its variant strains, such as the highly transmissible Delta variant) or any other outbreak of contagious disease or adverse public health development, could have a further material and adverse effect on our business operations. For example, government public health officials may place additional restrictions to curb the spread of COVID-19, limiting patients' access to our services, and patients may elect to defer certain testing, each of which would impede our progress in returning to profitability and recovering from the earlier effects of the COVID-19 pandemic. Such adverse effects could also include diversion or prioritization of healthcare resources away from the conduct of genetic testing, disruptions or restrictions on the ability of laboratories to process our tests, and delays or difficulties in patients accessing our tests.

As COVID-19 continues to affect individuals and businesses around the globe, we will likely experience further disruptions from time to time that could severely impact our business, including:

decreased volume of testing as a result of disruptions to healthcare providers and limitations on the ability of providers to administer tests;

disruptions or restrictions on the ability of our, our collaborators’, or our suppliers’ personnel to travel, and temporary closures of our facilities or the facilities of our collaborators or suppliers;

limitations on employee resources that would otherwise be focused on the development of our products, processing our diagnostic tests, and the conduct of our clinical trials, including because of sickness of employees or their families or requirements imposed on employees to avoid contact with large groups of people; and

delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or access.

In addition, the continued spread of COVID-19 globally could further adversely affect our manufacturing and supply chain. Parts of our direct and indirect supply chain are located overseas and both international and domestic components may continue to be subject to disruption as a result of COVID-19 and ongoing responses to it. If the supplies and components necessary to manufacture our products become unavailable or are disrupted as a result of COVID-19 and ongoing responses to it, then we may not be able to successfully perform our research or operate our business on a timely basis or at all. Additionally, our results of operations could be adversely affected to the extent that the continued spread of COVID-19 or any other public health emergency harms our business or the economy in general either domestically or in any other region in which we do business.
The extent to which COVID-19 continues to affect our operations and impede our recovery from the earlier effects of the COVID-19 pandemic will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration, spread and severity of COVID-19 outbreaks, the rate of vaccination and efficacy of approved vaccines against COVID-19 and its variant strains, actions taken to contain COVID-19 or treat its impact, new information that may emerge concerning the health effects of COVID-19, and how quickly and to what extent normal economic and operating conditions would resume if the pandemic subsided, any of which could have a further adverse effect on our business and financial condition.

38

If we fail to retain our key personnel and hire, train and retain qualified employees and consultants, we may not be able to successfully continue our business.
Because of the specialized scientific nature of our business, we are highly dependent upon our ability to attract and retain qualified management, scientific and technical personnel. Competition and compensation for such personnel and other qualified personnel rose as employment vacancies surged in the first half of 2021, and job applicants are often seeking a more flexible work arrangement over the long term as a condition of employment. Loss of the services of or failure to recruit additional key management, scientific and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our research and development programs and molecular diagnostic business and may have a material adverse effect on our business as a whole. In addition, inflation arising from the recovery from the COVID-19 pandemic, led by federal stimulus funding, increases to household savings, and the sudden macroeconomic shift in activity levels arising from the loosening or removal of many government restrictions and the broader availability of COVID-19 vaccines in the United States in the second quarter of 2021, may have an ongoing impact on the costs that we incur to attract and retain qualified personnel and may make it more difficult for us to attract and retain such personnel.
Our agreements with our employees generally provide for employment that can be terminated by either party without cause at any time, subject to specified notice requirements. Further, the non-competition provision to which each employee is subject expires for certain key employees on the applicable date of termination of employment or may not be enforceable under certain state or federal laws.
Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer Purchases of Equity Securities
Our Board of Directors has previously authorized us to repurchase up to $200.0 million of our outstanding common stock, of which $110.7 million is still available to repurchase as of June 30, 2021. We are authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management’s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. The repurchase program may be suspended or discontinued at any time without prior notice.
No stock repurchases were made under our stock repurchase program during the three months ended June 30, 2021.
Item 3.    Defaults Upon Senior Securities.
None.
Item 4.    Mine Safety Disclosures.
Not applicable.
Item 5.    Other Information.
None.
39

Item 6.    Exhibits.
31.1
31.2
32.1
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document
101.LABInline XBRL Taxonomy Extension Label Linkbase Document
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document
104The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, has been formatted in Inline XBRL.


40

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MYRIAD GENETICS, INC.
Date: August 4, 2021By:/s/ Paul J. Diaz
Paul J. Diaz
President and Chief Executive Officer
(Principal executive officer)
Date: August 4, 2021By:/s/ R. Bryan Riggsbee
R. Bryan Riggsbee
Chief Financial Officer
(Principal financial and accounting officer)

41
EX-31.1 2 exhibit311-certificationof.htm EX-31.1 Document

Exhibit 31.1
SARBANES-OXLEY SECTION 302(a) CERTIFICATION
I, Paul J. Diaz, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 4, 2021
By:/s/ Paul J. Diaz
Paul J. Diaz
President and Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 exhibit312-certificationof.htm EX-31.2 Document

Exhibit 31.2
SARBANES-OXLEY SECTION 302(a) CERTIFICATION
I, R. Bryan Riggsbee, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 4, 2021
By:/s/ R. Bryan Riggsbee
R. Bryan Riggsbee
Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 exhibit321-certificationpu.htm EX-32.1 Document

Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:
The Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 4, 2021Date: August 4, 2021
By:/s/ Paul J. DiazBy:/s/ R. Bryan Riggsbee
Paul J. DiazR. Bryan Riggsbee
President and Chief Executive OfficerChief Financial Officer
Principal Executive OfficerPrincipal Financial and Accounting Officer


EX-101.SCH 5 mygn-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Revenue - Total Revenue by Product and by US versus Rest of World (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2108103 - Disclosure - Marketable Investment Securities link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Marketable Investment Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2412406 - Disclosure - Marketable Investment Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2113104 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2417409 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2118105 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Property, Plant and Equipment, Net - Balances (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2122106 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2323305 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2425413 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2426414 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2127107 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2429415 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2130108 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2432416 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2433417 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2134109 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 2335308 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2436418 - Disclosure - Other Long-Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Preferred and Common Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2338309 - Disclosure - Preferred and Common Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2439419 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2440420 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2441421 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) link:presentationLink link:calculationLink link:definitionLink 2442422 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details) link:presentationLink link:calculationLink link:definitionLink 2143111 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2344310 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2445423 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2446424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2447425 - Disclosure - Stock-Based Compensation - RSU Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2448426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2149112 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2450427 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2151113 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2152114 - Disclosure - Segment and Related Information link:presentationLink link:calculationLink link:definitionLink 2353311 - Disclosure - Segment and Related Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2454428 - Disclosure - Segment and Related Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2455429 - Disclosure - Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2456430 - Disclosure - Segment and Related Information - Total Operating Loss for Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 2157115 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 2358312 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2459431 - Disclosure - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 2160116 - Disclosure - Divestitures link:presentationLink link:calculationLink link:definitionLink 2361313 - Disclosure - Divestitures (Tables) link:presentationLink link:calculationLink link:definitionLink 2462432 - Disclosure - Divestitures - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2463433 - Disclosure - Divestitures - Assets and Liabilities Classified as Held For Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2164117 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2465434 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 mygn-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 mygn-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 mygn-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT RSUs granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Other Other Nonoperating Income (Expense) Payment of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Marketable Investment Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Latest tax year Latest Tax Year [Member] Segments [Axis] Segments [Axis] RSUs vested (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Level 3 Fair Value, Inputs, Level 3 [Member] Loss on inventory Inventory Write-down Proceeds from maturities and sales of marketable investment securities Proceeds from Sale and Maturity of Marketable Securities Available-for-sale, Due after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Statistical Measurement [Domain] Statistical Measurement [Domain] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Share-Based Compensation [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Long-term deferred taxes Deferred Income Tax Liabilities, Net Security Exchange Name Security Exchange Name Intangibles, net Net, total Intangible Assets, Net (Excluding Goodwill) Germany Federal Ministry of Finance, Germany [Member] Operating loss Segment operating income (loss) Total operating loss for reportable segments Operating Income (Loss) Fees associated with refinancing of revolving credit facility Payments of Debt Issuance Costs Total current liabilities Liabilities, Current Reconciliation of Deferred Revenue Balances Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current RSUs outstanding, beginning (dollars per share) RSUs outstanding, ending (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Cost of pharmaceutical and clinical services Cost Of Pharmaceutical And Clinical Services [Member] Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included. Commitments and contingencies Commitments and Contingencies ASSETS Assets [Abstract] New York New York State Division of Taxation and Finance [Member] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Service period for award vesting (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accrued taxes payable Taxes Payable, Current Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture Scheduled principal payments prior to maturity date Debt Instrument, Annual Principal Payment Entity Address, State or Province Entity Address, State or Province RSUs vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Accounts payable Accounts Payable, Current Translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Accumulated deficit Retained Earnings (Accumulated Deficit) Repayment of revolving credit facility Principal repayment Repayments of Lines of Credit Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Myriad myPath LLC laboratory Myriad My Path LLC Laboratory [Member] Myriad My Path LLC Laboratory Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Earliest tax year Earliest Tax Year [Member] Cash paid during the period for income taxes Income Taxes Paid Options outstanding, beginning (shares) Options outstanding, ending (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Customer [Axis] Customer [Axis] Held for Sale Policy Net Assets Held For Sale [Policy Text Block] Net Assets Held For Sale Operating lease liabilities Operating Lease Liability Established Operating Lease Liability Established Federal agency issues US Treasury and Government [Member] Options exercisable at end of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Schedule of Other Long-Term Liabilities Other Noncurrent Liabilities [Table Text Block] Other long-term liabilities Total other long-term liabilities Other Liabilities, Noncurrent Options canceled or expired (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Marketable investment securities Marketable Securities, Current Awards granted after December 5, 2012 Options Granted After December Five Twenty Twelve [Member] Options granted after December 5, 2012. Stock-based payment expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Effect of foreign exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Options canceled or expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Inventory Inventory, Net Total revenue Revenues Revenue from Contract with Customer, Excluding Assessed Tax Performance obligation estimate Performance Obligation Estimated Transaction Price [Member] Performance Obligation Estimated Transaction Price Concentration risk (percent) Concentration Risk, Percentage Geographical Geographical [Domain] Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Available-for-sale, Due after five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Statement [Line Items] Statement [Line Items] Schedule of Potential Dilutive Common Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Deferred income taxes Increase (Decrease) in Deferred Income Taxes Interest rate (percent) Long-term Debt, Weighted Average Interest Rate, at Point in Time Net loss per share: Earnings Per Share, Basic and Diluted [Abstract] Tax Period [Axis] Tax Period [Axis] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Measurement Input Type Measurement Input Type [Domain] Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Non-cash lease expense Operating Lease, Right-of-Use Asset, Amortization Expense Net gain on sale of assets adjusted for transaction fees Gain (Loss) On Disposition of Assets, Net Of Transaction Fees Gain (Loss) On Disposition of Assets, Net Of Transaction Fees US government securities US Government Agencies Debt Securities [Member] Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations Schedule of Weighted Average Number of Shares [Table Text Block] Foreign Foreign Tax Authority [Member] Entity Small Business Entity Small Business Common shares issued and outstanding Increase (Decrease) in Stockholders' Equity [Roll Forward] Amended facility Amendment To Credit Agreement [Member] Amendment to Credit Agreement [Member]. Long-Term Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Selling, general, and administrative expense Selling, General and Administrative Expenses [Member] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Goodwill [Roll Forward] Goodwill [Roll Forward] Amendment Flag Amendment Flag Select operating assets and intellectual property of Myriad Autoimmune business unit and Myriad RBM, Inc Myriad Autoimmune Assets And Myriad RBM, Inc [Member] Myriad Autoimmune Assets And Myriad RBM, Inc Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Total, Gross unrealized holding losses Investments And Cash, Accumulated Gross Unrealized Loss, before Tax Investments And Cash, Accumulated Gross Unrealized Loss, before Tax Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Assets Disposal Group, Including Discontinued Operation, Assets, Current [Abstract] Shares available for grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other accrued liabilities Other Accrued Liabilities, Current Interest payment Payments Of Interest, Lines of Credit Payments Of Interest, Lines of Credit Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Entity Central Index Key Entity Central Index Key Noncurrent operating lease liabilities Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Select operating assets and intellectual property of Myriad Autoimmune business unit Myriad Autoimmune Assets [Member] Myriad Autoimmune Assets Schedule of Amortizable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Cost of molecular diagnostic testing Cost Of Molecular Diagnostic Testing [Member] Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosures [Text Block] U.S. [Member] Geographical [Axis] Subsequent Events Subsequent Events [Text Block] Segments [Domain] Segments [Domain] Available-for-sale, Amortized cost Debt Securities, Available-for-sale, Amortized Cost Unrecognized stock-based compensation expense related to stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Available-for-sale, Gross unrealized holding gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Effect of dilutive shares Weighted Average Number Diluted Shares Outstanding Adjustment Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Cash Cash [Member] State State and Local Jurisdiction [Member] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Selling, general, and administrative expense Selling, General and Administrative Expense Amortization of intangible assets Amortization of Intangible Assets Prepaid taxes Prepaid Taxes Proceeds from sale of subsidiary Proceeds from Divestiture of Interest in Consolidated Subsidiaries Other assets Other Assets, Noncurrent Plan Name [Axis] Plan Name [Axis] Cash received for income tax receivables Proceeds from Income Tax Refunds Segment and Related Information Segment Reporting Disclosure [Text Block] Cash and cash equivalents, Estimated fair value Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Long-term marketable investment securities Marketable Securities, Noncurrent Concentration Risk [Table] Concentration Risk [Table] Total assets Assets Scenario [Axis] Scenario [Axis] Revenues Revenue from Contract with Customer Benchmark [Member] Accrued liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Myriad RBM, Inc. Myriad RBM, Inc [Member] Myriad RBM, Inc RSUs outstanding, beginning (shares) RSUs outstanding, ending (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Disposal Group Classification [Axis] Disposal Group Classification [Axis] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Net, amortizable Finite-Lived Intangible Assets, Net Subsequent Event Type [Axis] Subsequent Event Type [Axis] Unrealized loss on available-for-sale debt securities, net of tax Fair value adjustment on marketable investment securities recorded to stockholders' equity OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Summary of Common Shares Issued and Outstanding Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Revenue recognized Contract With Customer, Liability, Including New Contract, Revenue Recognized Contract With Customer, Liability, Including New Contract, Revenue Recognized Interest expense Interest Expense Proceeds from sale of assets Proceeds from Sale of Productive Assets Product and Service Product and Service [Axis] Amortized cost Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract] Total liabilities Liabilities Income Taxes [Line Items] Income Tax Contingency [Line Items] Investment Type [Axis] Investment Type [Axis] Weighted-average period for recognition of stock-based compensation expense (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Other Other Segments [Member] RoW Non-US [Member] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Molecular Diagnostic - Pharmacogenomics Molecular Diagnostic Pharmacogenomics [Member] Molecular Diagnostic Pharmacogenomics Inventory Increase (Decrease) in Inventories Estimated fair value Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Medicare Medicare [Member] Medicare Accounts payable Increase (Decrease) in Accounts Payable RSUs, Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Impairment of goodwill and long-lived assets Impairment Of Goodwill And Long-Lived Assets Held For Use Impairment Of Goodwill And Long-Lived Assets Held For Use Debt Instrument [Axis] Debt Instrument [Axis] Additional paid-in capital Additional Paid-in Capital [Member] Measurement input, expected term Measurement Input, Expected Term [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Accrued liabilities Increase (Decrease) in Accrued Liabilities Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Common stock, shares outstanding Common stock outstanding (shares) Beginning common stock outstanding Common stock outstanding at end of period Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Loss on non-cancelable purchase commitment Inventory, Firm Purchase Commitment, Loss Costs and expenses: Operating Costs and Expenses [Abstract] Revolving credit facility Revolving Credit Facility [Member] Schedule of Goodwill [Table] Schedule of Goodwill [Table] Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Research and development expense Research and Development Expense Cash equivalents Cash Equivalents [Member] Tax year being audited in income tax examination Income Tax Examination, Year under Examination Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Subsequent event Subsequent Event [Member] Change in cash and cash equivalents classified as held for sale Net Change In Cash And Cash Equivalents Classified As Held For Sale Net Change In Cash And Cash Equivalents Classified As Held For Sale Options outstanding, beginning (dollars per share) Options outstanding, ending (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Common stock authorized (shares) Common Stock, Shares Authorized Schedule of Restricted Stock Unit Activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Property, plant and equipment, gross Property, Plant and Equipment, Gross Schedule of Segment Revenue and Operating Income (Loss) Schedule of Segment Reporting Information, by Segment [Table Text Block] Income Statement [Abstract] Income Statement [Abstract] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities Investments Classified by Contractual Maturity Date [Table Text Block] Gain on sale of assets Gain (Loss) on Disposition of Assets Advance Medicare payments to provide relief from economic impacts of COVID-19 CARES Act Of 2020 Medicare Payment Amount CARES Act of 2020 Medicare payment amount. Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Accrued royalties Accrued Royalties, Current Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Current assets: Assets, Current [Abstract] Interest income Investment Income, Interest Income Tax Authority [Domain] Income Tax Authority [Domain] Share repurchase program, remaining repurchase authorization Stock Repurchase Program, Remaining Authorized Repurchase Amount Comprehensive loss attributable to Myriad Genetics, Inc. stockholders Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Scenario [Domain] Scenario [Domain] Molecular diagnostic - Prenatal Molecular Diagnostic Prenatal Testing [Member] Molecular diagnostic Prenatal testing. City Area Code City Area Code Establishment of operating lease right-of-use assets and lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Income Tax Authority [Axis] Income Tax Authority [Axis] Document Period End Date Document Period End Date Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Shares available for issuance under the Plan Common Stock, Capital Shares Reserved for Future Issuance Share repurchase program, authorized amount Stock Repurchase Program, Authorized Amount Other Long-Term Liabilities Other Liabilities Disclosure [Text Block] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Schedule of Total Revenue by Product and by U.S versus Rest of World Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Less: intangible assets held for sale, gross Disposal Group, Including Discontinued Operation, Intangible Assets, Gross, Current Disposal Group, Including Discontinued Operation, Intangible Assets, Gross, Current Capital expenditures Payments to Acquire Productive Assets Unrecognized tax benefits Increase (Decrease) In Unrecognized Tax Benefits Increase (decrease) in unrecognized tax benefits. Revenue recognized due to expanded local coverage determination for which revenue was previously constrained Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained Payment of tax withheld for common stock issued under stock-based compensation plans Payment, Tax Withholding, Share-based Payment Arrangement Cover [Abstract] Cover [Abstract] Measurement Input Type Measurement Input Type [Axis] Non-employee director Non Employee Director [Member] Non employee director. Shares repurchased Stock Repurchased and Retired During Period, Shares Long-term debt discount Debt Instrument, Unamortized Discount, Noncurrent Molecular diagnostic - Tumor Profiling Molecular Diagnostic Tumor Profiling [Member] Molecular Diagnostic Tumor Profiling Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Less: intangible assets held for sale, accumulated amortization Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Current Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Current Debt, net Long-term Debt Goodwill [Line Items] Goodwill [Line Items] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Customer relationships Customer Relationships [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Cost of revenue Cost of Goods and Services Sold Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Available-for-sale, Estimated fair value Debt Securities, Available-for-sale Purchased licenses and technologies Purchased Licenses And Technologies [Member] Purchased licenses and technologies. Total, Gross unrealized holding gains Investments And Cash, Accumulated Gross Unrealized Gain, before Tax Investments And Cash, Accumulated Gross Unrealized Gain, before Tax Total costs and expenses Costs and Expenses Award Date [Domain] Award Date [Domain] Equity Components Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Current maturities of operating lease liabilities Operating Lease, Liability, Current Award Date [Axis] Award Date [Axis] Unrecognized stock-based compensation expense related to RSUs Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Net loss attributable to non-controlling interest Net Income (Loss) Attributable to Noncontrolling Interest RSUs canceled (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Entity Interactive Data Current Entity Interactive Data Current Total, Estimated fair value Total, Estimated fair value Investments and Cash U.S. UNITED STATES Options exercised (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Revenues: Revenues [Abstract] Diagnostics Diagnostics [Member] Diagnostics. Fair Value Measurements Fair Value Disclosures [Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Preferred and Common Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Schedule of Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Accounts receivable Accounts Receivable [Member] Customer [Domain] Customer [Domain] Assets held for sale Total assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Additional paid-in capital Additional Paid in Capital, Common Stock Other assets Disposal Group, Including Discontinued Operation, Other Assets, Current Molecular Diagnostic - Autoimmune Molecular Diagnostic Autoimmune [Member] Molecular Diagnostic Autoimmune Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Revenue and Concentration Risk [Line Items] Concentration Risk [Line Items] Current portion of long-term debt Debt Instrument, Carrying Amount, Current Amount, before unamortized (discount) premium and debt issuance costs, of current portion of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. Change in earnings (loss) per share (dollars per share) Increase Decrease In Earnings Loss Per Share Increase decrease in earnings (loss) per share. Eighth Share Repurchase Program Eighth Share Repurchase Program [Member] Eighth share repurchase program. Options, Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Gross Carrying Amount, total Intangible Assets, Gross (Excluding Goodwill) Number of reportable segments Number of Reportable Segments Change in the fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Available-for-sale, Due within one year Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One Research and development expense Research and Development Expense [Member] Change in fair value of contingent consideration Change In Fair Value Of Contingent Consideration Change in fair value of contingent consideration. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Held for sale Disposal Group, Held-for-sale, Not Discontinued Operations [Member] Trade accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Prepayments Contract With Customer, Liability, Prepayments Contract with customer, liability, prepayments. Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Available-for-sale, Gross unrealized holding losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trademarks Trademarks [Member] Disposed of by sale Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Goodwill Beginning balance Ending balance Goodwill Schedule of Available-for-sale Securities [Line Items] Debt Securities, Available-for-sale [Line Items] Available-for-sale, Due within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Other comprehensive income (loss), net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Document Transition Report Document Transition Report Title of Individual [Axis] Title of Individual [Axis] Short-term contingent consideration Business Combination, Contingent Consideration, Liability, Current Share-Based Compensation Expense [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Capitalized costs incurred to obtain or fulfill contract Capitalized Contract Cost, Gross In-process research and development In Process Research And Development With Indefinite Lives [Member] In process research and development with indefinite lives. Other income (expense): Nonoperating Income (Expense) [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Available-for-sale, Due after five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Cash consideration Disposal Group, Including Discontinued Operation, Consideration Document Quarterly Report Document Quarterly Report Molecular diagnostic - Other Molecular Diagnostic Other Testing [Member] Molecular diagnostic other testing. Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Equity [Abstract] Equity [Abstract] Financial assets Assets, Fair Value Disclosure Divestitures Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Deferred revenues Deferred revenue - beginning balance Deferred revenue - ending balance Contract with Customer, Liability, Current Subsequent Event [Line Items] Subsequent Event [Line Items] Options granted (dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Intangible Assets [Line Items] Intangible Assets [Line Items] Intangible assets. Customer concentration Customer Concentration Risk [Member] Credit Facility [Domain] Credit Facility [Domain] Diluted (shares) Weighted-average shares outstanding and dilutive securities used to compute diluted EPS Weighted Average Number of Shares Outstanding, Diluted 2012 Purchase Plan Employee Stock Purchase Plan Twenty Twelve [Member] Employee Stock Purchase Plan Twenty Twelve [Member] Schedule of Fair Value of Financial Assets and Liabilities Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Prepaid expenses Increase (Decrease) in Prepaid Expenses, Other Basic (in dollars per share) Earnings Per Share, Basic Entity File Number Entity File Number 2017 Plan Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member] Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan RSUs canceled (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Other liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Current Schedule of Assets and Liabilities Classified as Held For Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Contingent consideration Contingent Consideration [Member] Contingent consideration. Revenue, remaining performance obligation Revenue, Remaining Performance Obligation, Amount Total stock-based compensation expense Share-based Payment Arrangement, Expense Total, Amortized cost Investments And Cash, Amortized Cost Investments And Cash, Amortized Cost Unrecognized tax benefits Unrecognized Tax Benefits Weighted average shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Common stock, 77.7 million and 75.4 million shares outstanding at June 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Disposal Group Name [Axis] Disposal Group Name [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Current portion of long-term debt Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Inventory Disposal Group, Including Discontinued Operation, Inventory, Current Change in fair value recognized in the income statement Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Reconciliation of Deferred Revenue Change in Contract with Customer, Liability [Abstract] Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Subsequent Event [Table] Subsequent Event [Table] Purchases of marketable investment securities Payments to Acquire Debt Securities, Available-for-sale Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Non-controlling interest Stockholders' Equity Attributable to Noncontrolling Interest RSUs granted (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Common stock issued (shares) Beginning common stock issued Common stock issued at end of period Common Stock, Shares, Issued CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Cash and cash equivalents Cash and cash equivalents, Amortized cost Cash and Cash Equivalents, at Carrying Value Gain on deconsolidation of subsidiary Deconsolidation, Gain (Loss), Amount Measurement period for earn out liability Business Combination, Contingent Consideration, Liability, Measurement Input, Term Business Combination, Contingent Consideration, Liability, Measurement Input, Term New Jersey New Jersey Division of Taxation [Member] Divestitures [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Long-term debt Long-term debt, net Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Trade accounts receivable Increase (Decrease) in Accounts Receivable Debt Instrument [Line Items] Debt Instrument [Line Items] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total Myriad Genetics, Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Liabilities held for sale Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Concentration Risk Type [Domain] Concentration Risk Type [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Employee compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] RSUs Restricted Stock Units (RSUs) [Member] Pharmaceutical and clinical services Pharmaceutical And Clinical Services [Member] Pharmaceutical and clinical services. Minimum unrestricted cash and cash equivalents threshold per covenant Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum Non-cash interest expense Non Cash Interest Expense Non cash interest expense. Anti-dilutive options and RSUs excluded from EPS computation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Equity Component Equity Component [Domain] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Other assets Increase (Decrease) in Other Noncurrent Assets Property, plant, and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Entity Tax Identification Number Entity Tax Identification Number Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss attributable to Myriad Genetics, Inc. stockholders Net loss attributable to Myriad Genetics, Inc. stockholders Net loss Net Income (Loss) Attributable to Parent Other receivables Increase (Decrease) in Other Receivables Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] LIBOR London Interbank Offered Rate (LIBOR) [Member] Options and RSUs Options And Restricted Stock Units [Member] Options and Restricted Stock Units. Available-for-sale, Due after one year through five years Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Comprehensive loss attributable to non-controlling interest Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Recoupments payable and reserves Recoupments Payable And Reserve, Current Recoupments Payable And Reserve, Current Disposal Group Name [Domain] Disposal Group Name [Domain] Aggregate adjustments for working capital, indebtedness, and transaction costs Aggregate adjustments for working capital, indebtedness, and transaction costs Disposal Group, Including Discontinued Operation, Aggregate Transaction Adjustment Disposal Group, Including Discontinued Operation, Aggregate Transaction Adjustment Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Options, Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Goodwill and long-lived asset impairment charges Goodwill and Intangible Asset Impairment Total: Investments and Cash [Abstract] Non-controlling interest Noncontrolling Interest, Period Increase (Decrease) Options granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Switzerland Swiss Federal Tax Administration (FTA) [Member] LIBOR floor (percent) Debt Instrument, LIBOR Floor, Percentage Debt Instrument, LIBOR Floor, Percentage Other Other Sundry Liabilities, Noncurrent Entity Filer Category Entity Filer Category Schedule of Stock-Based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product and Service Product and Service [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Translation adjustments recognized in other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Molecular diagnostic - Hereditary Cancer Molecular Diagnostic Hereditary Cancer Testing [Member] Molecular diagnostic hereditary cancer testing. Schedule of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Leasehold improvements Leasehold Improvements [Member] Gross Carrying Amount, amortizable Finite-Lived Intangible Assets, Gross Money market funds Money Market Funds [Member] Municipal bonds Municipal Bonds [Member] Liabilities Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Prepaid taxes Increase (Decrease) in Prepaid Taxes Options exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Net increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Total other income, net Nonoperating Income (Expense) Impairment on asset group held for sale Impairment on write down of assets held for sale Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Stock options Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Basic (shares) Weighted-average shares outstanding used to compute basic EPS Weighted Average Number of Shares Outstanding, Basic Basis spread on rate (percent) Debt Instrument, Basis Spread on Variable Rate Available-for-sale: Debt Securities, Available-for-sale [Abstract] Subsequent Events [Abstract] Subsequent Events [Abstract] Debt securities, available-for-sale, in unrealized loss position Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions Change in foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Plan Name [Domain] Plan Name [Domain] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Revenue Revenue from Contract with Customer [Text Block] Tax Period [Domain] Tax Period [Domain] Total stockholders' equity Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Operating lease right-of-use assets Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] California California Franchise Tax Board [Member] Estimated fair value of long-term debt Long-term Debt, Fair Value Income tax expense (benefit) Income Tax Expense (Benefit) Accumulated Amortization, total Intangible Assets, Including Held For Sale, Accumulated Amortization Intangible Assets, Including Held For Sale, Accumulated Amortization Cash and cash equivalents at beginning of the period Cash and cash equivalents at end of the period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Maturity date Debt Instrument, Maturity Date Title of Individual [Domain] Title of Individual [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Financial liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Diluted (in dollars per share) Earnings Per Share, Diluted Held for sale reclassification Contract With Customer, Liability, Held For Sale Reclassification Contract With Customer, Liability, Held For Sale Reclassification Local Phone Number Local Phone Number Purchase commitment Recorded Unconditional Purchase Obligation Less: intangible assets held for sale, net Intangibles, net Disposal Group, Including Discontinued Operation, Intangible Assets, Current Schedule of Recorded Amortization Expense for Intangible Assets Finite-lived Intangible Assets Amortization Expense [Table Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Current Change in Fair Value of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of Non-amortizable Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Reconciliation of change in fair value of contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Schedule of Long-Term Debt Schedule of Long-term Debt Instruments [Table Text Block] Depreciation expense Depreciation Entity Address, Address Line One Entity Address, Address Line One Total net assets held for sale Disposal Group, Including Discontinued Operation, Assets, Net Of Liabilities Disposal Group, Including Discontinued Operation, Assets, Net Of Liabilities Awards granted prior to December 5, 2012 Options Granted Prior To December Five Twenty Twelve [Member] Options granted prior to December 5, 2012. Entity Emerging Growth Company Entity Emerging Growth Company Current portion of long-term debt discount Debt Instrument, Unamortized Discount, Current Non-amortizable Indefinite-lived Intangible Assets (Excluding Goodwill) Schedule Of Intangible Assets [Table] Schedule Of Intangible Assets [Table] Schedule of Intangible Assets [Table] Maximum aggregate principal commitment Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] RSUs, Weighted average grant date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Maximum Maximum [Member] Preferred stock authorized (shares) Preferred Stock, Shares Authorized Non-controlling interest Noncontrolling Interest [Member] Accumulated deficit Retained Earnings [Member] Preferred stock outstanding (shares) Preferred Stock, Shares Outstanding Goodwill held for sale reclassification Goodwill, Written off Related to Sale of Business Unit Payment of contingent consideration recognized at acquisition Payment for Contingent Consideration Liability, Financing Activities Approximate tax rate Effective Income Tax Rate Reconciliation, Percent Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Investments [Domain] Investments [Domain] Long-term Debt Long-term Debt, Unclassified [Abstract] Corporate bonds and notes Corporate Debt Securities [Member] Trading Symbol Trading Symbol Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary Options exercisable at end of period (dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Undrawn fee (percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Total Fair Value, Net Asset (Liability) Proceeds from common stock issued under stock-based compensation plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans Long-term debt Debt Instrument, Carrying Amount, Noncurrent Amount, before unamortized (discount) premium and debt issuance costs, of noncurrent long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Equipment Equipment [Member] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Income Tax Contingency [Table] Income Tax Contingency [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Molecular diagnostic testing Molecular Diagnostic Testing [Member] Molecular diagnostic testing. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 9 mygn-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 mygn-20210630_htm.xml IDEA: XBRL DOCUMENT 0000899923 2021-01-01 2021-06-30 0000899923 2021-07-28 0000899923 2021-06-30 0000899923 2020-12-31 0000899923 mygn:MolecularDiagnosticTestingMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTestingMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTestingMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTestingMember 2020-01-01 2020-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2021-04-01 2021-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2020-04-01 2020-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2021-01-01 2021-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember 2020-01-01 2020-06-30 0000899923 2021-04-01 2021-06-30 0000899923 2020-04-01 2020-06-30 0000899923 2020-01-01 2020-06-30 0000899923 us-gaap:CommonStockMember 2019-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000899923 us-gaap:RetainedEarningsMember 2019-12-31 0000899923 us-gaap:NoncontrollingInterestMember 2019-12-31 0000899923 2019-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000899923 2020-01-01 2020-03-31 0000899923 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0000899923 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000899923 us-gaap:CommonStockMember 2020-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000899923 us-gaap:RetainedEarningsMember 2020-03-31 0000899923 us-gaap:NoncontrollingInterestMember 2020-03-31 0000899923 2020-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000899923 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000899923 us-gaap:CommonStockMember 2020-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000899923 us-gaap:RetainedEarningsMember 2020-06-30 0000899923 us-gaap:NoncontrollingInterestMember 2020-06-30 0000899923 2020-06-30 0000899923 us-gaap:CommonStockMember 2020-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000899923 us-gaap:RetainedEarningsMember 2020-12-31 0000899923 us-gaap:NoncontrollingInterestMember 2020-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000899923 2021-01-01 2021-03-31 0000899923 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000899923 us-gaap:CommonStockMember 2021-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000899923 us-gaap:RetainedEarningsMember 2021-03-31 0000899923 us-gaap:NoncontrollingInterestMember 2021-03-31 0000899923 2021-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0000899923 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0000899923 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0000899923 us-gaap:CommonStockMember 2021-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000899923 us-gaap:RetainedEarningsMember 2021-06-30 0000899923 us-gaap:NoncontrollingInterestMember 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTestingMember country:US 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTestingMember country:US 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember country:US 2021-04-01 2021-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember country:US 2020-04-01 2020-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 country:US 2021-04-01 2021-06-30 0000899923 us-gaap:NonUsMember 2021-04-01 2021-06-30 0000899923 country:US 2020-04-01 2020-06-30 0000899923 us-gaap:NonUsMember 2020-04-01 2020-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticHereditaryCancerTestingMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTumorProfilingMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPrenatalTestingMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticPharmacogenomicsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticAutoimmuneMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticOtherTestingMember 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTestingMember country:US 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:MolecularDiagnosticTestingMember country:US 2020-01-01 2020-06-30 0000899923 mygn:MolecularDiagnosticTestingMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember country:US 2021-01-01 2021-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember country:US 2020-01-01 2020-06-30 0000899923 mygn:PharmaceuticalAndClinicalServicesMember us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 country:US 2021-01-01 2021-06-30 0000899923 us-gaap:NonUsMember 2021-01-01 2021-06-30 0000899923 country:US 2020-01-01 2020-06-30 0000899923 us-gaap:NonUsMember 2020-01-01 2020-06-30 0000899923 2019-07-01 2020-06-30 0000899923 mygn:PerformanceObligationEstimatedTransactionPriceMember 2021-01-01 2021-06-30 0000899923 mygn:PerformanceObligationEstimatedTransactionPriceMember 2021-04-01 2021-06-30 0000899923 mygn:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-04-01 2021-06-30 0000899923 mygn:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000899923 mygn:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-04-01 2020-06-30 0000899923 mygn:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-06-30 0000899923 mygn:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-06-30 0000899923 us-gaap:CashMember 2021-06-30 0000899923 us-gaap:CashEquivalentsMember 2021-06-30 0000899923 us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:MunicipalBondsMember 2021-06-30 0000899923 us-gaap:USTreasuryAndGovernmentMember 2021-06-30 0000899923 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:CashMember 2020-12-31 0000899923 us-gaap:CashEquivalentsMember 2020-12-31 0000899923 us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:MunicipalBondsMember 2020-12-31 0000899923 us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000899923 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2021-01-01 2021-06-30 0000899923 us-gaap:FairValueInputsLevel3Member 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2021-06-30 0000899923 us-gaap:MoneyMarketFundsMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalBondsMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:MunicipalBondsMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-06-30 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member 2021-06-30 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel2Member 2021-06-30 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2021-06-30 0000899923 mygn:ContingentConsiderationMember 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member 2021-06-30 0000899923 us-gaap:FairValueInputsLevel2Member 2021-06-30 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MoneyMarketFundsMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:MoneyMarketFundsMember 2020-12-31 0000899923 us-gaap:MoneyMarketFundsMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:CorporateDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:MunicipalBondsMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:MunicipalBondsMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:MunicipalBondsMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USTreasuryAndGovernmentMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0000899923 mygn:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0000899923 mygn:ContingentConsiderationMember 2020-12-31 0000899923 us-gaap:FairValueInputsLevel1Member 2020-12-31 0000899923 us-gaap:FairValueInputsLevel2Member 2020-12-31 0000899923 us-gaap:FairValueInputsLevel3Member 2020-12-31 0000899923 mygn:MyriadAutoimmuneAssetsAndMyriadRBMIncMember 2021-04-01 2021-06-30 0000899923 us-gaap:LeaseholdImprovementsMember 2021-06-30 0000899923 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000899923 us-gaap:EquipmentMember 2021-06-30 0000899923 us-gaap:EquipmentMember 2020-12-31 0000899923 mygn:DiagnosticsMember 2020-12-31 0000899923 us-gaap:AllOtherSegmentsMember 2020-12-31 0000899923 mygn:DiagnosticsMember 2021-01-01 2021-06-30 0000899923 us-gaap:AllOtherSegmentsMember 2021-01-01 2021-06-30 0000899923 mygn:DiagnosticsMember 2021-06-30 0000899923 us-gaap:AllOtherSegmentsMember 2021-06-30 0000899923 mygn:PurchasedLicensesAndTechnologiesMember 2021-06-30 0000899923 us-gaap:CustomerRelationshipsMember 2021-06-30 0000899923 us-gaap:TrademarksMember 2021-06-30 0000899923 mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember 2021-06-30 0000899923 mygn:PurchasedLicensesAndTechnologiesMember 2020-12-31 0000899923 us-gaap:CustomerRelationshipsMember 2020-12-31 0000899923 us-gaap:TrademarksMember 2020-12-31 0000899923 mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember 2020-12-31 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2018-07-31 2018-07-31 0000899923 us-gaap:RevolvingCreditFacilityMember 2016-12-23 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2018-07-31 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2020-12-31 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2021-02-21 0000899923 srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2021-09-30 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2021-06-30 0000899923 srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-04-01 2022-06-30 0000899923 srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2020-04-01 2022-06-30 0000899923 srt:MinimumMember srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-07-01 2022-07-01 0000899923 srt:MaximumMember srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-07-01 2022-07-01 0000899923 srt:MinimumMember srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2022-07-01 2022-07-01 0000899923 srt:MaximumMember srt:ScenarioForecastMember us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember 2022-07-01 2022-07-01 0000899923 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-06-30 0000899923 us-gaap:RevolvingCreditFacilityMember 2020-07-01 2020-12-31 0000899923 mygn:EighthShareRepurchaseProgramMember 2016-06-30 0000899923 mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember 2021-06-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0000899923 mygn:NonEmployeeDirectorMember mygn:OptionsAndRestrictedStockUnitsMember 2021-01-01 2021-06-30 0000899923 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000899923 mygn:OptionsGrantedAfterDecemberFiveTwentyTwelveMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000899923 mygn:OptionsGrantedPriorToDecemberFiveTwentyTwelveMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2021-06-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2021-06-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2021-04-01 2021-06-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2020-04-01 2020-06-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2021-01-01 2021-06-30 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2020-01-01 2020-06-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2021-04-01 2021-06-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2020-04-01 2020-06-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2021-01-01 2021-06-30 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2020-01-01 2020-06-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-04-01 2021-06-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-06-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0000899923 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:StateAndLocalJurisdictionMember us-gaap:CaliforniaFranchiseTaxBoardMember us-gaap:LatestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewJerseyDivisionOfTaxationMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewJerseyDivisionOfTaxationMember us-gaap:LatestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:StateAndLocalJurisdictionMember us-gaap:NewYorkStateDivisionOfTaxationAndFinanceMember us-gaap:LatestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:ForeignCountryMember us-gaap:FederalMinistryOfFinanceGermanyMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:ForeignCountryMember us-gaap:FederalMinistryOfFinanceGermanyMember us-gaap:LatestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember us-gaap:EarliestTaxYearMember 2021-01-01 2021-06-30 0000899923 us-gaap:ForeignCountryMember us-gaap:SwissFederalTaxAdministrationFTAMember us-gaap:LatestTaxYearMember 2021-01-01 2021-06-30 0000899923 mygn:DiagnosticsMember 2021-04-01 2021-06-30 0000899923 us-gaap:AllOtherSegmentsMember 2021-04-01 2021-06-30 0000899923 mygn:DiagnosticsMember 2020-04-01 2020-06-30 0000899923 us-gaap:AllOtherSegmentsMember 2020-04-01 2020-06-30 0000899923 mygn:DiagnosticsMember 2020-01-01 2020-06-30 0000899923 us-gaap:AllOtherSegmentsMember 2020-01-01 2020-06-30 0000899923 mygn:MyriadMyPathLLCLaboratoryMember 2021-05-28 2021-05-28 0000899923 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mygn:MyriadAutoimmuneAssetsMember 2021-05-01 0000899923 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember mygn:MyriadRBMIncMember 2021-05-21 0000899923 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2021-04-01 2021-06-30 0000899923 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember 2021-06-30 0000899923 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember mygn:MyriadRBMIncMember us-gaap:SubsequentEventMember 2021-07-01 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember us-gaap:SubsequentEventMember 2021-07-01 0000899923 us-gaap:SubsequentEventMember 2021-07-31 2021-07-31 0000899923 us-gaap:RevolvingCreditFacilityMember mygn:AmendmentToCreditAgreementMember us-gaap:SubsequentEventMember 2021-08-04 shares iso4217:USD iso4217:USD shares pure mygn:security mygn:segment false 0000899923 --12-31 2021 Q2 10-Q true 2021-06-30 false 0-26642 MYRIAD GENETICS, INC. DE 320 Wakara Way Salt Lake City UT 87-0494517 84108 801 584-3600 Common Stock, $0.01 par value MYGN NASDAQ Yes Yes Large Accelerated Filer false false false 78055365 118400000 117000000.0 46000000.0 33700000 94800000 89500000 17700000 27100000 225700000 0 18600000 108400000 17700000 13700000 538900000 389400000 86600000 59700000 19900000 21000000.0 43200000 40700000 426800000 576500000 240100000 329200000 4800000 2300000 1360300000 1418800000 28500000 20500000 90900000 79100000 12700000 13600000 22600000 32700000 12200000 0 104100000 0 271000000.0 145900000 31000000.0 30500000 58200000 71300000 83900000 50600000 0 224800000 13800000 14700000 457900000 537800000 77700000 75400000 800000 800000 1176900000 1109500000 -4000000.0 -2300000 -271200000 -227000000.0 902500000 881000000.0 -100000 0 902400000 881000000.0 1360300000 1418800000 178700000 83300000 338300000 233800000 10700000 9900000 24200000 23400000 189400000 93200000 362500000 257200000 48000000.0 32200000 92100000 75300000 5700000 4500000 11900000 11500000 19500000 17400000 42600000 37100000 134800000 107400000 280300000 240300000 400000 0 1300000 -3400000 1800000 0 1800000 98400000 210200000 161500000 430000000.0 459200000 -20800000 -68300000 -67500000 -202000000.0 200000 500000 400000 1300000 2000000.0 3100000 5000000.0 5400000 18800000 12400000 18700000 16500000 17000000.0 9800000 14100000 12400000 -3800000 -58500000 -53400000 -189600000 900000 -3000000.0 -9200000 -18900000 -4700000 -55500000 -44200000 -170700000 0 -100000 0 -100000 -4700000 -55400000 -44200000 -170600000 -0.06 -0.06 -0.74 -0.74 -0.58 -0.58 -2.29 -2.29 77200000 77200000 74600000 74600000 76600000 76600000 74600000 74600000 -4700000 -55400000 -44200000 -170600000 -100000 800000 -300000 700000 -300000 1800000 -1400000 -700000 -5100000 -52800000 -45900000 -170600000 0 0 0 0 -5100000 -52800000 -45900000 -170600000 700000 1085100000 -5300000 -3300000 100000 1077300000 200000 200000 7500000 7500000 -100000 -100000 -115200000 -115200000 100000 100000 -2600000 -2600000 700000 1092800000 -7800000 -118500000 0 967200000 1900000 1900000 1900000 1900000 -55400000 -55400000 2600000 2600000 700000 1096600000 -5200000 -173900000 0 918200000 800000 1109500000 -2300000 -227000000.0 0 881000000.0 26000000.0 26000000.0 9000000.0 9000000.0 -39500000 -39500000 -1300000 -1300000 800000 1144500000 -3600000 -266500000 0 875200000 23500000 23500000 8900000 8900000 -100000 -100000 -4700000 -4700000 -400000 -400000 800000 1176900000 -4000000.0 -271200000 -100000 902400000 -44200000 -170600000 35300000 35600000 800000 300000 6800000 6300000 17900000 9400000 11500000 49000000.0 400000 1000000.0 1300000 -3400000 6600000 0 1800000 98400000 0 1000000.0 32400000 0 4700000 -2400000 12300000 -50300000 -300000 -900000 800000 900000 -89800000 -24700000 2700000 0 8100000 600000 16100000 12700000 -9200000 29100000 67400000 46800000 11600000 5300000 0 21300000 32500000 0 36600000 15800000 25000000.0 33400000 9300000 33600000 50100000 2200000 600000 100000 3300000 0 1200000 1000000.0 120000000.0 0 -75000000.0 1100000 -300000 -500000 0 1500000 1400000 82500000 117000000.0 81200000 118400000 163700000 BASIS OF PRESENTATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad Genetics, Inc. and subsidiaries (collectively, the “Company” or “Myriad”) discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empowering every individual by revealing the answers inside each of us. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period ended December 31, 2020 (the “Transition Report on Form 10-K”). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30. Additionally, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the COVID-19 global pandemic (“COVID-19”), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company’s year over year results may not be comparable. Management continues to monitor the impacts of COVID-19, including variants of COVID-19, on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. The Company is not able to estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Sale Policy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net assets held for sale represent property, plant, and equipment, intangibles, and other assets and liabilities that have met the criteria of "held for sale" accounting, as specified by ASC 360, Property, Plant, and Equipment, and are recorded at the lower of carrying value or fair value less costs to sell. Fair value is based on the estimated proceeds from the sale of the net assets utilizing recent purchase agreements and costs to sell include direct costs that are estimable and probable. The Company expects to complete the sale of these net assets within twelve months following their initial classification as held for sale. See Note 16 for additional information regarding assets and liabilities held for sale.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.</span></div><div style="margin-top:6pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with no material impact to t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company's Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period ended December 31, 2020 (the “Transition Report on Form 10-K”). </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Sale Policy</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net assets held for sale represent property, plant, and equipment, intangibles, and other assets and liabilities that have met the criteria of "held for sale" accounting, as specified by ASC 360, Property, Plant, and Equipment, and are recorded at the lower of carrying value or fair value less costs to sell. Fair value is based on the estimated proceeds from the sale of the net assets utilizing recent purchase agreements and costs to sell include direct costs that are estimable and probable. The Company expects to complete the sale of these net assets within twelve months following their initial classification as held for sale. See Note 16 for additional information regarding assets and liabilities held for sale.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Standards</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with no material impact to t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company's Condensed Consolidated Financial Statements.</span></div> REVENUE<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myriad generates revenue by performing molecular diagnostic testing and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Autoimmune (Vectra), and Other. The Company previously provided clinical services until selling Privatklinik Dr. Robert Schindlbeck GmbH &amp; Co. KG (the “Clinic”) in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 as described in Note 16, Myriad myPath revenue was included in Other within molecular diagnostic revenues. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">338.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held for sale reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical services that may have terms longer than one year and include multiple performance obligations. As of June 30, 2021, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $6.7 million. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and six months ended June 30, 2021, the Company recognized $13.3 million and $13.2 million in revenue, respectively, which resulted in a $0.13 impact to earnings per share to each period for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $6.8 million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 16% and 18% of total revenue for the three and six months ended June 30, 2021, respectively, and 12% and 15% of total revenue for the three and six months ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. Medicare accounted for 11% of accounts receivable at June 30, 2021. No payor accounted for more than 10% of accounts receivable at December 31, 2020. The Company does not require collateral from its customers.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">RoW</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molecular diagnostic revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hereditary Cancer</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tumor Profiling</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prenatal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacogenomics</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Autoimmune</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total molecular diagnostic revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">295.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">338.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">233.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical and clinical service revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">319.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">239.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 73800000 12200000 86000000.0 34900000 5000000.0 39900000 18100000 11100000 29200000 8600000 1900000 10500000 29200000 200000 29400000 16500000 100000 16600000 22600000 0 22600000 8500000 0 8500000 10200000 0 10200000 7300000 0 7300000 200000 1100000 1300000 500000 0 500000 154100000 24600000 178700000 76300000 7000000.0 83300000 10700000 0 10700000 9900000 0 9900000 164800000 24600000 189400000 86200000 7000000.0 93200000 138900000 23200000 162100000 116200000 8900000 125100000 42300000 17900000 60200000 19300000 4900000 24200000 52800000 300000 53100000 36700000 200000 36900000 40200000 0 40200000 28900000 0 28900000 20900000 0 20900000 17700000 0 17700000 200000 1600000 1800000 1000000.0 0 1000000.0 295300000 43000000.0 338300000 219800000 14000000.0 233800000 24200000 0 24200000 19500000 3900000 23400000 319500000 43000000.0 362500000 239300000 17900000 257200000 29700000 A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - beginning balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.7 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepayments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held for sale reclassification</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue - ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 32700000 3600000 15500000 6100000 6300000 35300000 900000 0 22600000 32800000 6700000 13300000 13200000 0.13 0.13 6800000 0 0.16 0.18 0.12 0.15 0.11 MARKETABLE INVESTMENT SECURITIES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.8 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.7 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no debt securities classified as available-for-sale in a gross unrealized loss position as of June 30, 2021 or December 31, 2020.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information relating to fair value of marketable investment securities can be found in Note 4.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>unrealized<br/>holding<br/>losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47.9 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.8 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.8 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171.7 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 60400000 60400000 58000000.0 58000000.0 118400000 118400000 46100000 300000 0 46400000 13200000 100000 0 13300000 2500000 0 0 2500000 3700000 0 0 3700000 183900000 400000 0 184300000 47900000 47900000 69100000 69100000 117000000.0 117000000.0 28800000 500000 0 29300000 9400000 200000 0 9600000 4000000.0 0 0 4000000.0 11700000 100000 0 11800000 170900000 800000 0 171700000 <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2021:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated<br/>fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due within one year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after one year through five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due after five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183.9 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 60400000 60400000 58000000.0 58000000.0 45800000 46000000.0 19700000 19900000 0 0 183900000 184300000 0 0 FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—unobservable inputs.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 14.0 years, utilizing various potential pay-out scenarios.  Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.  Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company’s long-term debt, which it considers a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements.  The fair value of the Company's long-term debt is estimated to be $106.0 million at June 30, 2021. As of June 30, 2021, the Company intended to pay off the remaining balance of debt during the quarter ended September 30, 2021. As such, long-term debt was reclassified to Current portion of long-term debt in the Company's Condensed Consolidated Balance Sheets as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility (as defined in Note 8) on July 30, 2021, which is described in Note 17.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.4 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:6pt;padding-left:36pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company's assets and liabilities are also subject to nonrecurring fair value measurements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the approval of the Company's Board of Directors to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> test, from the Myriad Autoimmune business unit during the quarter ended June 30, 2021, the Company performed an interim impairment analysis for the assets held for sale. The Company did not recognize any impairment charges on the asset groups classified as held for sale. The fair value used in the analysis, which the Company considers a Level 2 measurement, was based on the sale prices of Myriad RBM, Inc. and the Myriad Autoimmune assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2020</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the income statement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> P14Y 106000000.0 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2021</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115.4 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds (a)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate bonds and notes</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Municipal bonds</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal agency issues</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US government securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69.1 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112.9 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:27.13pt">Money market funds are primarily comprised of exchange traded funds and accrued interest.</span></div> 58000000.0 0 0 58000000.0 0 46400000 0 46400000 0 13300000 0 13300000 0 2500000 0 2500000 0 3700000 0 3700000 0 0 8500000 8500000 58000000.0 65900000 -8500000 115400000 69100000 0 0 69100000 0 29300000 0 29300000 0 9600000 0 9600000 0 4000000.0 0 4000000.0 0 11800000 0 11800000 0 0 10900000 10900000 69100000 54700000 -10900000 112900000 0 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance December 31, 2020</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value recognized in the income statement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translation adjustments recognized in other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance June 30, 2021</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.5 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10900000 3300000 -1300000 400000 8500000 PROPERTY, PLANT AND EQUIPMENT, NET<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146.1 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153.6 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.2 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.7 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117.9 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, gross</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146.1 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153.6 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less accumulated depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(102.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.2 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.7 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.3 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 36500000 35700000 109600000 117900000 146100000 153600000 102900000 112900000 43200000 40700000 3400000 2500000 6300000 5100000 GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the six months ended June 30, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill held for sale reclassification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Company's entry into definitive agreements to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> test, from the Myriad Autoimmune business unit, the Company classified a portion of goodwill as assets held for sale. See Note 16 for further discussion.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">817.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(276.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">540.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">824.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(282.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: intangible assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(211.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(119.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">618.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">576.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill for the six months ended June 30, 2021:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.716%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diagnostic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill held for sale reclassification</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 272300000 56900000 329200000 31600000 56900000 88500000 -600000 0 -600000 240100000 0 240100000 The following summarizes the amounts reported as intangible assets:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">817.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(276.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">540.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">824.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(282.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: intangible assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(211.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(119.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">618.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">576.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> The following summarizes the amounts reported as intangible assets:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2021:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">817.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(276.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">540.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">824.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(282.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: intangible assets held for sale</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(211.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(119.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">618.1 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(191.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">426.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased licenses and technologies</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">818.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(248.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">570.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.5)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">825.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">571.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total unamortized intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total intangible assets</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">830.7 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(254.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">576.5 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 817100000 276600000 540500000 4700000 4700000 0 3000000.0 1600000 1400000 824800000 282900000 541900000 4800000 4800000 4800000 4800000 211500000 91600000 119900000 618100000 191300000 426800000 818200000 248200000 570000000.0 4700000 4500000 200000 3000000.0 1500000 1500000 825900000 254200000 571700000 4800000 4800000 4800000 4800000 830700000 254200000 576500000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.2 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13500000 15200000 29000000.0 30500000 ACCRUED LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoupments payable and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued taxes payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recoupments payable and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchase commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 50700000 48900000 3700000 4300000 8100000 9300000 0 3400000 5000000.0 3800000 5900000 0 17500000 9400000 90900000 79100000 LONG-TERM DEBT<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) by and among Myriad, as borrower, and the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 which effected an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million. On May 1, 2020, the Company entered into Amendment No. 2, which waived the Company’s compliance with certain financial covenants, amended compliance with certain operating covenants, and modified the interest rate and other terms during a modification period from March 31, 2020 through June 30, 2021 (the “Modification Period”). On February 22, 2021, the Company entered into Amendment No. 3 (the “Amended Facility”), which, among other things, decreased the maximum aggregate principal commitment from $350.0 million to $300.0 million, with a further reduction in the maximum aggregate principal commitment from $300.0 million to $250.0 million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company’s compliance with certain financial covenants through the quarter ending March 31, 2022, extended the Modification Period for an additional year, through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. There are no scheduled principal payments of the Amended Facility prior to its maturity date.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balance and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. The interest rate as of June 30, 2021 was 4.5%.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. A minimum liquidity covenant was added for the period beginning May 1, 2020 until March 31, 2021, and a minimum EBITDA covenant was added for the quarters ended December 31, 2020 and March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ending March 31, 2022 and also lowered the minimum liquidity covenant applicable through such quarter. Amendment No. 3 also removed the minimum EBITDA covenant and restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0 million, unless such borrowings are in connection with acquisitions. The Company was in compliance with all applicable financial covenants at June 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, the Company made principal repayments totaling $120.0 million on the Amended Facility. During the transition period ended December 31, 2020, the Company did not make any principal repayments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries and each such domestic subsidiary of Myriad has guaranteed the repayment of the Amended Facility. As of June 30, 2021, the Company intended to use the proceeds from the sale of Myriad RBM, Inc. to make a voluntary repayment in full on the Amended Facility during the quarter ended September 30, 2021. As a result, the Company classified the entire outstanding balance as current in its Condensed Consolidated Financial Statements as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility on July 30, 2021, which is described in Note 17. Also, see Note 17 for information on the sale of Myriad RBM, Inc. Amounts outstanding under the Amended Facility were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2023-07-31 300000000.0 350000000.0 350000000.0 300000000.0 300000000.0 250000000.0 0 0.0350 0.0050 0.0150 0.0250 0.0025 0.0045 0.010 0.045 150000000.0 120000000.0 0 Amounts outstanding under the Amended Facility were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30, <br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, <br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">226.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current portion of long-term debt discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">224.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 226700000 0 1900000 0 224800000 106400000 0 2300000 0 104100000 224800000 OTHER LONG-TERM LIABILITIES<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>The Company's balance of other long-term liabilities as of June 30, 2021 and December 31, 2020 consists of the Company’s portion of social security taxes that have been deferred under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) that do not have to be remitted until December 2022. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.037%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 8500000 7400000 5300000 7300000 13800000 14700000 PREFERRED AND COMMON STOCKHOLDERS' EQUITY<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at June 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 77.7 million shares issued and outstanding at June 30, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.  Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.  In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Repurchase Program</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company’s Board of Directors authorized a share repurchase program of $200.0 million of the Company’s outstanding common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.  As of June 30, 2021, the Company is authorized to repurchase up to $110.7 million of shares under this authorization. No shares were repurchased during the six months ended June 30, 2021 or 2020.</span></div> 5000000.0 0.01 0 150000000.0 0.01 77700000 77700000 <div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common shares issued and outstanding</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning common stock issued and outstanding</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.5 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock issued and outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.7 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 75400000 75400000 74500000 74500000 2300000 200000 77700000 77700000 74700000 74700000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding used to compute basic EPS</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effect of dilutive shares</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77.2 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74.6 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 77200000 74600000 76600000 74600000 0 0 0 0 77200000 74600000 76600000 74600000 These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive options and RSUs excluded from EPS computation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 7000000.0 7100000 200000000.0 110700000 0 0 STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of June 30, 2021, the Company has 3.6 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares, terms, and vesting periods are generally determined by the Company’s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to non-employee directors vest in full upon completion of one year of service on the anniversary following the date of the grant. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.24 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.81 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at June 30, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.25 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there was $3.4 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 2.1 years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.56 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.54 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2021, there was $74.5 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">weighted-average period of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2.5 years. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the “2012 Purchase Plan”), under which 2.0 million shares of common stock have been authorized.  Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.  As of June 30, 2021, approximately 0.1 million shares of common stock are available for issuance under the 2012 Purchase Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3600000 P4Y P1Y P4Y P8Y P10Y <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.24 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.93 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options canceled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.81 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at June 30, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.0 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.42 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercisable at June 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4 </span></td><td style="background-color:#cff0fc;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.25 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5200000 23.24 0 0 2100000 22.93 100000 24.81 3000000.0 23.42 2400000 26.25 3400000 P2Y1M6D <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2021 is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(number of shares in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number<br/>of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20.56 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.89 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.88 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs canceled</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.6)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.54 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs outstanding at June 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.0 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3200000 20.56 1500000 29.89 100000 18.88 600000 24.54 4000000.0 23.72 74500000 P2Y6M 2000000.0 100000 <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of molecular diagnostic testing</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of pharmaceutical and clinical services</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general, and administrative expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.6 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">     Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.9 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.4 </span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 400000 300000 700000 700000 0 100000 100000 200000 1000000.0 1200000 2500000 2300000 7500000 300000 14600000 6200000 8900000 1900000 17900000 9400000 INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for the three months ended June 30, 2021 was $0.9 million, or approximately (23.7)% of pre-tax loss compared to an income tax benefit of $3.0 million, or approximately 5.1% of pre-tax loss, for the three months ended June 30, 2020.  Income tax expense for the three months ended June 30, 2021 is based on the Company’s estimated annualized effective tax rate for the fiscal year ending December 31, 2021, adjusted for discrete items recognized during the period.  For the three months ended June 30, 2021, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, carrying back net operating losses under the provisions of the CARES Act, and release of a valuation allowance.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.  The Company is currently under audit by the State of California for the fiscal years June 30, 2017-2018, the State of New Jersey for the fiscal years June 30, 2013-2017; the State of New York for the fiscal years June 30, 2016-2018; Germany for the fiscal years June 30, 2013-2015; and Switzerland for the fiscal years June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.</span></div> 900000 -0.237 -3000000.0 0.051 2017 2018 2013 2017 2016 2018 2013 2015 2015 2016 COMMITMENTS AND CONTINGENCIESThe Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of June 30, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments. SEGMENT AND RELATED INFORMATIONThe Company’s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and operating income (loss) were as follows during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss for reportable segments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.8)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68.3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67.5)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.0)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated amounts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.8 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(189.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(170.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(170.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenue and operating income (loss) were as follows during the periods presented:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Diagnostics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(33.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(34.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six months ended June 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">362.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(115.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six months ended June 30, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">231.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">257.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment operating loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(127.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(74.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.215%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three months ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating loss for reportable segments</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20.8)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(68.3)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(67.5)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(202.0)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unallocated amounts:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.3 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.8 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.4 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.7 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.5 </span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(189.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9 </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.0)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9.2)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18.9)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(170.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Myriad Genetics, Inc. stockholders</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(170.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 177100000 12300000 189400000 15700000 1200000 16900000 37500000 -58300000 -20800000 81000000.0 12200000 93200000 16700000 1000000.0 17700000 -33800000 -34500000 -68300000 334900000 27600000 362500000 32700000 2600000 35300000 48000000.0 -115500000 -67500000 231500000 25700000 257200000 33500000 2100000 35600000 -127400000 -74600000 -202000000.0 -20800000 -68300000 -67500000 -202000000.0 200000 500000 400000 1300000 2000000.0 3100000 5000000.0 5400000 18800000 12400000 18700000 16500000 -3800000 -58500000 -53400000 -189600000 900000 -3000000.0 -9200000 -18900000 -4700000 -55500000 -44200000 -170700000 0 -100000 0 -100000 -4700000 -55400000 -44200000 -170600000 SUPPLEMENTAL CASH FLOW INFORMATION<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value adjustment on marketable investment securities recorded to stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six months ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid during the period for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received for income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value adjustment on marketable investment securities recorded to stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Establishment of operating lease right-of-use assets and lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1700000 1000000.0 1700000 4300000 89900000 0 -300000 700000 40500000 0 46700000 0 DIVESTITURES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2021, the Company entered into a definitive agreement with Castle Biosciences, Inc. for the sale of the Myriad myPath, LLC laboratory, which is the laboratory that offers the myPath Melanoma test. The transaction subsequently closed on May 28, 2021, and the Myriad myPath, LLC laboratory was sold for total cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a net gain of $31.2 million, in Other income on the Company’s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company’s diagnostics reporting segment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Held for Sale</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 1, 2021, the Company entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit (the "Autoimmune Business Transaction") to Laboratory Corporation of America Holdings for total cash consideration of $150.0 million. The Autoimmune Business Transaction is expected to close during the quarter ending September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 21, 2021, the Company entered into a definitive agreement to sell Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. This transaction closed on July 1, 2021.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured these businesses at the lower of their carrying value or fair value less any costs to sell. No impairment was recognized on the held for sale assets during the quarter ended June 30, 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations. The operations of the Myriad Autoimmune business and Myriad RBM, Inc. are included in the Company's diagnostics reporting segment and other reporting segment, respectively. The following table presents information related to the assets and liabilities classified as held for sale at June 30, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:83.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the divestiture transactions, the Company recognized losses of $5.9 million and $6.6 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the quarter ended June 30, 2021, as the Company will no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the quarter ended June 30, 2021.</span></div> 32500000 31200000 150000000.0 198000000.0 3900000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating results of these businesses do not qualify for reporting as discontinued operations. The operations of the Myriad Autoimmune business and Myriad RBM, Inc. are included in the Company's diagnostics reporting segment and other reporting segment, respectively. The following table presents information related to the assets and liabilities classified as held for sale at June 30, 2021:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:83.118%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">225.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncurrent operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities held for sale</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net assets held for sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">213.5 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3400000 119900000 88500000 13900000 225700000 5800000 3100000 3300000 12200000 213500000 5900000 6600000 SUBSEQUENT EVENTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2021, the Company completed its sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. As the sale qualified as a specified asset sale as defined under the Amended Facility, as of July 1, 2021, the Company's maximum aggregate principal commitment on its Amended Facility decreased from $300.0 million to $263.5 million.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, the Company made a voluntary principal payment of $106.4 million to pay off the remaining outstanding balances on the Amended Facility and a $0.4 million interest payment incurred on the Amended Facility. As a result, the Company has no outstanding balances under the Amended Facility as of the date of this filing.</span></div> 198000000.0 3900000 300000000.0 263500000 106400000 400000 0 XML 11 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover - shares
6 Months Ended
Jun. 30, 2021
Jul. 28, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2021  
Document Transition Report false  
Entity File Number 0-26642  
Entity Registrant Name MYRIAD GENETICS, INC.  
Entity Central Index Key 0000899923  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 87-0494517  
Entity Address, Address Line One 320 Wakara Way  
Entity Address, City or Town Salt Lake City  
Entity Address, State or Province UT  
Entity Address, Postal Zip Code 84108  
City Area Code 801  
Local Phone Number 584-3600  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol MYGN  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   78,055,365
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 118.4 $ 117.0
Marketable investment securities 46.0 33.7
Trade accounts receivable 94.8 89.5
Inventory 17.7 27.1
Assets held for sale 225.7 0.0
Prepaid taxes 18.6 108.4
Prepaid expenses and other current assets 17.7 13.7
Total current assets 538.9 389.4
Operating lease right-of-use assets 86.6 59.7
Long-term marketable investment securities 19.9 21.0
Property, plant, and equipment, net 43.2 40.7
Intangibles, net 426.8 576.5
Goodwill 240.1 329.2
Other assets 4.8 2.3
Total assets 1,360.3 1,418.8
Current liabilities:    
Accounts payable 28.5 20.5
Accrued liabilities 90.9 79.1
Current maturities of operating lease liabilities 12.7 13.6
Deferred revenues 22.6 32.7
Liabilities held for sale 12.2 0.0
Current portion of long-term debt 104.1 0.0
Total current liabilities 271.0 145.9
Unrecognized tax benefits 31.0 30.5
Long-term deferred taxes 58.2 71.3
Noncurrent operating lease liabilities 83.9 50.6
Long-term debt 0.0 224.8
Other long-term liabilities 13.8 14.7
Total liabilities 457.9 537.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 77.7 million and 75.4 million shares outstanding at June 30, 2021 and December 31, 2020, respectively 0.8 0.8
Additional paid-in capital 1,176.9 1,109.5
Accumulated other comprehensive loss (4.0) (2.3)
Accumulated deficit (271.2) (227.0)
Total Myriad Genetics, Inc. stockholders’ equity 902.5 881.0
Non-controlling interest (0.1) 0.0
Total stockholders' equity 902.4 881.0
Total liabilities and stockholders’ equity $ 1,360.3 $ 1,418.8
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Parenthetical) - shares
shares in Millions
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]        
Common stock, shares outstanding 77.7 75.4 74.7 74.5
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues:        
Total revenue $ 189.4 $ 93.2 $ 362.5 $ 257.2
Costs and expenses:        
Research and development expense 19.5 17.4 42.6 37.1
Selling, general, and administrative expense 134.8 107.4 280.3 240.3
Change in the fair value of contingent consideration 0.4 0.0 1.3 (3.4)
Goodwill and long-lived asset impairment charges 1.8 0.0 1.8 98.4
Total costs and expenses 210.2 161.5 430.0 459.2
Operating loss (20.8) (68.3) (67.5) (202.0)
Other income (expense):        
Interest income 0.2 0.5 0.4 1.3
Interest expense (2.0) (3.1) (5.0) (5.4)
Other 18.8 12.4 18.7 16.5
Total other income, net 17.0 9.8 14.1 12.4
Loss before income tax (3.8) (58.5) (53.4) (189.6)
Income tax expense (benefit) 0.9 (3.0) (9.2) (18.9)
Net loss (4.7) (55.5) (44.2) (170.7)
Net loss attributable to non-controlling interest 0.0 (0.1) 0.0 (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders $ (4.7) $ (55.4) $ (44.2) $ (170.6)
Net loss per share:        
Basic (in dollars per share) $ (0.06) $ (0.74) $ (0.58) $ (2.29)
Diluted (in dollars per share) $ (0.06) $ (0.74) $ (0.58) $ (2.29)
Weighted average shares outstanding:        
Basic (shares) 77.2 74.6 76.6 74.6
Diluted (shares) 77.2 74.6 76.6 74.6
Molecular diagnostic testing        
Revenues:        
Total revenue $ 178.7 $ 83.3 $ 338.3 $ 233.8
Costs and expenses:        
Cost of revenue 48.0 32.2 92.1 75.3
Pharmaceutical and clinical services        
Revenues:        
Total revenue 10.7 9.9 24.2 23.4
Costs and expenses:        
Cost of revenue $ 5.7 $ 4.5 $ 11.9 $ 11.5
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Statement of Comprehensive Income [Abstract]        
Net loss attributable to Myriad Genetics, Inc. stockholders $ (4.7) $ (55.4) $ (44.2) $ (170.6)
Unrealized loss on available-for-sale debt securities, net of tax (0.1) 0.8 (0.3) 0.7
Change in foreign currency translation adjustment, net of tax (0.3) 1.8 (1.4) (0.7)
Comprehensive loss (5.1) (52.8) (45.9) (170.6)
Comprehensive loss attributable to non-controlling interest 0.0 0.0 0.0 0.0
Comprehensive loss attributable to Myriad Genetics, Inc. stockholders $ (5.1) $ (52.8) $ (45.9) $ (170.6)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Non-controlling interest
Beginning balance at Dec. 31, 2019 $ 1,077.3 $ 0.7 $ 1,085.1 $ (5.3) $ (3.3) $ 0.1
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax 0.2   0.2      
Stock-based payment expense 7.5   7.5      
Non-controlling interest (0.1)         (0.1)
Net loss (115.2)       (115.2)  
Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary 0.1     0.1    
Other comprehensive income (loss), net of tax (2.6)     (2.6)    
Ending balance at Mar. 31, 2020 967.2 0.7 1,092.8 (7.8) (118.5) 0.0
Beginning balance at Dec. 31, 2019 1,077.3 0.7 1,085.1 (5.3) (3.3) 0.1
Net loss (170.6)          
Ending balance at Jun. 30, 2020 918.2 0.7 1,096.6 (5.2) (173.9) 0.0
Beginning balance at Mar. 31, 2020 967.2 0.7 1,092.8 (7.8) (118.5) 0.0
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax 1.9   1.9      
Stock-based payment expense 1.9   1.9      
Net loss (55.4)       (55.4)  
Other comprehensive income (loss), net of tax 2.6     2.6    
Ending balance at Jun. 30, 2020 918.2 0.7 1,096.6 (5.2) (173.9) 0.0
Beginning balance at Dec. 31, 2020 881.0 0.8 1,109.5 (2.3) (227.0) 0.0
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax 26.0   26.0      
Stock-based payment expense 9.0   9.0      
Net loss (39.5)       (39.5)  
Other comprehensive income (loss), net of tax (1.3)     (1.3)    
Ending balance at Mar. 31, 2021 875.2 0.8 1,144.5 (3.6) (266.5) 0.0
Beginning balance at Dec. 31, 2020 881.0 0.8 1,109.5 (2.3) (227.0) 0.0
Net loss (44.2)          
Ending balance at Jun. 30, 2021 902.4 0.8 1,176.9 (4.0) (271.2) (0.1)
Beginning balance at Mar. 31, 2021 875.2 0.8 1,144.5 (3.6) (266.5) 0.0
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax 23.5   23.5      
Stock-based payment expense 8.9   8.9      
Non-controlling interest (0.1)         (0.1)
Net loss (4.7)       (4.7)  
Other comprehensive income (loss), net of tax (0.4)     (0.4)    
Ending balance at Jun. 30, 2021 $ 902.4 $ 0.8 $ 1,176.9 $ (4.0) $ (271.2) $ (0.1)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:              
Net loss attributable to Myriad Genetics, Inc. stockholders $ (4.7) $ (39.5) $ (55.4) $ (115.2) $ (44.2)   $ (170.6)
Adjustments to reconcile net loss to net cash provided by operating activities:              
Depreciation and amortization 16.9   17.7   35.3   35.6
Non-cash interest expense         0.8   0.3
Non-cash lease expense         6.8   6.3
Stock-based compensation expense         17.9   9.4
Deferred income taxes         (11.5)   (49.0)
Unrecognized tax benefits         0.4   1.0
Change in fair value of contingent consideration         1.3   (3.4)
Loss on inventory 6.6       6.6   0.0
Impairment of goodwill and long-lived assets         1.8   98.4
Gain on deconsolidation of subsidiary         0.0   (1.0)
Gain on sale of assets         (32.4)   0.0
Changes in assets and liabilities:              
Prepaid expenses         (4.7)   2.4
Trade accounts receivable         (12.3)   50.3
Other receivables         0.3   0.9
Inventory         (0.8)   (0.9)
Prepaid taxes         89.8   24.7
Other assets         (2.7)   0.0
Accounts payable         8.1   0.6
Accrued liabilities         16.1   12.7
Deferred revenue         (9.2)   29.1
Net cash provided by operating activities         67.4   46.8
CASH FLOWS FROM INVESTING ACTIVITIES:              
Capital expenditures         (11.6)   (5.3)
Proceeds from sale of subsidiary         0.0   21.3
Proceeds from sale of assets         32.5   0.0
Purchases of marketable investment securities         (36.6)   (15.8)
Proceeds from maturities and sales of marketable investment securities         25.0   33.4
Net cash provided by investing activities         9.3   33.6
CASH FLOWS FROM FINANCING ACTIVITIES:              
Proceeds from common stock issued under stock-based compensation plans         50.1   2.2
Payment of tax withheld for common stock issued under stock-based compensation plans         (0.6)   (0.1)
Payment of contingent consideration recognized at acquisition         (3.3)   0.0
Fees associated with refinancing of revolving credit facility         (1.2)   (1.0)
Repayment of revolving credit facility         (120.0)   0.0
Net cash provided by (used in) financing activities         (75.0)   1.1
Effect of foreign exchange rates on cash and cash equivalents         (0.3)   (0.5)
Change in cash and cash equivalents classified as held for sale         0.0   1.5
Net increase in cash and cash equivalents         1.4   82.5
Cash and cash equivalents at beginning of the period   $ 117.0   $ 81.2 117.0 $ 163.7 81.2
Cash and cash equivalents at end of the period $ 118.4   $ 163.7   $ 118.4 $ 117.0 $ 163.7
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation BASIS OF PRESENTATION
Myriad Genetics, Inc. and subsidiaries (collectively, the “Company” or “Myriad”) discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The Company's mission and purpose is to advance health and well-being for all, empowering every individual by revealing the answers inside each of us. The Company generates revenue by performing molecular diagnostic tests and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, by providing pharmaceutical services to the pharmaceutical and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology. The Company’s corporate headquarters are located in Salt Lake City, Utah.
The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period ended December 31, 2020 (the “Transition Report on Form 10-K”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
The Company has historically experienced seasonality in its testing business. The volume of testing is negatively impacted by the summer season, which is generally reflected in the quarter ending June 30. Additionally, the quarter ending March 31 is typically negatively impacted by the annual reset of patient deductibles. The quarter ending December 31 is generally strong as the Company sees an increase in volumes from patients who have met their annual insurance deductible.
Due to the COVID-19 global pandemic (“COVID-19”), seasonality may not follow the same pattern as in prior years. Volumes and results of operations were impacted negatively in calendar year 2020 by COVID-19. As such, the Company’s year over year results may not be comparable. Management continues to monitor the impacts of COVID-19, including variants of COVID-19, on the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce. The Company is not able to estimate the effects of COVID-19 on results of operations, financial condition, or liquidity for future periods.
Held for Sale Policy
Net assets held for sale represent property, plant, and equipment, intangibles, and other assets and liabilities that have met the criteria of "held for sale" accounting, as specified by ASC 360, Property, Plant, and Equipment, and are recorded at the lower of carrying value or fair value less costs to sell. Fair value is based on the estimated proceeds from the sale of the net assets utilizing recent purchase agreements and costs to sell include direct costs that are estimable and probable. The Company expects to complete the sale of these net assets within twelve months following their initial classification as held for sale. See Note 16 for additional information regarding assets and liabilities held for sale.
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.

Recent Accounting Pronouncements
Recently Adopted Standards
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted with no material impact to the Company's Condensed Consolidated Financial Statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue
6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Revenue REVENUE
Myriad generates revenue by performing molecular diagnostic testing and, prior to the sale of Myriad RBM, Inc. on July 1, 2021 as described in Note 17, pharmaceutical services. Molecular diagnostic revenues consists of the following categories (products): Hereditary Cancer (myRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (myChoice CDx, Prolaris, and EndoPredict), Prenatal (Foresight and Prequel), Autoimmune (Vectra), and Other. The Company previously provided clinical services until selling Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) in February 2020. Prior to the sale of the Myriad myPath, LLC laboratory in May 2021 as described in Note 16, Myriad myPath revenue was included in Other within molecular diagnostic revenues. Revenue from the sale of molecular diagnostic tests and pharmaceutical and clinical services is recorded at the estimated amount of consideration to be received. The Company has determined that the communication of test results or the completion of pharmaceutical and clinical services indicates transfer of control for revenue recognition purposes.
The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):
Three months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$73.8 $12.2 $86.0 $34.9 $5.0 $39.9 
Tumor Profiling18.1 11.1 29.2 8.6 1.9 10.5 
Prenatal29.2 0.2 29.4 16.5 0.1 16.6 
Pharmacogenomics22.6 — 22.6 8.5 — 8.5 
Autoimmune10.2 — 10.2 7.3 — 7.3 
Other0.2 1.1 1.3 0.5 — 0.5 
Total molecular diagnostic revenue154.1 24.6 178.7 76.3 7.0 83.3 
Pharmaceutical and clinical service revenue10.7 — 10.7 9.9 — 9.9 
Total revenue$164.8 $24.6 $189.4 $86.2 $7.0 $93.2 
Six months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$138.9 $23.2 $162.1 $116.2 $8.9 $125.1 
Tumor Profiling42.3 17.9 60.2 19.3 4.9 24.2 
Prenatal52.8 0.3 53.1 36.7 0.2 36.9 
Pharmacogenomics40.2 — 40.2 28.9 — 28.9 
Autoimmune20.9 — 20.9 17.7 — 17.7 
Other0.2 1.6 1.8 1.0 — 1.0 
Total molecular diagnostic revenue295.3 43.0 338.3 219.8 14.0 233.8 
Pharmaceutical and clinical service revenue24.2 — 24.2 19.5 3.9 23.4 
Total revenue$319.5 $43.0 $362.5 $239.3 $17.9 $257.2 
The Company performs its obligation under a contract with a customer by processing diagnostic tests and communicating the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Company’s performance of its contractual obligations. When this occurs, the Company records a contract liability as deferred revenue. During the fiscal year ended June 30, 2020, the Company received approximately $29.7 million in advance Medicare payments to provide relief from the economic impacts of COVID-19 on the Company. The advanced Medicare payments began being applied against services performed in April 2021 and will continue until the funds previously received are fully earned. A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
Six months ended
June 30,
(in millions)20212020
Deferred revenue - beginning balance$32.7 $3.6 
Revenue recognized(15.5)(6.1)
Prepayments6.3 35.3 
Held for sale reclassification(0.9)— 
Deferred revenue - ending balance$22.6 $32.8 
In accordance with ASC Topic 606, Revenue from Contracts with Customers (“Topic 606”), the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of Company’s performance to date. However, the Company periodically enters into arrangements with customers to provide diagnostic testing and/or pharmaceutical services that may have terms longer than one year and include multiple performance obligations. As of June 30, 2021, the aggregate amount of the transaction price of such contracts that is allocated to the remaining performance obligations is $6.7 million. 
In determining the transaction price, Myriad includes an estimate of the expected amount of consideration as revenue. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices.

The estimate of revenue is affected by assumptions in payor behavior such as changes in payor mix, payor collections, current customer contractual requirements, and experience with collections from third-party payors. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company’s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Loss.

Cash collections for certain diagnostic tests delivered may differ from rates originally estimated, primarily driven by changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, and settlements with third party payors. During the three and six months ended June 30, 2021, the Company recognized $13.3 million and $13.2 million in revenue, respectively, which resulted in a $0.13 impact to earnings per share to each period for tests in which the performance obligation of delivering the tests results was met in prior periods. The changes were primarily driven by changes in the estimated transaction price. Additionally, during the three months ended March 31, 2021, the Company recognized $6.8 million of revenue due to expanded coverage for Prolaris, for which revenue was fully constrained in a prior period.
The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies that make payments on the customer's behalf, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 16% and 18% of total revenue for the three and six months ended June 30, 2021, respectively, and 12% and 15% of total revenue for the three and six months ended June 30, 2020, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. Medicare accounted for 11% of accounts receivable at June 30, 2021. No payor accounted for more than 10% of accounts receivable at December 31, 2020. The Company does not require collateral from its customers.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Investment Securities
6 Months Ended
Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Marketable Investment Securities MARKETABLE INVESTMENT SECURITIES
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
June 30, 2021
Cash and cash equivalents:
Cash$60.4 $— $— $60.4 
Cash equivalents58.0 — — 58.0 
Total cash and cash equivalents118.4 — — 118.4 
Available-for-sale:
Corporate bonds and notes46.1 0.3 — 46.4 
Municipal bonds13.2 0.1 — 13.3 
Federal agency issues2.5 — — 2.5 
US government securities3.7 — — 3.7 
Total$183.9 $0.4 $— $184.3 
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
December 31, 2020:
Cash and cash equivalents:
Cash$47.9 $— $— $47.9 
Cash equivalents69.1 — — 69.1 
Total cash and cash equivalents117.0 — — 117.0 
Available-for-sale:
Corporate bonds and notes28.8 0.5 — 29.3 
Municipal bonds9.4 0.2 — 9.6 
Federal agency issues4.0 — — 4.0 
US government securities11.7 0.1 — 11.8 
Total$170.9 $0.8 $— $171.7 

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2021:
(in millions)Amortized
cost
Estimated
fair value
Cash$60.4 $60.4 
Cash equivalents58.0 58.0 
Available-for-sale:
Due within one year45.8 46.0 
Due after one year through five years19.7 19.9 
Due after five years— — 
Total$183.9 $184.3 

There were no debt securities classified as available-for-sale in a gross unrealized loss position as of June 30, 2021 or December 31, 2020.

Additional information relating to fair value of marketable investment securities can be found in Note 4.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements FAIR VALUE MEASUREMENTS
The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:
Level 1—quoted prices in active markets for identical assets and liabilities.
Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.  Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.
Level 3—unobservable inputs.
All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs.  For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. For Level 3 contingent consideration, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using the Monte Carlo Method, which is consistent with the initial measurement of the expected earn out liability. This fair value measurement is considered a Level 3 measurement because the Company estimates projections during the expected measurement period of approximately 14.0 years, utilizing various potential pay-out scenarios.  Probabilities were applied to each potential scenario and the resulting values were discounted using a rate that considers weighted average cost of capital as well as a specific risk premium associated with the riskiness of the earn-out itself, the related projections, and the overall business. The contingent earn-out liabilities are classified as components of Accrued liabilities and Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.  Changes to contingent consideration liabilities are reflected in Change in the fair value of contingent consideration in the Company’s Condensed Consolidated Statements of Operations. Changes to the unobservable inputs could have a material impact on the Company’s financial statements.
The fair value of the Company’s long-term debt, which it considers a Level 3 measurement, is estimated using discounted cash flow analyses, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements.  The fair value of the Company's long-term debt is estimated to be $106.0 million at June 30, 2021. As of June 30, 2021, the Company intended to pay off the remaining balance of debt during the quarter ended September 30, 2021. As such, long-term debt was reclassified to Current portion of long-term debt in the Company's Condensed Consolidated Balance Sheets as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility (as defined in Note 8) on July 30, 2021, which is described in Note 17.
The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions)Level 1Level 2Level 3Total
June 30, 2021
Money market funds (a)$58.0 $— $— $58.0 
Corporate bonds and notes— 46.4 — 46.4 
Municipal bonds— 13.3 — 13.3 
Federal agency issues— 2.5 — 2.5 
US government securities— 3.7 — 3.7 
Contingent consideration— — (8.5)(8.5)
Total$58.0 $65.9 $(8.5)$115.4 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
(in millions)Level 1Level 2Level 3Total
December 31, 2020
Money market funds (a)$69.1 $— $— $69.1 
Corporate bonds and notes— 29.3 — 29.3 
Municipal bonds— 9.6 — 9.6 
Federal agency issues— 4.0 — 4.0 
US government securities— 11.8 — 11.8 
Contingent consideration— — (10.9)(10.9)
Total$69.1 $54.7 $(10.9)$112.9 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.

Nonrecurring Fair Value Measurements
In addition to assets and liabilities that are recorded at fair value on a recurring basis, the Company's assets and liabilities are also subject to nonrecurring fair value measurements.

As a result of the approval of the Company's Board of Directors to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit during the quarter ended June 30, 2021, the Company performed an interim impairment analysis for the assets held for sale. The Company did not recognize any impairment charges on the asset groups classified as held for sale. The fair value used in the analysis, which the Company considers a Level 2 measurement, was based on the sale prices of Myriad RBM, Inc. and the Myriad Autoimmune assets.

The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions)Carrying
Amount
Balance December 31, 2020$10.9 
Payment of contingent consideration(3.3)
Change in fair value recognized in the income statement1.3 
Translation adjustments recognized in other comprehensive loss(0.4)
Ending balance June 30, 2021$8.5 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, Net
6 Months Ended
Jun. 30, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment, Net PROPERTY, PLANT AND EQUIPMENT, NET
(in millions)June 30,
2021
December 31,
2020
Leasehold improvements$36.5 $35.7 
Equipment109.6 117.9 
Property, plant and equipment, gross146.1 153.6 
Less accumulated depreciation(102.9)(112.9)
Property, plant and equipment, net$43.2 $40.7 

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Depreciation expense$3.4 $2.5 $6.3 $5.1 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Intangible Assets
6 Months Ended
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets GOODWILL AND INTANGIBLE ASSETS
Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the six months ended June 30, 2021:
(in millions)DiagnosticOtherTotal
Beginning balance$272.3 $56.9 $329.2 
Goodwill held for sale reclassification(31.6)(56.9)(88.5)
Translation adjustments(0.6)— (0.6)
Ending balance$240.1 $— $240.1 

In connection with the Company's entry into definitive agreements to sell Myriad RBM, Inc. and select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit, the Company classified a portion of goodwill as assets held for sale. See Note 16 for further discussion.

Intangible Assets
Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At June 30, 2021:
Purchased licenses and technologies$817.1 $(276.6)$540.5 
Customer relationships4.7 (4.7)— 
Trademarks3.0 (1.6)1.4 
Total amortized intangible assets824.8 (282.9)541.9 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Less: intangible assets held for sale$(211.5)$91.6 $(119.9)
Total intangible assets$618.1 $(191.3)$426.8 
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At December 31, 2020:
Purchased licenses and technologies$818.2 $(248.2)$570.0 
Customer relationships4.7 (4.5)0.2 
Trademarks3.0 (1.5)1.5 
Total amortized intangible assets825.9 (254.2)571.7 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Total intangible assets$830.7 $(254.2)$576.5 

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Amortization of intangible assets$13.5 $15.2 $29.0 $30.5 
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Liabilities
6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
Accrued Liabilities ACCRUED LIABILITIES
(in millions)June 30,
2021
December 31,
2020
Employee compensation and benefits$50.7 $48.9 
Accrued taxes payable3.7 4.3 
Recoupments payable and reserves8.1 9.3 
Short-term contingent consideration— 3.4 
Accrued royalties5.0 3.8 
Purchase commitment5.9 — 
Other accrued liabilities17.5 9.4 
Total accrued liabilities$90.9 $79.1 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Long-Term Debt LONG-TERM DEBT
On December 23, 2016, the Company entered into a senior secured revolving credit facility (the “Facility”) by and among Myriad, as borrower, and the lenders from time to time party thereto. On July 31, 2018, the Company entered into Amendment No. 1 which effected an “amend and extend” transaction with respect to the Facility by which the maturity date thereof was extended to July 31, 2023 and the maximum aggregate principal commitment was increased from $300.0 million to $350.0 million. On May 1, 2020, the Company entered into Amendment No. 2, which waived the Company’s compliance with certain financial covenants, amended compliance with certain operating covenants, and modified the interest rate and other terms during a modification period from March 31, 2020 through June 30, 2021 (the “Modification Period”). On February 22, 2021, the Company entered into Amendment No. 3 (the “Amended Facility”), which, among other things, decreased the maximum aggregate principal commitment from $350.0 million to $300.0 million, with a further reduction in the maximum aggregate principal commitment from $300.0 million to $250.0 million by September 30, 2021 (if not previously reduced to such amount in connection with certain specified asset sales), waived the Company’s compliance with certain financial covenants through the quarter ending March 31, 2022, extended the Modification Period for an additional year, through June 30, 2022, and revised certain negative covenants in connection with the extension. The amendments were accounted for as modifications pursuant to guidance in ASC 470-50, Debt. There are no scheduled principal payments of the Amended Facility prior to its maturity date.
The Amended Facility contains customary loan terms, interest rates, representations and warranties, affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. The Amended Facility also contains certain customary events of default. Amendment No. 2 modified the Facility to increase the interest rate to be fixed at a spread of LIBOR plus 350 basis points on drawn balance and the undrawn fee was increased to 50 basis points during the Modification Period. At the end of the Modification Period, interest rates return to the previous pricing based on a spread of LIBOR plus 150-250 basis points on drawn balances and an undrawn fee ranging from 25 to 45 basis points, in each case, based on the Company's leverage ratio. The LIBOR floor was also increased to 1.0% during the Modification Period. The interest rate as of June 30, 2021 was 4.5%.
Covenants in the Amended Facility impose operating and financial restrictions on the Company. These restrictions may prohibit or place limitations on, among other things, the Company’s ability to incur additional indebtedness, create certain types of liens, and complete mergers, consolidations, or change in control transactions. The Amended Facility may also prohibit or place limitations on the Company’s ability to sell assets, pay dividends or provide other distributions to stockholders. Beginning with the quarter ended June 30, 2022, the Company must maintain specified leverage and interest ratios measured as of the end of each quarter as a financial covenant in the Amended Facility. Amendment No. 2 modified the Amended Facility's compliance with the leverage covenant and the interest coverage ratio covenant, which were waived through March 31, 2021. A minimum liquidity covenant was added for the period beginning May 1, 2020 until March 31, 2021, and a minimum EBITDA covenant was added for the quarters ended December 31, 2020 and March 31, 2021. Amendment No. 2 also revised certain negative covenants of the Amended Facility during the Modification Period. Amendment No. 3 waived compliance with the leverage ratio and the interest coverage ratio covenants through the quarter ending March 31, 2022 and also lowered the minimum liquidity covenant applicable through such quarter. Amendment No. 3 also removed the minimum EBITDA covenant and restricted the Company from borrowing under the Amended Facility if unrestricted cash and cash equivalents exceed $150.0 million, unless such borrowings are in connection with acquisitions. The Company was in compliance with all applicable financial covenants at June 30, 2021.
During the six months ended June 30, 2021, the Company made principal repayments totaling $120.0 million on the Amended Facility. During the transition period ended December 31, 2020, the Company did not make any principal repayments.
The Amended Facility is secured by a first-lien security interest in substantially all of the assets of Myriad and certain of its domestic subsidiaries and each such domestic subsidiary of Myriad has guaranteed the repayment of the Amended Facility. As of June 30, 2021, the Company intended to use the proceeds from the sale of Myriad RBM, Inc. to make a voluntary repayment in full on the Amended Facility during the quarter ended September 30, 2021. As a result, the Company classified the entire outstanding balance as current in its Condensed Consolidated Financial Statements as of June 30, 2021. The Company subsequently paid off the remaining debt balance under the Amended Facility on July 30, 2021, which is described in Note 17. Also, see Note 17 for information on the sale of Myriad RBM, Inc. Amounts outstanding under the Amended Facility were as follows:
(in millions)June 30,
2021
December 31,
2020
Long-term debt$— $226.7 
Long-term debt discount— (1.9)
Long-term debt, net— 224.8 
Current portion of long-term debt106.4 — 
Current portion of long-term debt discount(2.3)— 
Debt, net$104.1 $224.8 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Other Long-Term Liabilities
6 Months Ended
Jun. 30, 2021
Other Liabilities Disclosure [Abstract]  
Other Long-Term Liabilities OTHER LONG-TERM LIABILITIES
(in millions)June 30,
2021
December 31,
2020
Contingent consideration$8.5 $7.4 
Other5.3 7.3 
Total other long-term liabilities$13.8 $14.7 
The Company's balance of other long-term liabilities as of June 30, 2021 and December 31, 2020 consists of the Company’s portion of social security taxes that have been deferred under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) that do not have to be remitted until December 2022.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Preferred and Common Stockholders' Equity
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Preferred and Common Stockholders' Equity PREFERRED AND COMMON STOCKHOLDERS' EQUITY
The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at June 30, 2021.
The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 77.7 million shares issued and outstanding at June 30, 2021.
Common shares issued and outstanding
Six months ended
June 30,
(in millions)20212020
Beginning common stock issued and outstanding75.4 74.5 
Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan2.3 0.2 
Common stock issued and outstanding at end of period77.7 74.7 
Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding.  Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.  In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.
The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Denominator:
Weighted-average shares outstanding used to compute basic EPS77.2 74.6 76.6 74.6 
Effect of dilutive shares— — — — 
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS77.2 74.6 76.6 74.6 
Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
June 30,
(in millions)20212020
Anti-dilutive options and RSUs excluded from EPS computation7.0 7.1 
Stock Repurchase Program
In June 2016, the Company’s Board of Directors authorized a share repurchase program of $200.0 million of the Company’s outstanding common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company's management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors.  As of June 30, 2021, the Company is authorized to repurchase up to $110.7 million of shares under this authorization. No shares were repurchased during the six months ended June 30, 2021 or 2020.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation STOCK-BASED COMPENSATION
On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of restricted and unrestricted stock awards to employees, consultants, and directors. Stockholders have approved amendments to the 2017 Plan increasing the shares available to grant. As of June 30, 2021, the Company has 3.6 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued or reacquired shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. To the extent that awards outstanding under the Company's prior equity plans expire or are cancelled without delivery of shares of common stock, they also will be available for issuance pursuant to the 2017 Plan.
The number of shares, terms, and vesting periods are generally determined by the Company’s Board of Directors or a committee thereof on an award-by-award basis. RSUs granted to employees generally vest ratably over four years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of RSUs awarded to certain employees may be increased or reduced based on certain additional performance metrics. Options and RSUs granted to non-employee directors vest in full upon completion of one year of service on the anniversary following the date of the grant. Options generally vest ratably over service periods of four years. Options granted after December 5, 2012 expire eight years from the date of grant, and options granted prior to that date generally expire ten years from the date of grant.
Stock Options
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20205.2 $23.24 
Options granted— $— 
Less:
Options exercised(2.1)$22.93 
Options canceled or expired(0.1)$24.81 
Options outstanding at June 30, 20213.0 $23.42 
Options exercisable at June 30, 20212.4 $26.25 
As of June 30, 2021, there was $3.4 million of total unrecognized stock-based compensation expense related to stock options that will be recognized over a weighted-average period of 2.1 years.
Restricted Stock Units
A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20203.2 $20.56 
RSUs granted1.5 $29.89 
Less:
RSUs vested(0.1)$18.88 
RSUs canceled(0.6)$24.54 
RSUs outstanding at June 30, 20214.0 $23.72 
As of June 30, 2021, there was $74.5 million of total unrecognized stock-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.5 years. 
Employee Stock Purchase Plan
The Company also has an Employee Stock Purchase Plan that was approved by stockholders in 2012 (the “2012 Purchase Plan”), under which 2.0 million shares of common stock have been authorized.  Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period.  As of June 30, 2021, approximately 0.1 million shares of common stock are available for issuance under the 2012 Purchase Plan.
Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Cost of molecular diagnostic testing$0.4 $0.3 $0.7 $0.7 
Cost of pharmaceutical and clinical services— 0.1 0.1 0.2 
Research and development expense1.0 1.2 2.5 2.3 
Selling, general, and administrative expense7.5 0.3 14.6 6.2 
     Total stock-based compensation expense$8.9 $1.9 $17.9 $9.4 
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
6 Months Ended
Jun. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes INCOME TAXES
In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.
Income tax expense for the three months ended June 30, 2021 was $0.9 million, or approximately (23.7)% of pre-tax loss compared to an income tax benefit of $3.0 million, or approximately 5.1% of pre-tax loss, for the three months ended June 30, 2020.  Income tax expense for the three months ended June 30, 2021 is based on the Company’s estimated annualized effective tax rate for the fiscal year ending December 31, 2021, adjusted for discrete items recognized during the period.  For the three months ended June 30, 2021, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate primarily due to disallowed executive compensation expenses, disallowed meals and entertainment expenses, carrying back net operating losses under the provisions of the CARES Act, and release of a valuation allowance.
The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations.  The Company is currently under audit by the State of California for the fiscal years June 30, 2017-2018, the State of New Jersey for the fiscal years June 30, 2013-2017; the State of New York for the fiscal years June 30, 2016-2018; Germany for the fiscal years June 30, 2013-2015; and Switzerland for the fiscal years June 30, 2015-2016. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
6 Months Ended
Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies COMMITMENTS AND CONTINGENCIESThe Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of June 30, 2021, the management of the Company believes any reasonably possible liability that may result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Segment and Related Information SEGMENT AND RELATED INFORMATIONThe Company’s business is aligned with how the chief operating decision maker reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.
Segment revenue and operating income (loss) were as follows during the periods presented:
(in millions)DiagnosticsOtherTotal
Three months ended June 30, 2021
Revenues$177.1 $12.3 $189.4 
Depreciation and amortization15.7 1.2 16.9 
Segment operating income (loss)37.5 (58.3)(20.8)
Three months ended June 30, 2020
Revenues$81.0 $12.2 $93.2 
Depreciation and amortization16.7 1.0 17.7 
Segment operating loss(33.8)(34.5)(68.3)
Six months ended June 30, 2021
Revenues$334.9 $27.6 $362.5 
Depreciation and amortization32.7 2.6 35.3 
Segment operating income (loss)48.0 (115.5)(67.5)
Six months ended June 30, 2020
Revenues$231.5 $25.7 $257.2 
Depreciation and amortization33.5 2.1 35.6 
Segment operating loss(127.4)(74.6)(202.0)

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Total operating loss for reportable segments$(20.8)$(68.3)$(67.5)$(202.0)
Unallocated amounts:
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Loss from operations before income taxes(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest— (0.1)— (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Cash Flow Information
6 Months Ended
Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information SUPPLEMENTAL CASH FLOW INFORMATION
Six months ended
June 30,
(in millions)20212020
Cash paid during the period for income taxes$1.7 $1.0 
Cash paid for interest1.7 4.3 
Cash received for income tax receivables89.9 — 
Fair value adjustment on marketable investment securities recorded to stockholders' equity(0.3)0.7
Establishment of operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets$40.5 $— 
Operating lease liabilities46.7 — 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Divestitures
6 Months Ended
Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Divestitures DIVESTITURES
On April 26, 2021, the Company entered into a definitive agreement with Castle Biosciences, Inc. for the sale of the Myriad myPath, LLC laboratory, which is the laboratory that offers the myPath Melanoma test. The transaction subsequently closed on May 28, 2021, and the Myriad myPath, LLC laboratory was sold for total cash consideration of $32.5 million. The transaction was accounted for as a sale of assets and the Company recognized a net gain of $31.2 million, in Other income on the Company’s Condensed Consolidated Statements of Operations related to the sale. Prior to the sale, Myriad myPath operations were included in the Company’s diagnostics reporting segment.
Held for Sale
On May 1, 2021, the Company entered into a definitive agreement to sell select operating assets and intellectual property, including the Vectra® test, from the Myriad Autoimmune business unit (the "Autoimmune Business Transaction") to Laboratory Corporation of America Holdings for total cash consideration of $150.0 million. The Autoimmune Business Transaction is expected to close during the quarter ending September 30, 2021.
On May 21, 2021, the Company entered into a definitive agreement to sell Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. This transaction closed on July 1, 2021.
The Company measured these businesses at the lower of their carrying value or fair value less any costs to sell. No impairment was recognized on the held for sale assets during the quarter ended June 30, 2021.

The operating results of these businesses do not qualify for reporting as discontinued operations. The operations of the Myriad Autoimmune business and Myriad RBM, Inc. are included in the Company's diagnostics reporting segment and other reporting segment, respectively. The following table presents information related to the assets and liabilities classified as held for sale at June 30, 2021:
(in millions)Total
Assets
Inventory$3.4 
Intangibles, net119.9 
Goodwill88.5 
Other assets13.9 
Total assets held for sale$225.7 
Liabilities
Accrued liabilities$5.8 
Noncurrent operating lease liabilities3.1 
Other liabilities3.3 
Total liabilities held for sale$12.2 
Total net assets held for sale$213.5 
Inventory
In connection with the divestiture transactions, the Company recognized losses of $5.9 million and $6.6 million for a non-cancelable inventory purchase commitment and inventory, respectively, during the quarter ended June 30, 2021, as the Company will no longer have use for the goods. Both of these losses are included in Other income (expense) in the Company's Condensed Consolidated Statements of Operations for the quarter ended June 30, 2021.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
6 Months Ended
Jun. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS
On July 1, 2021, the Company completed its sale of Myriad RBM, Inc., a wholly owned subsidiary of the Company, to IQVIA RDS, Inc. for cash consideration of $198.0 million, adjusted for working capital, indebtedness, and transaction costs, which adjustment amounts are estimated to be $(3.9) million in the aggregate. As the sale qualified as a specified asset sale as defined under the Amended Facility, as of July 1, 2021, the Company's maximum aggregate principal commitment on its Amended Facility decreased from $300.0 million to $263.5 million.
On July 30, 2021, the Company made a voluntary principal payment of $106.4 million to pay off the remaining outstanding balances on the Amended Facility and a $0.4 million interest payment incurred on the Amended Facility. As a result, the Company has no outstanding balances under the Amended Facility as of the date of this filing.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Basis of Presentation (Policies)
6 Months Ended
Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The Condensed Consolidated Financial Statements herein should be read in conjunction with the Company’s audited Consolidated Financial Statements and notes thereto included in the Company’s Transition Report on Form 10-K for the transition period ended December 31, 2020 (the “Transition Report on Form 10-K”).
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Operating results for the three and six months ended June 30, 2021 may not necessarily be indicative of results to be expected for any other interim period or for the full year.
Held for Sale Policy
Held for Sale Policy
Net assets held for sale represent property, plant, and equipment, intangibles, and other assets and liabilities that have met the criteria of "held for sale" accounting, as specified by ASC 360, Property, Plant, and Equipment, and are recorded at the lower of carrying value or fair value less costs to sell. Fair value is based on the estimated proceeds from the sale of the net assets utilizing recent purchase agreements and costs to sell include direct costs that are estimable and probable. The Company expects to complete the sale of these net assets within twelve months following their initial classification as held for sale. See Note 16 for additional information regarding assets and liabilities held for sale.
Reclassifications
Reclassifications
Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders’ equity, cash flows from operations, or net loss for the period.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted Standards
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASC 2019-12 is a new accounting standard to simplify accounting for income taxes and remove, modify, and add to the disclosure requirements of income taxes. The standard is effective for fiscal years beginning after December 15, 2020, with early adoption permitted. This guidance was adopted with no material impact to the Company's Condensed Consolidated Financial Statements.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue (Tables)
6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Total Revenue by Product and by U.S versus Rest of World
The following table presents detail regarding the composition of the Company’s total revenue by category and by U.S. versus rest of world (“RoW”):
Three months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$73.8 $12.2 $86.0 $34.9 $5.0 $39.9 
Tumor Profiling18.1 11.1 29.2 8.6 1.9 10.5 
Prenatal29.2 0.2 29.4 16.5 0.1 16.6 
Pharmacogenomics22.6 — 22.6 8.5 — 8.5 
Autoimmune10.2 — 10.2 7.3 — 7.3 
Other0.2 1.1 1.3 0.5 — 0.5 
Total molecular diagnostic revenue154.1 24.6 178.7 76.3 7.0 83.3 
Pharmaceutical and clinical service revenue10.7 — 10.7 9.9 — 9.9 
Total revenue$164.8 $24.6 $189.4 $86.2 $7.0 $93.2 
Six months ended June 30,
20212020
(in millions)U.S.RoWTotalU.S.RoWTotal
Molecular diagnostic revenues:
Hereditary Cancer$138.9 $23.2 $162.1 $116.2 $8.9 $125.1 
Tumor Profiling42.3 17.9 60.2 19.3 4.9 24.2 
Prenatal52.8 0.3 53.1 36.7 0.2 36.9 
Pharmacogenomics40.2 — 40.2 28.9 — 28.9 
Autoimmune20.9 — 20.9 17.7 — 17.7 
Other0.2 1.6 1.8 1.0 — 1.0 
Total molecular diagnostic revenue295.3 43.0 338.3 219.8 14.0 233.8 
Pharmaceutical and clinical service revenue24.2 — 24.2 19.5 3.9 23.4 
Total revenue$319.5 $43.0 $362.5 $239.3 $17.9 $257.2 
Reconciliation of Deferred Revenue Balances A reconciliation of the beginning and ending balances of deferred revenue is shown in the table below:
Six months ended
June 30,
(in millions)20212020
Deferred revenue - beginning balance$32.7 $3.6 
Revenue recognized(15.5)(6.1)
Prepayments6.3 35.3 
Held for sale reclassification(0.9)— 
Deferred revenue - ending balance$22.6 $32.8 
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Investment Securities (Tables)
6 Months Ended
Jun. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security
The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
June 30, 2021
Cash and cash equivalents:
Cash$60.4 $— $— $60.4 
Cash equivalents58.0 — — 58.0 
Total cash and cash equivalents118.4 — — 118.4 
Available-for-sale:
Corporate bonds and notes46.1 0.3 — 46.4 
Municipal bonds13.2 0.1 — 13.3 
Federal agency issues2.5 — — 2.5 
US government securities3.7 — — 3.7 
Total$183.9 $0.4 $— $184.3 
(in millions)Amortized
cost
Gross
unrealized
holding
gains
Gross
unrealized
holding
losses
Estimated
fair value
December 31, 2020:
Cash and cash equivalents:
Cash$47.9 $— $— $47.9 
Cash equivalents69.1 — — 69.1 
Total cash and cash equivalents117.0 — — 117.0 
Available-for-sale:
Corporate bonds and notes28.8 0.5 — 29.3 
Municipal bonds9.4 0.2 — 9.6 
Federal agency issues4.0 — — 4.0 
US government securities11.7 0.1 — 11.8 
Total$170.9 $0.8 $— $171.7 
Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities
Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities were as follows at June 30, 2021:
(in millions)Amortized
cost
Estimated
fair value
Cash$60.4 $60.4 
Cash equivalents58.0 58.0 
Available-for-sale:
Due within one year45.8 46.0 
Due after one year through five years19.7 19.9 
Due after five years— — 
Total$183.9 $184.3 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Financial Assets and Liabilities
The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis:
(in millions)Level 1Level 2Level 3Total
June 30, 2021
Money market funds (a)$58.0 $— $— $58.0 
Corporate bonds and notes— 46.4 — 46.4 
Municipal bonds— 13.3 — 13.3 
Federal agency issues— 2.5 — 2.5 
US government securities— 3.7 — 3.7 
Contingent consideration— — (8.5)(8.5)
Total$58.0 $65.9 $(8.5)$115.4 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
(in millions)Level 1Level 2Level 3Total
December 31, 2020
Money market funds (a)$69.1 $— $— $69.1 
Corporate bonds and notes— 29.3 — 29.3 
Municipal bonds— 9.6 — 9.6 
Federal agency issues— 4.0 — 4.0 
US government securities— 11.8 — 11.8 
Contingent consideration— — (10.9)(10.9)
Total$69.1 $54.7 $(10.9)$112.9 
(a)Money market funds are primarily comprised of exchange traded funds and accrued interest.
Change in Fair Value of Contingent Consideration
The following table reconciles the change in the fair value of the contingent consideration during the periods presented:
(in millions)Carrying
Amount
Balance December 31, 2020$10.9 
Payment of contingent consideration(3.3)
Change in fair value recognized in the income statement1.3 
Translation adjustments recognized in other comprehensive loss(0.4)
Ending balance June 30, 2021$8.5 
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, Net (Tables)
6 Months Ended
Jun. 30, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment, Net
(in millions)June 30,
2021
December 31,
2020
Leasehold improvements$36.5 $35.7 
Equipment109.6 117.9 
Property, plant and equipment, gross146.1 153.6 
Less accumulated depreciation(102.9)(112.9)
Property, plant and equipment, net$43.2 $40.7 

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Depreciation expense$3.4 $2.5 $6.3 $5.1 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Changes in Carrying Amount of Goodwill
The following table summarizes the changes in the carrying amount of goodwill for the six months ended June 30, 2021:
(in millions)DiagnosticOtherTotal
Beginning balance$272.3 $56.9 $329.2 
Goodwill held for sale reclassification(31.6)(56.9)(88.5)
Translation adjustments(0.6)— (0.6)
Ending balance$240.1 $— $240.1 
Schedule of Amortizable Intangible Assets The following summarizes the amounts reported as intangible assets:
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At June 30, 2021:
Purchased licenses and technologies$817.1 $(276.6)$540.5 
Customer relationships4.7 (4.7)— 
Trademarks3.0 (1.6)1.4 
Total amortized intangible assets824.8 (282.9)541.9 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Less: intangible assets held for sale$(211.5)$91.6 $(119.9)
Total intangible assets$618.1 $(191.3)$426.8 
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At December 31, 2020:
Purchased licenses and technologies$818.2 $(248.2)$570.0 
Customer relationships4.7 (4.5)0.2 
Trademarks3.0 (1.5)1.5 
Total amortized intangible assets825.9 (254.2)571.7 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Total intangible assets$830.7 $(254.2)$576.5 
Schedule of Non-amortizable Intangible Assets The following summarizes the amounts reported as intangible assets:
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At June 30, 2021:
Purchased licenses and technologies$817.1 $(276.6)$540.5 
Customer relationships4.7 (4.7)— 
Trademarks3.0 (1.6)1.4 
Total amortized intangible assets824.8 (282.9)541.9 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Less: intangible assets held for sale$(211.5)$91.6 $(119.9)
Total intangible assets$618.1 $(191.3)$426.8 
(in millions)Gross
Carrying
Amount
Accumulated
Amortization
Net
At December 31, 2020:
Purchased licenses and technologies$818.2 $(248.2)$570.0 
Customer relationships4.7 (4.5)0.2 
Trademarks3.0 (1.5)1.5 
Total amortized intangible assets825.9 (254.2)571.7 
In-process research and development4.8 — 4.8 
Total unamortized intangible assets4.8 — 4.8 
Total intangible assets$830.7 $(254.2)$576.5 
Schedule of Recorded Amortization Expense for Intangible Assets
The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Amortization of intangible assets$13.5 $15.2 $29.0 $30.5 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Liabilities (Tables)
6 Months Ended
Jun. 30, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Liabilities
(in millions)June 30,
2021
December 31,
2020
Employee compensation and benefits$50.7 $48.9 
Accrued taxes payable3.7 4.3 
Recoupments payable and reserves8.1 9.3 
Short-term contingent consideration— 3.4 
Accrued royalties5.0 3.8 
Purchase commitment5.9 — 
Other accrued liabilities17.5 9.4 
Total accrued liabilities$90.9 $79.1 
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt (Tables)
6 Months Ended
Jun. 30, 2021
Debt Disclosure [Abstract]  
Schedule of Long-Term Debt Amounts outstanding under the Amended Facility were as follows:
(in millions)June 30,
2021
December 31,
2020
Long-term debt$— $226.7 
Long-term debt discount— (1.9)
Long-term debt, net— 224.8 
Current portion of long-term debt106.4 — 
Current portion of long-term debt discount(2.3)— 
Debt, net$104.1 $224.8 
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Other Long-Term Liabilities (Tables)
6 Months Ended
Jun. 30, 2021
Other Liabilities Disclosure [Abstract]  
Schedule of Other Long-Term Liabilities
(in millions)June 30,
2021
December 31,
2020
Contingent consideration$8.5 $7.4 
Other5.3 7.3 
Total other long-term liabilities$13.8 $14.7 
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Preferred and Common Stockholders' Equity (Tables)
6 Months Ended
Jun. 30, 2021
Equity [Abstract]  
Summary of Common Shares Issued and Outstanding
Common shares issued and outstanding
Six months ended
June 30,
(in millions)20212020
Beginning common stock issued and outstanding75.4 74.5 
Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan2.3 0.2 
Common stock issued and outstanding at end of period77.7 74.7 
Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations
The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Denominator:
Weighted-average shares outstanding used to compute basic EPS77.2 74.6 76.6 74.6 
Effect of dilutive shares— — — — 
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS77.2 74.6 76.6 74.6 
Schedule of Potential Dilutive Common Shares These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:
June 30,
(in millions)20212020
Anti-dilutive options and RSUs excluded from EPS computation7.0 7.1 
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Tables)
6 Months Ended
Jun. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20205.2 $23.24 
Options granted— $— 
Less:
Options exercised(2.1)$22.93 
Options canceled or expired(0.1)$24.81 
Options outstanding at June 30, 20213.0 $23.42 
Options exercisable at June 30, 20212.4 $26.25 
Schedule of Restricted Stock Unit Activity
A summary of the RSU activity under the Company’s equity plans and inducement awards, including RSU awards with performance metrics, for the six months ended June 30, 2021 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20203.2 $20.56 
RSUs granted1.5 $29.89 
Less:
RSUs vested(0.1)$18.88 
RSUs canceled(0.6)$24.54 
RSUs outstanding at June 30, 20214.0 $23.72 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:
Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Cost of molecular diagnostic testing$0.4 $0.3 $0.7 $0.7 
Cost of pharmaceutical and clinical services— 0.1 0.1 0.2 
Research and development expense1.0 1.2 2.5 2.3 
Selling, general, and administrative expense7.5 0.3 14.6 6.2 
     Total stock-based compensation expense$8.9 $1.9 $17.9 $9.4 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information (Tables)
6 Months Ended
Jun. 30, 2021
Segment Reporting [Abstract]  
Schedule of Segment Revenue and Operating Income (Loss)
Segment revenue and operating income (loss) were as follows during the periods presented:
(in millions)DiagnosticsOtherTotal
Three months ended June 30, 2021
Revenues$177.1 $12.3 $189.4 
Depreciation and amortization15.7 1.2 16.9 
Segment operating income (loss)37.5 (58.3)(20.8)
Three months ended June 30, 2020
Revenues$81.0 $12.2 $93.2 
Depreciation and amortization16.7 1.0 17.7 
Segment operating loss(33.8)(34.5)(68.3)
Six months ended June 30, 2021
Revenues$334.9 $27.6 $362.5 
Depreciation and amortization32.7 2.6 35.3 
Segment operating income (loss)48.0 (115.5)(67.5)
Six months ended June 30, 2020
Revenues$231.5 $25.7 $257.2 
Depreciation and amortization33.5 2.1 35.6 
Segment operating loss(127.4)(74.6)(202.0)

Three months ended
June 30,
Six months ended
June 30,
(in millions)2021202020212020
Total operating loss for reportable segments$(20.8)$(68.3)$(67.5)$(202.0)
Unallocated amounts:
Interest income0.2 0.5 0.4 1.3 
Interest expense(2.0)(3.1)(5.0)(5.4)
Other18.8 12.4 18.7 16.5 
Loss from operations before income taxes(3.8)(58.5)(53.4)(189.6)
Income tax expense (benefit)0.9 (3.0)(9.2)(18.9)
Net loss(4.7)(55.5)(44.2)(170.7)
Net loss attributable to non-controlling interest— (0.1)— (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders$(4.7)$(55.4)$(44.2)$(170.6)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Cash Flow Information (Tables)
6 Months Ended
Jun. 30, 2021
Supplemental Cash Flow Elements [Abstract]  
Schedule of Supplemental Cash Flow Information
Six months ended
June 30,
(in millions)20212020
Cash paid during the period for income taxes$1.7 $1.0 
Cash paid for interest1.7 4.3 
Cash received for income tax receivables89.9 — 
Fair value adjustment on marketable investment securities recorded to stockholders' equity(0.3)0.7
Establishment of operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets$40.5 $— 
Operating lease liabilities46.7 — 
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Divestitures (Tables)
6 Months Ended
Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Assets and Liabilities Classified as Held For Sale
The operating results of these businesses do not qualify for reporting as discontinued operations. The operations of the Myriad Autoimmune business and Myriad RBM, Inc. are included in the Company's diagnostics reporting segment and other reporting segment, respectively. The following table presents information related to the assets and liabilities classified as held for sale at June 30, 2021:
(in millions)Total
Assets
Inventory$3.4 
Intangibles, net119.9 
Goodwill88.5 
Other assets13.9 
Total assets held for sale$225.7 
Liabilities
Accrued liabilities$5.8 
Noncurrent operating lease liabilities3.1 
Other liabilities3.3 
Total liabilities held for sale$12.2 
Total net assets held for sale$213.5 
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Total Revenue by Product and by US versus Rest of World (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Disaggregation of Revenue [Line Items]        
Total revenue $ 189.4 $ 93.2 $ 362.5 $ 257.2
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 164.8 86.2 319.5 239.3
RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 24.6 7.0 43.0 17.9
Molecular diagnostic testing        
Disaggregation of Revenue [Line Items]        
Total revenue 178.7 83.3 338.3 233.8
Molecular diagnostic testing | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 154.1 76.3 295.3 219.8
Molecular diagnostic testing | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 24.6 7.0 43.0 14.0
Molecular diagnostic - Hereditary Cancer        
Disaggregation of Revenue [Line Items]        
Total revenue 86.0 39.9 162.1 125.1
Molecular diagnostic - Hereditary Cancer | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 73.8 34.9 138.9 116.2
Molecular diagnostic - Hereditary Cancer | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 12.2 5.0 23.2 8.9
Molecular diagnostic - Tumor Profiling        
Disaggregation of Revenue [Line Items]        
Total revenue 29.2 10.5 60.2 24.2
Molecular diagnostic - Tumor Profiling | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 18.1 8.6 42.3 19.3
Molecular diagnostic - Tumor Profiling | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 11.1 1.9 17.9 4.9
Molecular diagnostic - Prenatal        
Disaggregation of Revenue [Line Items]        
Total revenue 29.4 16.6 53.1 36.9
Molecular diagnostic - Prenatal | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 29.2 16.5 52.8 36.7
Molecular diagnostic - Prenatal | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.2 0.1 0.3 0.2
Molecular Diagnostic - Pharmacogenomics        
Disaggregation of Revenue [Line Items]        
Total revenue 22.6 8.5 40.2 28.9
Molecular Diagnostic - Pharmacogenomics | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 22.6 8.5 40.2 28.9
Molecular Diagnostic - Pharmacogenomics | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Molecular Diagnostic - Autoimmune        
Disaggregation of Revenue [Line Items]        
Total revenue 10.2 7.3 20.9 17.7
Molecular Diagnostic - Autoimmune | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 10.2 7.3 20.9 17.7
Molecular Diagnostic - Autoimmune | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 0.0 0.0 0.0 0.0
Molecular diagnostic - Other        
Disaggregation of Revenue [Line Items]        
Total revenue 1.3 0.5 1.8 1.0
Molecular diagnostic - Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 0.2 0.5 0.2 1.0
Molecular diagnostic - Other | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue 1.1 0.0 1.6 0.0
Pharmaceutical and clinical services        
Disaggregation of Revenue [Line Items]        
Total revenue 10.7 9.9 24.2 23.4
Pharmaceutical and clinical services | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenue 10.7 9.9 24.2 19.5
Pharmaceutical and clinical services | RoW        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0.0 $ 0.0 $ 0.0 $ 3.9
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Reconciliation of Deferred Revenue Balances (Details) - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Reconciliation of Deferred Revenue    
Deferred revenue - beginning balance $ 32.7 $ 3.6
Revenue recognized (15.5) (6.1)
Prepayments 6.3 35.3
Held for sale reclassification (0.9) 0.0
Deferred revenue - ending balance $ 22.6 $ 32.8
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2020
Revenue from Contract with Customer [Abstract]            
Advance Medicare payments to provide relief from economic impacts of COVID-19           $ 29,700,000
Revenue, remaining performance obligation $ 6,700,000     $ 6,700,000    
Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments 13,300,000     13,200,000    
Revenue recognized due to expanded local coverage determination for which revenue was previously constrained   $ 6,800,000        
Capitalized costs incurred to obtain or fulfill contract $ 0     $ 0    
Performance obligation estimate            
Revenue and Concentration Risk [Line Items]            
Change in earnings (loss) per share (dollars per share) $ 0.13     $ 0.13    
Revenues | Customer concentration | Medicare            
Revenue and Concentration Risk [Line Items]            
Concentration risk (percent) 16.00%   12.00% 18.00% 15.00%  
Accounts receivable | Customer concentration | Medicare            
Revenue and Concentration Risk [Line Items]            
Concentration risk (percent)       11.00%    
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Cash and cash equivalents:    
Cash and cash equivalents, Amortized cost $ 118.4 $ 117.0
Cash and cash equivalents, Estimated fair value 118.4 117.0
Total:    
Total, Amortized cost 183.9 170.9
Total, Gross unrealized holding gains 0.4 0.8
Total, Gross unrealized holding losses 0.0 0.0
Total, Estimated fair value 184.3 171.7
Cash    
Cash and cash equivalents:    
Cash and cash equivalents, Amortized cost 60.4 47.9
Cash and cash equivalents, Estimated fair value 60.4 47.9
Cash equivalents    
Cash and cash equivalents:    
Cash and cash equivalents, Amortized cost 58.0 69.1
Cash and cash equivalents, Estimated fair value 58.0 69.1
Corporate bonds and notes    
Available-for-sale:    
Available-for-sale, Amortized cost 46.1 28.8
Available-for-sale, Gross unrealized holding gains 0.3 0.5
Available-for-sale, Gross unrealized holding losses 0.0 0.0
Available-for-sale, Estimated fair value 46.4 29.3
Municipal bonds    
Available-for-sale:    
Available-for-sale, Amortized cost 13.2 9.4
Available-for-sale, Gross unrealized holding gains 0.1 0.2
Available-for-sale, Gross unrealized holding losses 0.0 0.0
Available-for-sale, Estimated fair value 13.3 9.6
Federal agency issues    
Available-for-sale:    
Available-for-sale, Amortized cost 2.5 4.0
Available-for-sale, Gross unrealized holding gains 0.0 0.0
Available-for-sale, Gross unrealized holding losses 0.0 0.0
Available-for-sale, Estimated fair value 2.5 4.0
US government securities    
Available-for-sale:    
Available-for-sale, Amortized cost 3.7 11.7
Available-for-sale, Gross unrealized holding gains 0.0 0.1
Available-for-sale, Gross unrealized holding losses 0.0 0.0
Available-for-sale, Estimated fair value $ 3.7 $ 11.8
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Amortized cost    
Cash and cash equivalents $ 118.4 $ 117.0
Available-for-sale, Due within one year 45.8  
Available-for-sale, Due after one year through five years 19.7  
Available-for-sale, Due after five years 0.0  
Total, Amortized cost 183.9 170.9
Estimated fair value    
Cash and cash equivalents 118.4 117.0
Available-for-sale, Due within one year 46.0  
Available-for-sale, Due after one year through five years 19.9  
Available-for-sale, Due after five years 0.0  
Total, Estimated fair value 184.3 171.7
Cash    
Amortized cost    
Cash and cash equivalents 60.4 47.9
Estimated fair value    
Cash and cash equivalents 60.4 47.9
Cash equivalents    
Amortized cost    
Cash and cash equivalents 58.0 69.1
Estimated fair value    
Cash and cash equivalents $ 58.0 $ 69.1
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Marketable Investment Securities - Narrative (Details) - security
Jun. 30, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]    
Debt securities, available-for-sale, in unrealized loss position 0 0
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2021
USD ($)
Jun. 30, 2021
USD ($)
Select operating assets and intellectual property of Myriad Autoimmune business unit and Myriad RBM, Inc    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Impairment on asset group held for sale $ 0  
Level 3    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Estimated fair value of long-term debt $ 106,000,000.0 $ 106,000,000.0
Level 3 | Measurement input, expected term    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Measurement period for earn out liability   14 years
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total $ 115.4 $ 112.9
Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 58.0 69.1
Corporate bonds and notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 46.4 29.3
Municipal bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 13.3 9.6
Federal agency issues    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 2.5 4.0
US government securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 3.7 11.8
Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial liabilities (8.5) (10.9)
Level 1    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 58.0 69.1
Level 1 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 58.0 69.1
Level 1 | Corporate bonds and notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 1 | Municipal bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 1 | Federal agency issues    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 1 | US government securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 1 | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial liabilities 0.0 0.0
Level 2    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total 65.9 54.7
Level 2 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 2 | Corporate bonds and notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 46.4 29.3
Level 2 | Municipal bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 13.3 9.6
Level 2 | Federal agency issues    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 2.5 4.0
Level 2 | US government securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 3.7 11.8
Level 2 | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial liabilities 0.0 0.0
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total (8.5) (10.9)
Level 3 | Money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 3 | Corporate bonds and notes    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 3 | Municipal bonds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 3 | Federal agency issues    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 3 | US government securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial assets 0.0 0.0
Level 3 | Contingent consideration    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Financial liabilities $ (8.5) $ (10.9)
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)
$ in Millions
6 Months Ended
Jun. 30, 2021
USD ($)
Reconciliation of change in fair value of contingent consideration  
Beginning balance $ 10.9
Payment of contingent consideration (3.3)
Change in fair value recognized in the income statement 1.3
Translation adjustments recognized in other comprehensive loss (0.4)
Ending balance $ 8.5
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, Net - Balances (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 146.1 $ 153.6
Less accumulated depreciation (102.9) (112.9)
Property, plant and equipment, net 43.2 40.7
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross 36.5 35.7
Equipment    
Property, Plant and Equipment [Line Items]    
Property, plant and equipment, gross $ 109.6 $ 117.9
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.21.2
Property, Plant and Equipment, Net - Depreciation Expense (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 3.4 $ 2.5 $ 6.3 $ 5.1
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)
$ in Millions
6 Months Ended
Jun. 30, 2021
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 329.2
Goodwill held for sale reclassification (88.5)
Translation adjustments (0.6)
Ending balance 240.1
Diagnostics  
Goodwill [Roll Forward]  
Beginning balance 272.3
Goodwill held for sale reclassification (31.6)
Translation adjustments (0.6)
Ending balance 240.1
Other  
Goodwill [Roll Forward]  
Beginning balance 56.9
Goodwill held for sale reclassification (56.9)
Translation adjustments 0.0
Ending balance $ 0.0
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Intangible Assets [Line Items]    
Gross Carrying Amount, amortizable $ 824.8 $ 825.9
Accumulated Amortization (282.9) (254.2)
Net, amortizable 541.9 571.7
Non-amortizable 4.8 4.8
Less: intangible assets held for sale, gross (211.5)  
Less: intangible assets held for sale, accumulated amortization 91.6  
Less: intangible assets held for sale, net (119.9)  
Gross Carrying Amount, total 618.1 830.7
Accumulated Amortization, total (191.3) (254.2)
Net, total 426.8 576.5
Purchased licenses and technologies    
Intangible Assets [Line Items]    
Gross Carrying Amount, amortizable 817.1 818.2
Accumulated Amortization (276.6) (248.2)
Net, amortizable 540.5 570.0
Customer relationships    
Intangible Assets [Line Items]    
Gross Carrying Amount, amortizable 4.7 4.7
Accumulated Amortization (4.7) (4.5)
Net, amortizable 0.0 0.2
Trademarks    
Intangible Assets [Line Items]    
Gross Carrying Amount, amortizable 3.0 3.0
Accumulated Amortization (1.6) (1.5)
Net, amortizable 1.4 1.5
In-process research and development    
Intangible Assets [Line Items]    
Non-amortizable $ 4.8 $ 4.8
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.21.2
Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]        
Amortization of intangible assets $ 13.5 $ 15.2 $ 29.0 $ 30.5
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.21.2
Accrued Liabilities (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Employee compensation and benefits $ 50.7 $ 48.9
Accrued taxes payable 3.7 4.3
Recoupments payable and reserves 8.1 9.3
Short-term contingent consideration 0.0 3.4
Accrued royalties 5.0 3.8
Purchase commitment 5.9 0.0
Other accrued liabilities 17.5 9.4
Total accrued liabilities $ 90.9 $ 79.1
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt - Narrative (Details) - USD ($)
6 Months Ended 27 Months Ended
Jul. 01, 2022
Jul. 31, 2018
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
Jun. 30, 2022
Sep. 30, 2021
Feb. 21, 2021
Dec. 23, 2016
Debt Instrument [Line Items]                  
Principal repayment     $ 120,000,000.0   $ 0        
Revolving credit facility                  
Debt Instrument [Line Items]                  
Maximum aggregate principal commitment                 $ 300,000,000.0
Principal repayment     120,000,000.0 $ 0          
Revolving credit facility | Amended facility                  
Debt Instrument [Line Items]                  
Maturity date   Jul. 31, 2023              
Maximum aggregate principal commitment   $ 350,000,000.0 300,000,000.0 $ 350,000,000.0       $ 300,000,000.0  
Scheduled principal payments prior to maturity date     $ 0            
Interest rate (percent)     4.50%            
Minimum unrestricted cash and cash equivalents threshold per covenant               $ 150,000,000.0  
Revolving credit facility | Amended facility | Forecast                  
Debt Instrument [Line Items]                  
Maximum aggregate principal commitment             $ 250,000,000.0    
Undrawn fee (percent)           0.50%      
LIBOR floor (percent)           1.00%      
Revolving credit facility | Amended facility | Forecast | Minimum                  
Debt Instrument [Line Items]                  
Undrawn fee (percent) 0.25%                
Revolving credit facility | Amended facility | Forecast | Maximum                  
Debt Instrument [Line Items]                  
Undrawn fee (percent) 0.45%                
Revolving credit facility | Amended facility | LIBOR | Forecast                  
Debt Instrument [Line Items]                  
Basis spread on rate (percent)           3.50%      
Revolving credit facility | Amended facility | LIBOR | Forecast | Minimum                  
Debt Instrument [Line Items]                  
Basis spread on rate (percent) 1.50%                
Revolving credit facility | Amended facility | LIBOR | Forecast | Maximum                  
Debt Instrument [Line Items]                  
Basis spread on rate (percent) 2.50%                
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt - Schedule of Long-Term Debt (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Long-term Debt    
Long-term debt $ 0.0 $ 226.7
Long-term debt discount 0.0 (1.9)
Long-term debt, net 0.0 224.8
Current portion of long-term debt 106.4 0.0
Current portion of long-term debt discount (2.3) 0.0
Debt, net $ 104.1 $ 224.8
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.21.2
Other Long-Term Liabilities (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Other Liabilities Disclosure [Abstract]    
Contingent consideration $ 8.5 $ 7.4
Other 5.3 7.3
Total other long-term liabilities $ 13.8 $ 14.7
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.21.2
Preferred and Common Stockholders' Equity - Narrative (Details) - USD ($)
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2016
Class of Stock [Line Items]          
Preferred stock authorized (shares) 5,000,000.0        
Preferred stock, par value (dollars per share) $ 0.01        
Preferred stock outstanding (shares) 0        
Common stock authorized (shares) 150,000,000.0        
Common stock, par value (dollars per share) $ 0.01        
Common stock issued (shares) 77,700,000 74,700,000 75,400,000 74,500,000  
Common stock outstanding (shares) 77,700,000 74,700,000 75,400,000 74,500,000  
Share repurchase program, remaining repurchase authorization $ 110,700,000        
Shares repurchased 0 0      
Eighth Share Repurchase Program          
Class of Stock [Line Items]          
Share repurchase program, authorized amount         $ 200,000,000.0
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.21.2
Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) - shares
shares in Millions
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Common shares issued and outstanding    
Beginning common stock issued 75.4 74.5
Beginning common stock outstanding 75.4 74.5
Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan 2.3 0.2
Common stock issued at end of period 77.7 74.7
Common stock outstanding at end of period 77.7 74.7
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.21.2
Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) - shares
shares in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Equity [Abstract]        
Weighted-average shares outstanding used to compute basic EPS 77.2 74.6 76.6 74.6
Effect of dilutive shares 0.0 0.0 0.0 0.0
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 77.2 74.6 76.6 74.6
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.21.2
Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details) - shares
shares in Millions
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Equity [Abstract]    
Anti-dilutive options and RSUs excluded from EPS computation 7.0 7.1
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Narrative (Details)
$ in Millions
6 Months Ended
Jun. 30, 2021
USD ($)
shares
Share-Based Compensation [Line Items]  
Unrecognized stock-based compensation expense related to stock options | $ $ 3.4
Options and RSUs | Non-employee director  
Share-Based Compensation [Line Items]  
Service period for award vesting (in years) 1 year
Stock options  
Share-Based Compensation [Line Items]  
Service period for award vesting (in years) 4 years
Weighted-average period for recognition of stock-based compensation expense (in years) 2 years 1 month 6 days
Stock options | Awards granted after December 5, 2012  
Share-Based Compensation [Line Items]  
Award expiration period (in years) 8 years
Stock options | Awards granted prior to December 5, 2012  
Share-Based Compensation [Line Items]  
Award expiration period (in years) 10 years
RSUs  
Share-Based Compensation [Line Items]  
Service period for award vesting (in years) 4 years
Unrecognized stock-based compensation expense related to RSUs | $ $ 74.5
Weighted-average period for recognition of stock-based compensation expense (in years) 2 years 6 months
2017 Plan  
Share-Based Compensation [Line Items]  
Shares available for grant 3,600,000
2012 Purchase Plan  
Share-Based Compensation [Line Items]  
Number of shares authorized 2,000,000.0
Shares available for issuance under the Plan 100,000
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Stock Option Activity (Details)
shares in Millions
6 Months Ended
Jun. 30, 2021
$ / shares
shares
Options, Number of shares  
Options outstanding, beginning (shares) | shares 5.2
Options granted (shares) | shares 0.0
Options exercised (shares) | shares (2.1)
Options canceled or expired (shares) | shares (0.1)
Options outstanding, ending (shares) | shares 3.0
Options exercisable at end of period (shares) | shares 2.4
Options, Weighted average exercise price  
Options outstanding, beginning (dollars per share) | $ / shares $ 23.42
Options granted (dollars per share) | $ / shares 0
Options exercised (dollars per share) | $ / shares 22.93
Options canceled or expired (dollars per share) | $ / shares 24.81
Options outstanding, ending (dollars per share) | $ / shares 23.24
Options exercisable at end of period (dollars per share) | $ / shares $ 26.25
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - RSU Activity (Details) - RSUs
shares in Millions
6 Months Ended
Jun. 30, 2021
$ / shares
shares
RSUs, Number of shares  
RSUs outstanding, beginning (shares) | shares 3.2
RSUs granted (shares) | shares 1.5
RSUs vested (shares) | shares (0.1)
RSUs canceled (shares) | shares (0.6)
RSUs outstanding, ending (shares) | shares 4.0
RSUs, Weighted average grant date fair value  
RSUs outstanding, beginning (dollars per share) | $ / shares $ 20.56
RSUs granted (dollars per share) | $ / shares 29.89
RSUs vested (dollars per share) | $ / shares 18.88
RSUs canceled (dollars per share) | $ / shares 24.54
RSUs outstanding, ending (dollars per share) | $ / shares $ 23.72
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Share-Based Compensation Expense [Line Items]        
Total stock-based compensation expense $ 8.9 $ 1.9 $ 17.9 $ 9.4
Cost of molecular diagnostic testing        
Share-Based Compensation Expense [Line Items]        
Total stock-based compensation expense 0.4 0.3 0.7 0.7
Cost of pharmaceutical and clinical services        
Share-Based Compensation Expense [Line Items]        
Total stock-based compensation expense 0.0 0.1 0.1 0.2
Research and development expense        
Share-Based Compensation Expense [Line Items]        
Total stock-based compensation expense 1.0 1.2 2.5 2.3
Selling, general, and administrative expense        
Share-Based Compensation Expense [Line Items]        
Total stock-based compensation expense $ 7.5 $ 0.3 $ 14.6 $ 6.2
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Taxes [Line Items]        
Income tax expense (benefit) $ 0.9 $ (3.0) $ (9.2) $ (18.9)
Approximate tax rate (23.70%) 5.10%    
State | California | Earliest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2017  
State | California | Latest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2018  
State | New Jersey | Earliest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2013  
State | New Jersey | Latest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2017  
State | New York | Earliest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2016  
State | New York | Latest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2018  
Foreign | Germany | Earliest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2013  
Foreign | Germany | Latest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2015  
Foreign | Switzerland | Earliest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2015  
Foreign | Switzerland | Latest tax year        
Income Taxes [Line Items]        
Tax year being audited in income tax examination     2016  
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information - Narrative (Details)
6 Months Ended
Jun. 30, 2021
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Segment Reporting Information [Line Items]        
Revenues $ 189.4 $ 93.2 $ 362.5 $ 257.2
Depreciation and amortization 16.9 17.7 35.3 35.6
Segment operating income (loss) (20.8) (68.3) (67.5) (202.0)
Diagnostics        
Segment Reporting Information [Line Items]        
Revenues 177.1 81.0 334.9 231.5
Depreciation and amortization 15.7 16.7 32.7 33.5
Segment operating income (loss) 37.5 (33.8) 48.0 (127.4)
Other        
Segment Reporting Information [Line Items]        
Revenues 12.3 12.2 27.6 25.7
Depreciation and amortization 1.2 1.0 2.6 2.1
Segment operating income (loss) $ (58.3) $ (34.5) $ (115.5) $ (74.6)
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.21.2
Segment and Related Information - Total Operating Loss for Reportable Segments (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2021
Jun. 30, 2020
Segment Reporting [Abstract]            
Total operating loss for reportable segments $ (20.8)   $ (68.3)   $ (67.5) $ (202.0)
Interest income 0.2   0.5   0.4 1.3
Interest expense (2.0)   (3.1)   (5.0) (5.4)
Other 18.8   12.4   18.7 16.5
Loss before income tax (3.8)   (58.5)   (53.4) (189.6)
Income tax expense (benefit) 0.9   (3.0)   (9.2) (18.9)
Net loss (4.7)   (55.5)   (44.2) (170.7)
Net loss attributable to non-controlling interest 0.0   (0.1)   0.0 (0.1)
Net loss attributable to Myriad Genetics, Inc. stockholders $ (4.7) $ (39.5) $ (55.4) $ (115.2) $ (44.2) $ (170.6)
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Cash Flow Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Supplemental Cash Flow Elements [Abstract]        
Cash paid during the period for income taxes     $ 1.7 $ 1.0
Cash paid for interest     1.7 4.3
Cash received for income tax receivables     89.9 0.0
Fair value adjustment on marketable investment securities recorded to stockholders' equity $ (0.1) $ 0.8 (0.3) 0.7
Establishment of operating lease right-of-use assets and lease liabilities        
Operating lease right-of-use assets     40.5 0.0
Operating lease liabilities     $ 46.7 $ 0.0
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.21.2
Divestitures - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended
May 28, 2021
Jun. 30, 2021
Jun. 30, 2021
Jun. 30, 2020
May 21, 2021
May 01, 2021
Divestitures [Line Items]            
Proceeds from sale of assets     $ 32,500,000 $ 0    
Loss on non-cancelable purchase commitment   $ 5,900,000        
Loss on inventory   6,600,000 $ 6,600,000 $ 0    
Myriad myPath LLC laboratory            
Divestitures [Line Items]            
Proceeds from sale of assets $ 32,500,000          
Net gain on sale of assets adjusted for transaction fees $ 31,200,000          
Held for sale            
Divestitures [Line Items]            
Impairment on write down of assets held for sale   $ 0        
Held for sale | Select operating assets and intellectual property of Myriad Autoimmune business unit            
Divestitures [Line Items]            
Cash consideration           $ 150,000,000.0
Held for sale | Myriad RBM, Inc.            
Divestitures [Line Items]            
Cash consideration         $ 198,000,000.0  
Aggregate adjustments for working capital, indebtedness, and transaction costs         $ (3,900,000)  
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.21.2
Divestitures - Assets and Liabilities Classified as Held For Sale (Details) - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Assets    
Intangibles, net $ 119.9  
Total assets held for sale 225.7 $ 0.0
Liabilities    
Total liabilities held for sale 12.2 $ 0.0
Held for sale    
Assets    
Inventory 3.4  
Intangibles, net 119.9  
Goodwill 88.5  
Other assets 13.9  
Total assets held for sale 225.7  
Liabilities    
Accrued liabilities 5.8  
Noncurrent operating lease liabilities 3.1  
Other liabilities 3.3  
Total liabilities held for sale 12.2  
Total net assets held for sale $ 213.5  
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details) - USD ($)
6 Months Ended
Jul. 31, 2021
Jun. 30, 2021
Dec. 31, 2020
Jun. 30, 2020
Aug. 04, 2021
Jul. 01, 2021
Feb. 21, 2021
Jul. 31, 2018
Dec. 23, 2016
Subsequent Event [Line Items]                  
Principal repayment   $ 120,000,000.0   $ 0          
Revolving credit facility                  
Subsequent Event [Line Items]                  
Maximum aggregate principal commitment                 $ 300,000,000.0
Principal repayment   120,000,000.0 $ 0            
Revolving credit facility | Amended facility                  
Subsequent Event [Line Items]                  
Maximum aggregate principal commitment   $ 300,000,000.0 $ 350,000,000.0       $ 300,000,000.0 $ 350,000,000.0  
Subsequent event                  
Subsequent Event [Line Items]                  
Principal repayment $ 106,400,000                
Interest payment $ 400,000                
Subsequent event | Revolving credit facility | Amended facility                  
Subsequent Event [Line Items]                  
Maximum aggregate principal commitment         $ 0 $ 263,500,000      
Subsequent event | Myriad RBM, Inc. | Disposed of by sale                  
Subsequent Event [Line Items]                  
Cash consideration           198,000,000.0      
Aggregate adjustments for working capital, indebtedness, and transaction costs           $ 3,900,000      
EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

@;RB>Z-(-A1O_,.'%IW# NC*"/W&&-WOVSLRC?!U'?5T S[O>X1*@TJ0*Z!VJV8/N/40=P)!J1Y$',]=SL1 M]83)@Y=?L#O[<:[0/TS>BIQ5&;S*-/UV0Y.28^F?TY9Z,'6DZLVY.]V]V$?50_6!O'KNWPA#D]Y"A@MB);=W&V"J M)W2U<;KPS]:Y=I2)?KFB?QUHF(#N%YKF2+UA!;O_,<._ 5!+ P04 " #% M@ 13?F[)T[\" #!!0 &0 'AL+W=O$!%KH DHTYA:#4&[/4Q[<)*#6'7LS'9*^>]W3B!E M4MN7O<0_[K[OOKOX;KA3^L'DB!:>"B'-R,NM+:^"P*0Y%LSXJD1)EHW2!;-T MU-O E!I95H,*$41A>!$4C$MO/*SOEGH\5)457.)2@ZF*@NG]%(7:C;R.=[Q8 M\6UNW44P'I9LBVNT]^52TREH63)>H#1<2="X&7F3SM6TZ_QKAQ\<=^9D#RZ3 M1*D'=UAD(R]T@E!@:AT#H^419RB$(R(9?PZ<7AO2 4_W1_8O=>Z42\(,SI3X MR3.;C[R^!QEN6"7L2NV^XB&?GN-+E3#U%W:-;QQ[D%;&JN( )@4%E\W*G@YU M. 'TPU< T0$0U;J;0+7*:V;9>*C5#K3S)C:WJ5.MT22.2_=3UE:3E1/.CB=I MJBO,X(:SA MN.9IA8(G8F8/T0#)M2*)72"[@5DF;&YC+#+-_\0$):E5%1U73 MZ$W";Y7T(0[/(0JCSAM\<9ME7//%K_ MV9XE @TPF4&=,A,&?DT28S6]B]]O MA.BV(;IUB.[_%?)-$M>!5Z9D*8X\:C&#^A&]\60V6]W/K^%F,9DN;A9WB_D: M/G!)KT$(>MCF(U"YL"[7-:98)*@A[IS#O"B%VB-"J@KJ8<.:-J *)"AQPZV! M,^B%_B4MW;X_@&,*ECU1J/886IJDKJ1_MLL,+@&PO=V]R:W-H965T>^#\B+M39?[5((Q[Z7A;*7@Z5SU>OQV*9+47([TI50>))K4W*' M2[,8V\H(GOE-93%.)I.7XY)+-;BZ\/<^F:L+7;M"*O'),%N7)3>;&U'H]>5@ M.FAN?):+I:,;XZN+BB_$%^'^47TRN!JW4C)9"F6E5LR(_')P/7U]S^;J2_ M\[;#ECFWXE87_Y296UX.7@U8)G)>%^ZS7O]=1'O.2%ZJ"^O_9^NP-CD?L+2V M3I=Q,Q"44H6__'OT0V?#J\F1#4G<<=O[HP>LT,K88T^N%-];L! M3BH*RA=G\%1BG[OZH-7BQ8,P);L3*>VTKGHK+ 4K*"K,2@ZL/'__X MVXN'MY_OV=W;FP?V44%X*LJY,"R9D5^F+X?,+06[U67%U88)Y801&9/*:<:9 M%4IJU)U(:[IKQ$H7*ZD6+,6E="SGJ2RDV[!G).2O?WF5)),W[^)-?SE]\YS- M-XRKC/$2)K+[C9$\&S)NV5P;.$F8H7],$@J!T!O+D26_U\6&S:;>BE>/6'&-NL_PS[$_L''*UDN9+IG($&VR%S1X;M#;VDIU!.-U%E=>&[F;<_=\PX+*R0_[+1E&V]89 M,Z4=!(N5U+5%Z7@8H91LC4C"*S6T %.JE1*=HFWRBDHWY ^W%DS%\D)8"GE$:]G(-V;'M UA[(*\8>!*U)YZAU>(V]&P$-\.#69J$ MXB#/4/P;B(I" <,Z" _XA@!X--:WB =<\B8W+4.'QG6:DF=%1&5[)65951M; M0SP%8E'+S#L+FJZ_W++3\\F+,Z"DN>:%DSC\4X@9B&%6%Y"Z39:*;X)>M$L" MMEL)M!00H$AB4:_-!NA[&V N.<-&$D3566@XUC>)8;^'X-H(/T"Q)]A&?EUS M@RG@)#WG>2Z)Q)%;Z=F^CTDF$QS13E&-0Z3F_#]Q8'0@2-1$4$&YD"+?6W6X M+&H*ACUB$B^L[M@5H[T5+E:-"R.M'.WV\WX?;0636^-(.=!@\70ND/??J7P< M$01/WTG/A_@G16XFTT-+#4"PS?(VZYH7/C&;0U2KE93\YN&K58.DWJ5PO2M,*H7)!$&!H2)B#, M"XU*(6E49J;:<[ M>6;;2$D1/!\JH6^I1X.MO24EIWZ@EW(.-@I;JP(,N%M:C&;7H5EYJ-'S>;<( M:M-MO1)VS-'_E+#838Z$-YK",<44JC(4_S4$%A4"K, J1U2O5I=H#G& MH@?>=(DL$+$G.X,S6X=M'BM^,MH']"G+GS(2)]HBC$&@0=]EF5S)#-JLEV@T M746_99+<3;7)W^:_[Y" <8R+P M5EW3\%HKZ,FV:-N%+_QA"J1TB/>/]Q=/Z8B.MW&D+=GS99?D\ ],W8< M[C/[!WC,,7KPY)C88=W1RX_&,03I1X/X$RPPN)@L+N@DW##WXW'E%5"F?%Z( M5HDGOE'+OGG1G:5>[0C?#6>@CZ&W]HEP&%'AM$XFU'1(/]+>>_2QIM1!X.>#[!YDCQ1;'TPF,W]V*OE7ZJ>;@\".S!L0DN8-$+W*@=>, M=2]HU(7[?DU3$]3!Z[EUQ);A[8UW>:S5,&KH*KP%"IG1'/AS3^@S74*,3+T4 M)#\W,O(GW]=]8NROV72$+A'Z!) N;US9U9,<8 MD93%S0LK2A"D=P?+YYO[(7NOTA'M"KYG*UV@W1+F+2PZ3=;DJ".TJ=/4^F-U M_YCL3>%4RJ#]?1/2 A'83C,HEJ@K73L*5Q;H;B3H=%@R)D*CN-QJZ%/4DV]; M&D,(VPKZ MXA0GX?((G]ZJ2XH1E@,1*DXI+F=AXC142 H!#=:O$\TG)T\RJP MC5H8H;GL,]Z(@XDX&"QUM^?DD5/DMTZO!H+*_]6P;; M\]PC",,!&DFB"W1Y^YH] YQ8\_;YUD^]$O;O@^F$&AQQXE\,39,W^)4D+T?G MNPO S_P)O5WW;#KZ[?G.JB$&Z79%DIR.7K';&.=*FV \6&Q?]'3R&PO M=V]R:W-H965TH#YO4)2$)+:H@$K1L M9:)K1=GV,.W!)$=BU;&9;4KW[W=V(&72RM->8I]]]]WW7>X\W"G]9&I$"R^- MD&84U-9NKJ+(%#4VS(1J@Y)NUDHWS)*IJ\AL-++2!S4B2N+X(FH8ET$^]&\1B$< M$-'XM<<,NI0N\'A_0/_HM9.6%3-XK<1W7MIZ% P"*''-ML(NU.X6]WKZ#J]0 MPO@O[%K?+ Z@V!JKFGTP,6BX;%?VLJ_#4<#@K8!D'Y!XWFTBS_*&698/M=J! M=MZ$YC9>JH\F+SVM]E4CW'!3"&6V&N''>&6LIC;Y>2)3UF7*?*;L_]3U))@;S"NS806. M IH\@_H9@_Q^>3M=P/S^RZPK_J&!WU:H.Z\A-IB,)6VK9MN]-NZ,=MK[^Z MMR_&'=,5EP8$KBDT#B_[ >AV"EO#JHWO_)6R-$=^6]/#A=HYT/U:*7LP7(+N M**DW[=QBKFP@2Y0T3]S;7+AZ-,L^K8P*!(OE&?]* R/^[F0JG=QYM?NS<69 M+ETF%=X;L&6>"[.ZPDPOSWN#7K,PD8O4\4+_XJP0"YRB^US<&_KJMRB)S%%9 MJ148G)_W+@[S?\(7%I.^_ ELRT?N"/#\EY+V1"F&'L&$'0XQ&O,V!PG.19FYB5Z^Q]J>(\:+ M=6;]+RRKO<.H!W%IG?DJJG3\4.JLP2- M?0GCKZ5TJ[.^(W4LU(]KZ*L*.MH#?0RW6KG4PE@EF&S*]XEFRS5JN%Y%SP+^ M4JH #L,#B,)H\ S>86O[H<<[W(-7&09_7?S^#.6PQAQYS^"/\^1_0 MD_&[\60ROH'+CS=P?7=[>_<1II_NKG]]?_?;S7@R)>C?/W_X]"=\2I%5%T*M M0%H0I4NUD?\0*:=IP98(9<'O1T%(295E7!\V%08MZ#D4K0V6B1] (0P\BHS$ M7H1!.( "3;4]8%4&8>D&H!P@%%$-L(!M_/5U52%[GG$=T.?%IO()\BKUD5,?7DG5:+2O/1+_A'"%"ZD4BW0- MV0<[.@J&,!H&1RV+[NZRH!5\0A-+B^P;77#;LP?PB-:Q/*T1:6=D[)K00JFD MLUY349HXI?9F:8WR%# O,KU"K#RZ)*W I1Y"[+"9OQ",:&AJ@RGQ&8H2^ M.RNZ5 *XD9G'_*$J#T"J."N]\0R0L%(:/8#S.@X@[!)0)K*$C^ E[K,$M)*=E "".7DEEU5.<]U1G.>3>>"IH2+M8IE M)ENMWB.H-,TRX;2QS=K,YP(G3[(_2*]^_NEM%(6GX_NI?QN5MFI:=0K5UA!-SO:(L_T81L?\PV_C-A%: M']:8;-4@.MW[_!XNK0\]+L:ED4YR76]Q;/R\C^4U&D>GN@WLNJEX'7N:21.C MR?2S;8/D.^^.C%S'KIN1.R(_PUB0 5ZJKJ-.1LX0JYQ\TQCNLY';E7946%)D M:Y?$W1Y^0)4EXY2.5"M"66\B/\U+5QI\AM0!U+52)3UE7SLM]J7899?CAC?9 M75L>XL!T/32B&3@*!M5Q B;8]N1[HQ=&Y-PO/(,H'!P?=+N%3Y_1J84K3?V! M77TCJ31]_76FKJB=;=;010U-(B_HH-^9PG7=;FOH9LM&FZN"3@=Z]JU_:L,] MEKM)'-,QW8BZ]TKN/D:7BQ3X\D&Q,0_4H^B,IJR(*Y>1;&&H;3K,5M3!%IIB MS.(;FR@T"3HT5,J,O.H2?FD)5U$)T0VC[ETBUZ5R/AK$KQZ9%?FU1YKYR%"- M@W,A8]= )>^?VX<4C8"_^VQJA/;ZFSU8C (.R>B]5AK[.Q ^#P, MX*-N]OBZ7D-2XZ%N4\\]N]UW-VAR!+DD@EV'[G[G0I.C6?AK&P]HBD]UMVE7 MVYOA974A6F^OKI6WPM ART*&&PO=V]R:W-H965TR)G-X/G7Z 2$AB0P*Z &A9]]??LPN"HFS9GFDS_6"9#^QB]^S9 M!WBV,O:'6RCEQ6-5:G?>6WB__-#ONVRA*ND2LU0:;V;&5M+CUL[[;FF5S%FH M*OOI8'#4KV2A>Q=G_.S.7IR9VI>%5G=6N+JJI%U?J=*LSGO#7GSPK9@O/#WH M7YPMY5Q-E/^^O+.XZ[=:\J)2VA5&"ZMFY[W+X8>K,:WG!?\LU,IUK@5Y,C7F M!]U\SL][ S)(E2KSI$'BWX.Z5F5)BF#&;XW.7KLE"7:OH_:_LN_P92J=NC;E MKT7N%^>]DY[(U4S6I?]F5G]3C3^'I"\SI>-?L0IKQZ.>R&KG3=4(PX*JT.&_ M?&QPZ B<#%X02!N!E.T.&[&5GZ27%V?6K(2EU=!&%^PJ2\.X0E-0)M[B;0$Y M?S'Q)OMQ< 6_ZT3,1KLBW20#E_1-VI=';&^T4NN+J15!U-V]4ZNP2PO M+JV5>J[X^E^74^;/Q3\#U54V4E1_<4F;JO(>T<\H^J-[% MY/[V^A\'5Y>3FT_B^O;+W7]Y]NOXE:+K^9!55-E&^R&Q_O"+Q1;(?7Z MSW\Z28?''YUP9.'"E+FR3LCETD(LYY4R-TM.&3/C>](A;JIE:=9*[8M/A45* M&2ND)M^T0P)(X'?S6UWXM?BL,Z")5!-WI=1B3T([\ 4G@AUD0#KXR$II!=\/ M/[Y/Q'WZ_-;SAV MXHU-G1@E1R@>94G8-+H@E $E>A \:W6CT@?E';A;RQ+Q>08?Q;?)]P"&RG%7Z [\/K"N9I6D36[[0J^U)I6!DW )0/3+,4D MB/B%]&*E+'"JI_\!\A%/,G(%MX6 >@B$FN2B2.7;^! MQQK)X4QP[;]S"K>ZYB+1[@3-RE8-@Q] ?/)KJ> $?"5SYTHKBZQ1!_%R@(E6F3LYU;"%+ MA47KF^(&>454JZU8*XD]P;@%^:A#7=.:T'4R ,QE1'I%KU>+(EM$SKA IK@Q M#,]K&U.QHB:'_&Q$7(V?KF+2"&>SK+9/<6;5,6G@3J:L)UYNW*KDF@+:9'_D M>UYGBC&A![H5DWE>4+63)86)YS,*>Z6H9 &]6R[BCN/Y%$EM]$'<=E.N IA0 M/:O!K'I)FR&PI8J%UJ#*$++,&G2B(E.[P)T9JMT1L8!QP+LI6M&TU\(8]4<* M0L,FLAT5C5-R!DZ*3RH+O>^06U\:,XZ'LX84,VNJ+<-81>"]>:(UY# G$!*? M!38V-[I1&%[5W#2!UN++. %'4$(!;GHNCZE4,9Z5E#:YMDH*65UHH@@/,:$V M[7,E8-W%8Z LQ*@';W<**M-H#R%>[H/8>UH4B Q-XW#OQ=?P]E=&$[JB1]U* M")C:((R&O,U '":I>"?249*.GP6.W4H_XGV\^D4YV!+7J4=ELX*XOYD M)TU.1^W[4$5#KH2(8.6@63E.3H8OF;F-Q"@9!!/'Z=.MN;0^$TB3,0D<)>GA MBTT8[%@!WW?0VO9?"KKQ2%H:+S(SU\7O<;QHAM.L.\K )5PKE(%2-LG;Y4OL M?DTKZ&CD))(H92%8!Y@]+(Y933Z1&8 S9M.WS: 3R/I=%WX'5;GM_QR&HLB5 M-<>BG24<-\)=U>S_1&@NDV^R>138/$@.C[8+ZS YI!>GR2>.(( MO3X%Z&],T3SA3Q4Z@JPQTED"!?6_&=]MF'B?CLSI4R]6U/<()#09&29EI1D] MS+X+_)\INYG.7C@#, 2/186X00VX]^8)P+XX2KYF;M/>=IQUQ4W#GLG;]&H9 M%*H%E09%%TUYP?XZJ-?.E$4N0Z7"OW" @B^W0$-N)AXRQ*H%?3Y"2'XQS@5B MH#!D+-TM$_<+J]1V69D\K3-[6Y4CM "J!INK:X,9!I94IE1976),R@LYUWA: M9)@2PD3]#J$8\^^(?X^;WRB\1' JG/9K""%-R96L+#3?-".1:SLE137\I53" MP1B>1G$"50^J-$LNN!'D(>@[Q$+*P!2[3W#V@$7[<:()$Y#,,=@7]"&$S_!1 M^!A"9/)PC*,D>A[.151%WBP<[\1)\[]3(+#K&TN_\QVK4G;.7^M0 M)4VM??BDU3YM/PA>AN]@F^7A:^(7:><%J%"J&40!\&%/V/"%+MQXL^2O8E/C MO:GX*';1?+)*[[\WU M9G9]LM+FHRV8':VK4MG30>%<_6PTLFG!E;")KEEA)=>F$@ZO9CFRM6&115!5 MCJ;C\<&H$E(-SD[BMRMS=J*]*Z7B*T/65Y4PFW,N]>IT,!EL/US+9>'"A]'9 M22V6?,/N?7UE\#;J6#)9L;)2*S*V%_W/";Y)7M/5.(9*'UQ_!R MF9T.QL$A+CEU@4'@YY8ON"P#$=SXU'(..I,!V'_>LK^,L2.6A;!\H:* MT\'1@#+.A2_=M5[]PFT\^X$OU:6-?VG5[)W-!I1ZZW35@N%!)57S*]9M'GJ MH_%7 -,6,(U^-X:BE\^%$V$C3\73R -^L"V\6^6:/AD?/I4U+;;UA^FN^L,Y $'\_8&*O,[$73>S] MQPP^@GY[\>N;%_1N_L>+&[I4I$W&AIR&LAP;%)S)%4P7NJJ%VOSPW=%T/B MJI!I<<\[#)D(3>B"C<,L(2N72N8R%25M]&RX\J20!$MUR)@D /#J<;N MSW"P-=WFAS*85LL[@["4IMY$ST%-"P1!5GN3,ND\>BP6LI1NLV7:D9[=:P7POQQ.DL.?_H^.(H!_#28@: MI2&)!HSP!3'=:0#A*/BMWH__7^A]I>T2^[\E&PN]JRZMP1R=#JEL6)A@+PC@.:=<+5"N MV:0Q.B21?A(:TH<: @(IZ" M;7%0V][>BD5I8T^P3AOMI10&^:"7-_Y*RD*[IIU.20HV^EK*2+QNU]FY DQH1!$I#<)C+A M,W328A,#NHFVP7 !.<(I)<4N^=F^(":'3_'G:'B?X"TN+J]1<8RF1PEF@>#P M^$N"/W'S>1Q^$.T?TRL<+#&QWV1O_SAF^P9)_(P3)SP_"MP/P(.$YLUQ$3 R M*$M6L5 ]@:!\I<\PA2OME0NS#/<]I!NJ5.A9:T4X63358D,BZ,P&9=KFB*I$ MF/T6%["F7W@M<&(V8HJS3,+1. 9Z\CBF J*_9=,4HC%,X-B.PEK(C'P=+YU6 MEWY+)ZWUD$TPVG0I!0 .C!*@KE];/I&FQG.6[+I@C'K7M8K-,EY*0^@ -C>W M[FMW[YTWU[V[[[N M;,(&K.=:N^U+,-#]-W#V#U!+ P04 " #%@ 13#\^_C%T# E!P &0 M 'AL+W=OXY/" >)HG3#,PEC"CANU:&9DGM??,R3:FH40L:V08-WU36:>%YZS8I-0Y%&9VT2K/Q^"+50IID M/HUG]VX^M:U7TN"] VJU%FY_C,QE"!L?C]0']==3.6G)!N+3JHRQ]/4NN$BBQ$JWR'^SN+?9Z MS@->817%)^PZV_,L@:(E;W7OS RT--U;?._S<.1P-?Z#0]8[9)%W%RBRO!%> MS*?.[L %:T8+BR@U>C,Y:4)1'KSC6\E^?KZT6DO/6?8$PI2PM,9+LT%32*1I MZCE$,$R+'NZZ@\O^ '6O_BE3&_AE!W[7V9. [UHS@M/Q"63C M;/($WNF@]S3BG?X?O7 CJ5"66H?P:9&3=_S1?'XBZMD0]2Q&/?M;6?X/N/>K MU=WCZG;]^ "+]0TLWZ\?[]9O;M?+N]N'QQH97S?"[$$2=UO^A3L O(6M<-*V M!(424G=$%&Z$@L;9 K%D1GQIM^AXQ1^9]^@(?"T\L"JC6/-]"9<+[Y!?]#@N403\O M;-O$%#G\UB)QIGN%TI4O&N$X!8W86Q;%,QJ$XIHRJ5!&/H[?W B./XI2DM@X MQ) $7\>H+,>S(3.G0R%XZI<=_3XH8]>BX^.XM[DPP.=2QQ2P2'2/^6 MQ>\:*3T:71K=)@[HD-_6^&Z*#:?#/V#1C;Z?YMT/9"7<1K( A16[CD>7YPFX M;BAW&V^;. ASZWFLQF7-_S%TP8#O*VO]81,"#'_&^0]02P,$% @ Q8 $ M4]VU!JZ^!0 - T !D !X;"]W;W)K&ULK5?; M4B,W$/T5E4.E["HRGHNO&Z *%G9#:F&W@$T>4GF09^09%3.2(VDPY.MS6K+' M)KM 'O)B::3NUNG3%\E':VWN;26$8X]-K>QQKW)N]6XXM'DE&FXCO1(*.TMM M&N[P:OU M<2_I;1=N9%DY6AB>'*UX*6Z%^[KZ8O U[*P4LA'*2JV8$N.),7]^=;Z M!^\[?%EP*][K^G=9N.JX-^NQ0BQY6[L;O?Y%;/P9D[URUOK M=+-1!H)&JC#RQPT/>PJS^ 6%=*.0>MSA((_RG#M^%>]-L!) M14&Y=0:[$GKNY%:4H-@QK@IV(VKN1,$N50@V6#L:.AQ"HL-\8_ L&$Q?,#AA M5UJYRK(+58CBN?X0X#J$Z1;A6?JJP5];%;$L/F1IG":OV,LZCS-O+WO#XQNQ MTL9)5;(_3A?6&>3'GZ^8'W7F1][\Z/\C] V#%Q^O+J[OV.GU.;NY^'1Z=W'. M+J\_?+ZY.KV[_'Q]5PGV7C@4+DTI=9P^^%0;$]4/8S['O@*A?>']JUG3#,DX+B)9EP M.QP1(U =B%9)9UG%'[ F! JQ+(TH/3%2.=![$CE>=&PTHC"IGSFMD5=GCM)/Q9PVT$STCGMTJA!&9@ MT5+OL2SGBA%PN<2^LH743N25TK4NGT(2;1P#'8*;O +\ M GW.P,'#W2))[@4ID):C-@(IVU.1GEO?;)"1*J];@IMKLZ)PBYVT;=A]S3J*>B-=M2@8;4!4J,/%:H!4IWE).L:\J" 3O?2^S//B!WV@';766$ M8$WHL8)Z+$.'%%V'1-/QP"P[8,ET&B4TIE%&PVP>C=BYP)E(J7 I CUOJ _^ M'1:2<31E292R9!+-.V=?83J,)?4Y2^/@Z MK"P%FA3BV1A$OT7:: 8'^@F8]O"F-+P*[QEG:98 #T8*% W3-UD#'V/ 2PC> MY$76$C@\ J#I*)KX:*91_-UP?H/U>>)Z/CWJW2RD[K].I-K]3M^'4YM4.M@& M[V!+TT&'ZZOBJ*G0;LT\>N='-UAMJV0L!7\3V5,JOE]I>M"&!]$C_/ (QWY2&PO=V]R:W-H965TLVE9I)2'0CG: !!VH3'U!I5T_3/M@DH-X=>S4=J#]]SL[@;%JK39I7^*W M>YY[[NR[=-=*WYL,T<)C+J3I!9FUQ4D8FB3#G)F&*E#2R4+IG%E:ZF5H"HTL M]:!5/>[JK2"2YQJ,&6>,_TT1*'6O: 9;#:N^3*S;B/L M=PNVQ!G:VV*J:15N65*>HS1<2="XZ 6#YLFP[>R]P5>.:[,S!Q?)7*E[MYBD MO2!R@E!@8AT#HV&%IRB$(R(9#S5GL'7I@+OS#?O8QTZQS)G!4R7N>&JS7M ) M(,4%*X6]5NLSK.,Y='R)$L9_85W9MEL!)*6Q*J_!I"#GLAK98YV''4 G>@$0 MUX#8ZZX<>96?F67]KE9KT,Z:V-S$A^K1)(Y+=RDSJ^F4$\[V9V51"*0L6R;@ ME)D,QG1/,)'5?5/BNJ$E/\XZ3&K.8<49O\!Y!!=*VLS 2*:8_HX/2=]69+P1 M.8Q?)?Q2R@:TH@\01W'S%;[6-NB6YVO]6]"C:L_ M\'<6$T/YOLKSMI;9VWO MK/U?,_PJIZO4$U.P!'L!E:)!O<*@/[N=3L]'%Z/+F\$YG YF9S ^O[J#R>7X MZOIB<#.YNH09?X2\NAMT=P/ON:17)02I,/L^O>X353H+QE-(2\WE$FR&4*#F M*@72#5PF*D>P[!$-[$&S\=%_=X&5F4729[U!N]&JCC4F2*7XG*G>9W-!G)WC MQC&\?=.)F_$G&#.N8<5$B<#2'U04+IM -4U]Y!ZM0Q#/"NL#@PF)MIQHB%)I M%ZA50+64W&=*I*C-.\"'DMLG>!\U6OL0D;R1<43<9!7Y JCQ:;H?"EX@U3UH M5^ ':G%0TH(9@_12F$SK4\'9G(O*Z]5?(/>@'34.:=@$^1RT2]@^(H$;PS^] MR7"G ^2HE[[/&4A4*6W5#+:[VU8ZJ#K(+_.J#U\PO>32D(H%02DSAT$5P&9A M5>'[R5Q9ZDY^FM'O +4SH/.%4G:S< ZV/YC^3U!+ P04 " #%@ 13#^ZQ ME4\& "I#P &0 'AL+W=OG7TL9Z&.AC3\=K$,HGXU&/EO+0OC$EM)@9&E=(0*: M;C7RI9,BCXL*/4K'XZ-1(909G)W$OFMW=F*KH)61UXY\513";<^EMIO3P630 M=MRHU3IPQ^CLI!0K>2O#+^6U0VO46Q)PMK_^3&97XZ&#,@J646V(+ WP=Y(;5F0X#QOK$YZ+;DA?WOUOJ/T7?X MLA!>7EC]J\K#^G1P/*!<+D6EPXW=O)*-/S.VEUGMXR]MZKFSV8"RR@=;-(N! MH%"F_A**)\+H(X.W%V0XYGPQI_1%?C:H!3AI-R M&QQ&%=:%L^>(B0\J5$[ZDU& 1>X?9L_J([JR)JP]O3"YS/?7CX"D M@Y.V<,[3KQI\79F$IN,AI>-T\A5[T\Z]:;0WO=<]GP&A,I7,Z6TIG6 N>!(F M)XR5U@M-+YVM2D^_S1<^.-#D]Z]L?-AM?!@W/OR/<7U@]>6[%[=WEW>_W+RX MI;>&YJ53FM*C.BY#"FM)%[8HA=F2-$$Z>*=,L"28DDQ<(B M?M9MA[19JVQ-RL>YNP$T18")I73U4+V>KJ06QA:" H*2T!U&$&GC15V:OEIX M^;X"4KVE3%L/=]!]);:4'K<^<\H>1$8;X M3--DAHK2&AV?0V([(LMLA>C6QKBC"Y'P7@;?86ISX61F5T;]A26"#"1U!5FL M=YLD:;O;$+FBMUCG\)'90K*S/3/??G.<3I[\X-%&61F.!K[@EC;=8[5#F'D"B-#F,Z%KIV(HNJ[A?@C)[@QLP"3&I*L\,NJ+J'(E5L:"W!GO M6%J'\EJ1ERN&E- KV43_EF/UMD[CY+\R%R.0<$VUCK=8L5\O UB/*1BND.W2 M\9RP'39^\%S>]!W&G?CVF\F3PQ\B#8>T=+;H4VI>!:N*HC*2%I5'27I/%1#1 M(YXTZ V?M\-W.\H,'C/8-SLJ7EA7VAWAYH5T*A/T"NP$*/\P0R>S<3+>I^@# M&+@BY<<2KM8LB+5$>>7:*+ROA$/0$?H8F%M9@DD+=+2:F[092_]WRIJHWIQ? MU3J#$H9N6(T:MQL#(USV"FQ"K!K5:;89LHW+G]]=SNGF^6U/I>X+U-/C7:"P M3?X'#LZF;/E2P*YFHE2(-=,BEPN,D%, .Q?:MOM:'HE"A8"L W% @+ M>]$6VD+2P:-I\O1QNW];-F*%B*PPC3/'2MG?I=.XUY7NJJ-.<1OJ0@I?<:QA MS.\8*8$AU+)K4:Y-Y!3'QKDM>_I!Z J2XF@IT%VW-!.%K4;_VA0E]),EA>V4 MJX\)X?L2UJC2NBWH*'Y-W7V94UCTFKFY8Q-[M"M:'(:X+?D&]+Y7N25C UO3 M:KF-&^[41;#L]([RG6;M;<$:MG^ ?:FF.>>?DC,F]A[E^^X!S8L&;=3SS\:& M[#,7)&I$;VNP2]2 W<3PB05"BMNTCVJN3'W+KB^\>UK>DSNMQ$)I5!V"EFD, MJ*7B \=_FJFPGXQG] A^-2SUC^DN:L^\-GQI/@ "R]8!39-#M(,P*P5XJ 8^ MR2:3I\E3>FEMOH$%.C[&Z5F?80VT"8J@L=GT[,,YH#2=)4_H30_^/,LJ! MRC#?9P)W-AT9HSHX9>6R-4<%]XA"A8Z.W8Q] @[_8>$.F4Y]Y#'IQ@*V66') M6D#R*R^[N^,*Q$ MGEN^4+35W?CX:6GM77T>\7F%.\[CSXONWUY_6BQ?$Z0O M7>U'O><3#NE5?"2BMECQZY=4U]N]0^?U\VLWO7[$7@FW4H"BY1)+Q\D3//M< M_3"L&\&6\3&VL %/N_BYQEM:.IZ \:6UH6WP!MWK_.QO4$L#!!0 ( ,6 M!%-_0K$PA , ,0' 9 >&PO=V]R:W-H965T2(95]%\&LYNS7RJ&R>XPEL#MI&2F=T2A6YGT2@Z M'-SQLG+^()E/:U;B&MU]?6MHE_0H!9>H+-<*#&YGT6+T;CGQ^D'A@6-KC];@ M(]EH_=UOKHM9E'I"*#!W'H'1[PFO4 @/1#0>]YA1[](;'J\/Z!]"[!3+AEF\ MTN(++UPUBRXB*'#+&N'N=/L'[N,Y\WBY%C9\H>UTL\L(\L8Z+??&Q$!RU?W9 MCWT>C@PNTA,&V=X@"[P[1X'E>^;8?&IT"\9K$YI?A%"#-9'CRA=E[0Q).=FY M^;K96'QL4#E8/='73A-'L%Z8Y'N(90>1G8 XAQNM7&5AI0HL7MHG1*?GE!TX M+;,W 3\V*H9Q.H0LS49OX(W[&,A6D;(EHKS@U'M>_0B0T#5^4LP@H'6<^H\< M$,T-PN#7<7SYV\$_.0BQL+(T6)):# L;3D)B'ALF^):3,2,TL#7FAZVEF1=T M2$*-S'V.&F)K@O6">-!]A@\LYX([2A*I4?0GR_*+]8W)92.?N4!MN,IYS80O MFN1=<)XTQ?9O#T0BI\%J?2:-EC 8I^ESGGWP@^Q\')\=3N+^EAR:Y>4UD:R@ MV.!)"TJEK_HSF9KM.B:^FNEY/#GV0D(2=#?$H)_LOJ TT:VC\OGUA@FF 7/ET% I>]_$I3&&K$Z A#HR8F!IPKZ,K*)2*/TZI=,5W!?0 MBPI?F[#F%K8D567\VBA(CB:K1%.&]\-2+2FCW9#M3_LG:M%-YF?U[GV[8:;D MRH+ +9FF\>]G$9CNS>@V3M=A3F^THZD?EA4]LVB\ LFW6KO#QCOH'^[Y/U!+ M P04 " #%@ 13XR>45R0' !)$@ &0 'AL+W=O MB6A @ 5 V^JO[[D 2,JIK":S+S9! /?SW'.O>'YOW2=?$07Q4&OC+T95",VK MZ=07%=723VQ#!CL;ZVH9L'3;J6\JO5T,9N=3FNIS.CR/+Z[<9?GM@U: M&;IQPK=U+=WNBK2]OQC-1]V+#VI;!7XQO3QOY)96%#XV-PZK:2^E5#49KZP1 MCC87H^7\U=49GX\'?E5T[_>>!7NRMO83+WXN+T8S-H@T%8$E2/R[HVO2F@7! MC-^SS%&ODB_N/W?2WT;?XKJV^C^J#-7%Z+N1*&DC6QT^V/N?*/OSDN45 M5OOX5]SGL[.1*%H?;)TOPX):F?1?/N0X?,F%1;ZPB'8G1='*'V20E^?.W@O' MIR&-'Z*K\3:,4X:3L@H.NPKWPN65],H+NQ$WCCR9(&.LGMU8K0I%_OGY-$ + MGYT66>)5DKAX0N*I>&=-J+QX8THJ']^?PKK>Q$5GXM7BJ,!_M68B3F9CL9@M MYD?DG?0NGT1Y)T_(^\5MI5%_1$_'XMH:#V?+Y+@TY>-((#)OE9&F4%*+%5X2 M$!F\^.]R[8,#IOYWQ*(7O44OHD4OOB8)AR)_7,QM14!Y8>M&FITR6_:M1/U0 MN>:A MJ*391C=KY2.U=%:MWEQW1DW$4NMD50YGYU$2@\P;+XND:8@4:842C3%&K(I] M9$W$SR8:9!ME,K!J:0(PGQE6UTB;H)[28[7;ZU)9!WE[\&1$S,_>XWHMZ4*7Z2'O3DU.G,PC5\W$,SZ>T75<^ \#F>JN)Z GLH' L9%HL)NR >B^7NKD-,]='&: M:_F)! $AJ*E<"]*C$S<)PZ&20L%R<9IH LJ]9"78]P7]\1H]T_:Y>B.3$M1!STTC$,O MRC:"?K@3J2BF:R)^P8.,;V PVO? ?J%RE"1Y]2#JU,A2>M&&J&]#B.>.T=77 MDD+M ,O*E& E'C2294DZXH\]MJU@VUD94XIE8/;=GWF)='F\-/I)/FE01GQOZ^.]1BOEZ*>$]]GJMNW_,^(I_9I7$8(UW8C46C M)?-=3!:0VB3Z0Q! RPIT[M->BLT3Z(EHC;1;4P)2 8Y'_"1'??3(B-%>+XIP M\LB"VBCD8;T3R]6U.#E%4F]Z V\& ]\,!L:"<>P2P2TF;Y^P@)E43\3;81O-GR?+DBF!A79U6G+<"J(2 '6VCGLQ ML+EDS!#X-B X?R1(%S'BK4.K\P#S%I >*/&1%1TEHH =EW[>C&3@.CNXQ\86 M[.R:%QWEI[Z84!TE0K2)/ I\A;(+^3N(]6%[,3U-=E64DV<]&"$P&TI6Q#1Z&U&.Q1^KMM*^W MTZ.5\H$>V^X/%=M7BA#7@"CW?\Q4,#4S1D>%PQSB^HN 4$Q,#,7057DFB"!) M$IJ]L3-EU_U%=91NT$21]B)T2 TV\* 18SK.J[VPCL'EMOA465V2\[G1QKKG M2BNDK\0&><_PMHF6H6W,]<.805,9R#G3]Y'DG/7).?N[R++[RV%*1?T;/!>I M4@[EZO^3*-(!=(EE:>.(C%'%E "EY\FPGQT6L_GW:1I\NUQ=@1E\B[/+U<>X M\^U\,<9Q%!J)6_G (_4M!LI"G+V8/7\E5DB.5IM=U_GVK.$8/KZ8YY(]T7O3 M+V@QOV1RDLC%_?Y,[[/MD4>RTOW]---';2%J2Z-H;>]HC)(O<3Q3:EEV$_TP M0W0S3 H<.&1?5,)G;P"LHSBV<,MEM1N(D:EM@E5IJXR)9;]!?QC"/'^91K1Q MJ@DW54&NR,&@ORG_YKI M^""XIWL_[VMRV_@1@_L)HIU^Z?=O^^\DR_1Y8#B>/K*\DPX1\6A(&UR=3<[0 M[EWZ<)$6P3;Q8\':AF#K^%AA/B?'!["_L2#;O& %_=>CRS\!4$L#!!0 ( M ,6 !%/0?/:+ZP0 .$+ 9 >&PO=V]R:W-H965TCFNA]&AQ%O:N[>+,-+Y26EY;YIJZ%O;Q M4E9F=SY*1MW&C5IO/&V,%V=;L9:WTG_>7EM0XUY+J6JIG3*:6;DZ'UTD)Y<9 M\0>&WY3) D. MUYWV#R%VQ+(43EZ9ZEZ5?G,^RD>LE"O15/[&[#[*?3S!P<)4+ORS7>4IJ+<>HM3!3F_N)$/4C>2'=V)927=\=G80RN=C8N]ALM6 W]#PY1],MIO M'/M)E[)\+C^&-[U+O'/IDA]4^$NC(Y;&/S >\^2 OK0/,0WZTG\(<65-S:[@ MJP44D&:_85>432696;$[XT7%.A>6 MC^S:FK*!?:%+(C]'M^Q!6MXVB-M4:#VEU\Q3C5DXU=X!O%ZH"JVU%K8,Y^ N3+TU3H66@3.T=84MH1^_ M_R[GR>S4,1]BLD\Q%<++M;&/@Z"B+BJ[CVI'4;$C4L+CTQMS'U;)Z?$)N]M8 M*5G=HD@2BA@P('L,T%_,CI1& U05''/'K0EHV2?X!?G)H.N;2EA6*K'6QGE5 M= Z[$_916EDJCTN(70E=H/[OV"R-#QCE-9N(Z3X&;Q0DNDDE":8!YE3$D.)J%*S4)MY"N)6??V_ M492D>4 ,3X-SR90C;_@FK;/M8<(S[+Y$TH0CD\D,'--0K3E(@A_"YD]0RCAR M$>,H2Z$CG2)_Q(W%_%LH38;H" 3/!\D.Q !,/!X>$@%W!L4B8@@G@GJ.7_S$ M@O6_@!.?9Q1<"NX4"4L91[30-,$&3ZD1_PNB0H)ZMR=M[C*64NY20.4EGM)P M_*ZU#Q(URD+)*./OVA* S&;0=. UR/K7(#OX&MS(PN@"-1;=G?I>KJ0%=OIG MX5)4!"#WVJ5_4/GKE_X%@GUID^[QI5PKK0EKE$^T""V7>]O$5':.=]Y;3SWW_J7:'P>N[.U3(3CPA0]PU26&XEAK]1IX0@@ /%TY*+?<:$,:#L0M#Q#H,EPXO:*-].X'UN_W\>M&.;4_L[?#[ M25@DQ+%*KB"*6Q%EM^U V1+>;,,0MS0>$TM8;C"#2TL,.%\9XSN"#/13_>)O M4$L#!!0 ( ,6 !%/U;<;(500 -H+ 9 >&PO=V]R:W-H965T7;M0UXKS0%%EC$F_2AZ ,MC2UV M*=(A*3ONK^^0LF3Y[.9%$N?\YN!H1ANI7G4&8,B/G L]]C)C5L,@T$D&.=6^ M7(% SD*JG!H\JF6@5PIHZI1R'L1AV URRH0W&3G:LYJ,9&$X$_"LB"[RG*KM M+7"Y&7N15Q&^L&5F+"&8C%9T"3,P7U?/"D]!;25E.0C-I" *%F-O&@UO.U;> M"7QCL-&-;V(CF4OY:@^?T[$76D# (3'6 L77&NZ $M"O%.(7:X2T<.Y3TU=#)2J'H%0^<Q!FTPX8;,("D4,PPT>?]BF?K#*##HSBH%R<[T;6DZ MOF"Z2YZD,)DF#R*%]% _0)@UUKC">AM?-?A'(7S2"F](',;1%7NM.O:6L]>Z M8&\?L+XA]S WA(J4/'POF-DV4_#7=*Z-PO[Y^XK3=NVT[9RV+SB=X;5*"TRW M7)!'RA3Y1GD!!*\7F:XIXS;;'_'T<491J(%BOB5/]!\4V]&VY&6[ @?YCE.M MK<&*=:Y85V'9NS_4*YK V,/+K4&MP9N\9&@_E\JP?R$EB=3FABR51%^%P G M'3F3/&5B298X ?05/D"Z"MQ4@2=5X#6+ M&H)M G6;.+%[2""?@R*MR%%#L@&%%C1ZYSB6])"\9P*O%^/2.BW:B-(:).G0K"$K1!#*1^U_!BEHKVK%JH\0@H*97"NBV1+F-8%6HS] MS@DR2_LZ(TNY!B7<\&F4ON7W3A0LK4S".Q+U6_X W\?IC?IM!/%S-3UIDN$; M"MON.?_G"NM8)X7M#AJIJMZ.^/^%[9WIB9+Z]$R$B.JB]L)=4?N'1>U9M2LCN%./X,Z; M1[ MT$U9IH=]LLLI]41-A1@EW0^B,8_=T&4+AJV#@V1?@'X< MEUB/&Z/$FA]@32W61L*3 ZS7Q^W1:#R9J)=GY?XN'8Z]*R/./P('$*AX]*%PY-+@+NL\,EV]05@#Y"XEW>G>P#NIU?O(?4$L#!!0 M ( ,6 !%-3*4Z!/P0 !$+ 9 >&PO=V]R:W-H965T!FVQ 8)-=OM0](&6QC8;BE1) MRH[[ZSNDCEB%[;0/?1&ON;^9T]$VAD66>*1?])(K&_9QQ&2QF_NY1+V:JM()+?-1@RCQG^G"' M0NWG01PT%Y_Y9FO=17\Q*]@&G]!^*1XUG?JME(SG* U7$C2NY\%M?',W MX"O'O3G:@_-DI=2+._R=?%DQ@TLE?N69WU_PEK?[R!J1+&?V%?T8ZF :2EL2JO MFKZ943GUW<,Z[A*Q,EP@,R4VJDB%L#U\]L)=#T9GU+6AQM/ZTEWE42DS,2 MQ_"@I-T:^%%FF'7Y^V1=:V+2F'B77!3X2RE#&$3?01(E\05Y@];E@9-_E MC]RD0CFO#?QVNS)64Y;\?D''L-4Q]#J&9W0\4?%DI4!0:SC2YTY<,IER)N#6 M&*1(,YG!)\Y67'#+T9P*^&5=SUN$M1)47EQNP#KLIERHOF#Q0!7Z?5QEBP)4376Q*P7Q1<',#UUQ2@@I!M69Z M\ EW*""NUZ1>!_"L+.DD2+&%U.4+'BBI]0LUH74I,TH_UH,K&$W"B)9OOYDD M?EDH72C.+L%*.R_D@E24#&\+A.!QV#P^EY"DOR(B*IWF,!^&@>[C' M#+4+T 9E>@!N3'DD.0E'G?V7)]BH'6KIZH?BGY:Z"F1#- @_=/9+JA("S%&G M%#+NE/E&U1 UZ_4D'/7J;Q6^-C+C43BEI7J[@C@>D8] M9FG KF,S&E+67#6/#NV$T/]?T;[0"4=M)QQ=[$[+2A=E3;1R34_WO MH@8WMMR8@J4X#V@N,:AW&)QLBAHI^BD7OKLAI*UEIUMD>@ZUC!!W0HFF0,T5 M1<\KIJAE_^R#2Z;UP5'?,4$-%T_4!"%)B,(C._B,(NUG-5]37R*9K>%'1COG M-I+_Y>'SMG%)L-.OP%+5>,DQU<2S9M*(2AK+_J !H_K?=]D5\>LJ:W#K)K = M OTGJ5BC<-AS?W;GTJIVJ=O-KX"Z$9S*G/[1F)*CWOAAS)":4MIJ8FEOVWGO MMAISWLBK8?&!Z0V7!@2NB34*/U"*Z&H JPY6%7[H62E+(Y3?;FEF1>T(Z'VM MJ'G4!Z>@G8(7?P-02P,$% @ Q8 $4Q[' EBQ @ ^04 !D !X;"]W M;W)K&ULG53;;MLP#/T5PNA#"P2^)[T@"="T';:A M'8*FVQZ&/2@V$QN5)5>2F_3O1\F)ZP)M"NQ%E&CR\) F.=Y(]:@+1 /;B@L] M\0ICZHL@T%F!%=.^K%'0EY54%3/T5.M UPI9[IPJ'L1A. HJ5@IO.G:ZN9J. M96-X*7"N0#=5Q=3+#+G<3+S(VRONRW5AK"*8CFNVQ@6:G_5SU-H[@U\E;G3O#C:3I92/]O$MGWBA)80<,V,1&(EGO$+.+1#1 M>-IA>EU(Z]B_[]&_N-PIER73>"7Y[S(WQ<0[\R#'%6NXN9>;K[C+9VCQ,LFU M.V'3VJ:G'F2--K+:.1.#JA2M9-M='7H.9^$'#O'.(7:\VT".Y34S;#I6<@/* M6A.:O;A4G3>1*X7]*0NCZ&M)?F8Z5_1_E7D9P)PS88")'&Z>FK*FPIL!_*"V M.'Y@2X[Z9!P8"FC=@FP'/FO!XP_ 1W GA2DTW(@<\[?^ 1'MV,9[MK/X(.#W M1OB0A .(PS@Z@)=TV2<.+_F?[.'/Y5(;17WS]T"HM N5NE#I!Z$6-$YYPQ'D M"CXO^GNU/HAOA_="URS#B4?3J5$]HS<]+@4U#>?4__H$J'KHJG>-&59+5)!$ M [A%:NI"\AS*JE;R&2T)#4>0C/RA%4/_M%>4*#SW1Q!%I_YY+X^ZRP-?\U@K MJ35$ZAQ%,;^^0G)R,E/X 7UYA&D MB1];$1++AT(A0M7V'-J>@T6Y?:MX6Q+;1_8(>[?K/B?&UL M[5C!;N,V$/T50@T*!^C:DFS92FH;<)S=;8KN-DC2]E#T0$MCBUV)5$DJ3O;K M.T-9BN/$AMM#@0*YF"+%F7F<]S@B/5XK_<5D )8]%+DT$R^SMCSO]4R20<%- M5Y4@\.J,BKP7^OZP5W AO>G8C5WKZ5A5-A<2KC4S55%P M_7@!N5I/O,!K!F[$*K,TT)N.2[Z"6["_E-<:>[W62RH*D$8HR30L)]XL.+\8 MT7PWX5.#;W,(<\)T<(XZ^-3Z\-28;; MSXWW#V[MN)8%-S!7^6\BM=G$BSV6PI)7N;U1ZQ]@LYZ(_"4J-^Z7K>NYPX'' MDLI856R,$4$A9-WRATT>M@QB?X]!N#$('>XZD$-YR2V?CK5:,TVST1L]N*4Z M:P0G))%R:S6^%6AGIQ^52M[ &?C= -MF6C-R0!%1JXCH:$4@ M^]J*KXZ<%YI\30@'71\CA!T)U%0;3&F)2)!/3G)H@7 '9)?6CUH9PV9)4A45 M)ABM/N/G9&9WQ7!=:928P?>Y2+"P8TS:?!:23*IJY*%8NS8_883S5^8]USKE)0A(SR?L#%=& T%P1G#KH"\=G+!A$-RAAW+4$>X(.CIQ+7Y:/:2QHAH MC(ZB,4+B.F$TH*C1*$#'_Q6-^UF(^S[B.&EQ43:&N)X#-638UI#AT37DLY+O M^#^M(P?=O]61MSKR5D?^SW5DU-:1T=%UY 82I>E(UQQ*W,GI_4-)-#DA'559 M#@;<7UGFJBBY?*2S78V";Z. #8JTTNXTF]$AT)3@[GBL!"U4:II#*LY[F49N M-L4+]\I=I@&>'V-O=\^USR5.=<@I>.OI69HP?Z]1%_21)VPB)V<\T_ITMO7W MD-?;NM>ARE?N]FI80J6UON*UH^T%>5;?"Y^FU[?K3USC&=NP')9HBOK!@Z.N M;ZQUQZK2W1(7RN*6&PO=V]R:W-H965TLFEJI(R$)+72 !&VG;5HU5+KMP[0/)CF(54?[^S RF3 M@"_QR]WSW',7WPW72C^; M'":RFD&06%M=5-&)JLP)*9CJI0DF6I=,DL'?4J M-)5&EGM0*<(XBJ["DG$9C(?^;J;'0U5;P27.-)BZ+)G>3%&H]2CH!KN+1[XJ MK+L(Q\.*K7".]DU_HS;?'J.+U/"^"^L&]\D"2"KC57E%DP*2BZ;E;UNZ[ ' MZ$=' /$6$'O=32"O\HY9-AYJM0;MO(G-;7RJ'DWBN'0_96XU63GA['B29;K& M'+YQMN""6XX&SI_80J"Y&(:6(CB_,-NR31NV^ C;%3PH:0L#]S+'_']\2,I: M>?%.WC0^2?BUEAU(HDN(H[A[@B]ITTT\7W*$;\8V/C=@,@>?.Q,&?D\6QFIZ M('].A$C;$*D/D1X),:>^R6N!H)9PH+J'BGJ2T+7EC:E8AJ. ^LZ@?L%@?,XE M/0/^N'W?CCT2>MF&UVC#A7V"O$Y&E#[-:9P7UG,N@ MY-;%)MN@17^W!>7*MGBQ]X:[UYT>B4GA25DF#KJ2\ W4R,YF!5Y;MT MH2SUO-\6-&11.P>R+Y6RNX,+T([M\3]02P,$% @ Q8 $4P7^MJR; @ ML04 !D !X;"]W;W)K&ULA51=;]HP%/TK5UDU M@=3EPU#*&"!!6;5-JU2UW?8P[<$D%Q+5L3/;*>V_W[4#*:T*>TG\<<[QN3>5(I(A;' M@ZCDA0RF8[]VK:=C55M12+S68.JRY/IICD)M)D$2[!9NBG5NW4(T'5=\C;=H M?U37FF91JY(5)4I3* D:5Y-@EHSF?8?W@)\%;LS>&%PE2Z7NW>1K-@EB9P@% MIM8I<'H]X 4*X83(QM^M9M >Z8C[XYWZI:^=:EER@Q=*_"HRFT^"80 9KG@M M[(W:?,%M/6=.+U7"^"=L&BP[#R"MC57EEDP.RD(V;_ZX[<,>81@?(+ M@7G? MS4'>Y8);/AUKM0'MT*3F!KY4SR9SA70?Y=9JVBV(9Z??E5Q_N$-=P@*7%CIW M?"G0=,>1)7$'B=*MT+P18@>$!G"EI,T-?)899B_Y$9EJG;&=LSD[*OBMEB'T MXE-@,4N.Z/7:2GM>KW= S]>W*$PJE*DUPN_9TEA-?\6?(^+]5KSOQ?L'Q&\I M+%DM$-0*7K;TK4X>U7(Q')F*IS@)*&<&]0,&TUFI:FD-4*Z,Y3(KY!IJZK0& MFR/,*";4=;CD:2$*^P0;I JY@942%#LS@DXAZ?<1@I)@ND"]1=_;!:98+DFE MEYPVQJTSGKE>G<#[=T.6L$\T8FP0GK\&9-1,YZK%=9+P8_<5ZA0D/B,8ZX=# MN*BU1N)52OMH4M/$2^DD'H3]EO5_?&NEP\)>MR4N6@,G)-D/$U^*L_#6-X_V M8E2B7OO+PH 7;A+5KK;WT:R)X3.\N06)(F*52HC41ATS:!AH!M#],>G.2:6#AV9CL4_OW.3IIU$O0E]MGW???= MY<[+K=)/ID&T\-(*:59!8VUW$46F;+!E)E0=2KK9*-TR2Z:N(]-I9)4'M2)* MXO@L:AF70;[T9W"B[Q3H/IVY;IUS4*M5T%LV!W<,_KQKJ#*%]VK,8' MM-^[.TU6-+%4O$5IN)*@<;,*+F<7Z\SY>X MV'NU_8QC/G/'5RIA_!>V@V\6!U#VQJIV!)."ELMA92]C'?8 B_< R0A(O.XA MD%=YS2S+EUIM03MO8G,;GZI'DS@NW4]YL)IN.>%L_LTVJ.%&R?K#(^H6;C@K MN."6HX'C1U8(-"?+R%(DYQ^5(^MZ8$W>83V#6R5M8^"CK+#Z'Q^1PDEFLI.Y M3@X2?NUE"&E\"DF=+#Z>]E^PU-Z50IM<(ORX+8S7UR^\#D;(I M4N8C9>]$>J QJGJ!H#9PH-AOU?@@L9O6"].Q$E(6:^0DY@D4XI^]YF(U2YV%*5@J/ MRC(!RI\))]\Z^6*O?$T__YFG)?2"J)^(#C.S#//C!][/-]K\VAS ,>>"ZGL M(LB=*V=A:),<"FX'N@2%7S)M"N[PU>Q"6QK@J75KN@@B(@02$D<('/^>X :D)""D M\;O!#+J0Y'@X;M'_]KEC+EMNX4;+GR)U^2+X'+ 4,EY)=Z_W7Z#)YY+P$BVM M?[)]8QL%+*FLTT7CC P*H>I__MS4X2,.<>,0>]YU(,_RECN^G!N]9X:L$8T& M/E7OC>2$HD79.(-?!?JYY1J+ ,9 RKA*V8TN"BS5QNGD,=_*^%> MV-D#WTJPY_/085SR#I,FQJJ.$9^(,6'?M'*Y97J"O"R..-3N U&?ZZWEIG4"?_]6"..\RQQQR?P-S4*F#,9N. M!Y=MPF^LJQ)GX!E,(BQ0571)V])>L">PCOQQ#DD[(Q*']K5SI82S/E)9F23' M[6=Q#G7)H"BE?@%H#-O/K)1-91(63F/88])I9?$<:D\Y, R+?%4IBH(K#*6_SU9AT;I.\(TM^U(IPUI M:$EC%6O]L;,___@0&5_"-%C\LSM?1045G[*<_ MAR']Q)_ 8%MI]\+ADE<6<9UNR+39($U:^YC6?L*F$WK0Z"[+L(50YCY7;"(M M)F4UC*]._G^$2U=#CPM)9803I/)W'-LZGV+9H]5)I]5)_Y&%'3^MI-^=:^U M.<%EK4HB]^88.R;"7O23(J0]VP7K*I$<'F07;)^+),>^]\*V\&J$Y$%(RERVV@=18?= WSW.*6L:^3RJ0O2G%-^H>XWWU&6SXFL2)F9T85?CP-1 ML^D@PM_PZ'J$!WVZ +/SMQ&+[I5R=&PO=V]R:W-H965TZ;2P#.G5!:])(I&O9(+&6/O1FDXJO80'VKKK6N.MU*)DH01JA)-.PF@;S^.)R M1/).X'O[G$N#)VI4JLM>$N7<>W?%F .9GT+)HAX5[:0%YZ MR.0%R!'[I*3-#7LO,\B>Z_?0O<['I/7Q,CD(^%LM0]:/3ED2)?$!O'X7<]_A M]5^*.><:WBQ=S-?\$2EFV5QK+M?@UG_,E\9JY,N?!XP-.F,#9VSPDC%LHZPN M@*D5<\EF7RJ7X#GQ4=C'?0D^"$E]>F$JGL(TP$8TH!\@F,W;OB)#-@=FG#%5 M/9$?C;$::Z+=.56;R\>??QHG\=E;P^!;30)5P:5A7&9,R*Q.?4;XANO,G#*\ M!#RVV++2%QFHR Q+!%V)F$ @\(%MKRY8,>R+I=H%1TSE'J#T,CEHD#/S G[ M[$^_N@9"+)\?P_ *,18=$7+-N&7O )TAP7[LS$1L&";LB"7],!ET2FLL(X&X ML)*W>-ZN/H)!7UHYV().!3'@. GC$\))PO-^=YYRF>+5D3&,&+:5T"09-9*# MWU=X4D')#"*$R&[ #[AAW[AJ]FWPT@JT5*V?%$ MO)/"'J3A0>Q7TO!FZ9&X7#D-5J:QN&0#L[#\7E#4'?\@*7:(5P\#L=C?]+Q$L]F'@[UN M/ ]ST#+Q+#E$K%%'K-&_N];V_8>\W](:]E'K(/I^:GDS_MI.=\V -X,S0JK6 M4OR%YYY!1!>@14,YK+[T3DJC"I%QWPOX(IX9BN4+4HG[/B4,"D=#3D/( ["/ MRB#AD"T5E?*6/*D5#BYU 77+!-\ M+?&K2)E%8E!YCUCD+HHH[+OG6?-LE2ND;HGYJU&)%RZ4%)/L-I1.D2*QVYL1 M6=;\$KHD@.LT=RH9/.#45KDF;),<(X]B%$R0N0E:7^! A1Z=LC5(3%UQZC1Y MAK.*H']1&KHZY3-4(I?C03AB>,>Q6V7)HW^J[!$;A^?4"/YYYE[GF(%]3.[M M3$,EZ+6;^;!S5"VM'XRZK]U8.??3U).XGTD_<;T62(4"5JB*"<8;4?LYSV^L MJMQLM506)S6WS'$T!DT">+Y2RK8;,M -V[/O4$L#!!0 ( ,6 !%.[<= M M( 0 ,8) 9 >&PO=V]R:W-H965T(1IX:IM.GWLK8]9G0:#+%;9"^W*-'?U92-4*0T.U#/1: MH:BL4]L$<1CF02OJSIM-[=RMFDWEQC1UA[<*]*9MA?IZB8WOR0['O;WZ#_;V"F6N=#X7C9_ MUI59G7MC#RI*1MMO[!UMEGN0;G11K8[9V+0UIUKQ=-. MAP.'<7C$(=XYQ):W6\BRO!)&S*9*;D&Q-:%QQX9JO8E0<;F1G5AI^ MZBJL7OH'Q+*G&N^I7L9O OZVZ7Q(PG<0AW'T!E[2AYY8O.1$Z'>XELK4W1+^ MNIAKHZA0_GX#/NWA4PN?'H.G_5-M&@2Y@.>EOF"W0:OVQS4J89>][DK9(@P_ M2/VZT"<6VH&K W#9@]<[\(;!88N*##0L9$/;44.U46QD5@CD4$C>2AXD$8T\+!2B-"Z9",G&RA5V*=J'[6& M 41%X4?2S I/ S M&&9C/QG!, []\>@4O_"0WSCR0T MPA'3RX^J%E' *1$J4C^WV8S]\-5T?L/U M9>%:/2WKYYXKW?^L2,<>[2(^#?C0 ^UX<8R[4AKLDS?8RS3H>7WJ!.VITIZ@ M%.R&',]H:QO:<=KL!0])FI!B#ZGL(\I,_Q^?Z)K5E!&+-4S\B+Z9[6ZCH9AACA0+[E)U99W((E[ MW1L^,YECAXO:C(CLA)V9R\2/K9,_&<'O]&1PB4K]@A%=^:2ILRE"GNV-A#&J MGF^1.B>^_&\=1_",,0];@Y>@HVLU758L*?B'*?#Z] MXX!\H-NS?%S)ID)EDVAY#BS3U'8._6#@[NU1;6T+P@-)2?87;/] M;/](N7!W\[.Y>^'<"+6L*3D-+LB5Y,D\4.[5X 9&KNU-/9>&[GW;7=%#"Q4; MT/^%E&8_X 7ZI]OL7U!+ P04 " #%@ 13/1)LU^," !>!@ &0 'AL M+W=O'7L8#MM^?<[.VG6(>BV+_';/<\]=_9=1BNE%Z9 M+ N MA33CH+"V.@M#DQ98,M-3%4HZR94NF:6EGH>FTL@R#RI%&$?1<5@R+H/)R._= MZH%"K<= /-AOW?%Y8MQ%.1A6;XQ3ME^I.TRKL6#)> MHC1<2="8CX/S_ME%XNR]P5>.*[,U!Q?)3*F%6]QDXR!R@E!@:AT#HV&)ERB$ M(R(9#RUGT+ETP.WYAOW:QTZQS)C!2R6^\@$0MX#8ZVX<>97OF663D58K MT,Z:V-S$A^K1)(Y+=RE3J^F4$\Y.IG55":0L6R;@DID"KNF>X$8V]^T2M_^9 MS02:@U%HR:&#A6E+?M&0QR^0'\.MDK8P<"4SS/[$AR2T4QMOU%[$.PD_UK(' M@^@MQ%'+[!_T5_U>P9^'X^,U;3R_FQPUG2.4N\L^0E9U1062T0 M5 Y_3_MSV=[)[\KWS%0LQ7% ]6E0+S&83/D:RN82T%T"['-)[T@(Q!OW?BO]O QLPB.;?>(.D- MFF.-*5+Q/65J]_WS@N%I[Q1>OQK&_?@=7#.N8!#S>TC[$>]P0%$)._*.")N MBH8\!VIUFI)/P0ND2@?M2OI0Y8^( MADV03T';A,DQ"=P8/O?XPJV:+U'/?69XW/>.W>=-Y;YF> M&PO=V]R:W-H965T>YZ[XVF^)_/-EH@.?E1*VT54.E=?)XG-2ZR$ MC:E&S3=;,I5PO#6[Q-8&11&<*I6DH]%54@FIH^4\G-V;Y9P:IZ3&>P.VJ2IA M#FM4M%]$X^AX\"!WI?,'R7)>BQT^HONCOC>\2WJ40E:HK20-!K>+:#6^7D^\ M?3#X4^+>#M;@E6R(OOG-;;&(1IX0*LR=1Q#\]XPWJ)0'8AK?.\RH#^D=A^LC M^F]!.VO9"(LWI/Z2A2L7T2R" K>B4>Z!]I^PTS/U>#DI&WYAW]I>91'DC754 M=<[,H)*Z_1<_NCP,'&:C,PYIYY &WFV@P/*#<&(Y-[0'XZT9S2^"U.#-Y*3V M17ETAF\E^[GE!\Z)==(U!BV\>1(;A?;M/'$,[0V2O(-9MS#I&9@KN"/M2@N_ MZ@*+4_^$*?6\TB.O=?HJX.=&QY"-+B$=I>-7\+)>9Q;PLK,Z;S6LR MP9'9%<,\4I_'& 8A?%Y;;+@[&"D*6#6.9%4U^B56R$)W_;"^NX1;G<<@#(+4 MN6JXBW@1,&ZHJH4^_.*#BYTF;M?<#EA9W/&4< &0V,'\_^[2:ZXQ3 !U:,EN M2?%$\D;.=SV$;&E.B]3MK&O'CA*.J3@*5,1+ =6@@/E) 4M?0)\X;BEV/.ZSKC5C\S!3('N( LGO#>";V3_E%>@N81/1Z_ MC]_#1Z)BSP@PF\53^!HT=]3&&=^WF-W)*9T+2--I_.ZD_U9Y;GPYAY(N8!K/ MX'?2>6.,S^Y+^RCD*7ABG,7CCL7I:=8Q&9[^E\XXC=/.S L\1YIU3>%GSS$9 MS+X*S2Y,>"X)-=JU8[ _[3\BJW9VOIBW7Z [87:2>U?AEEU'\;MI!*:=ZNW& M41TFZ88$F,?6Y=J@Z<>SG S6N:_9Z?M"[('W&4Y+>+4U$\?UBM\OU)QT&^3)]U M8GYY2K,X*,QF=ESESYD.#E50'*WH>BU7<1 FB[N;ZKN'[.XF/1=1F.B'C.3G M. ZR/S_I*'V]77B+MR^^A,=347ZQNKMY#H[Z41=?GQ\RL[6ZCG((8YWD89J0 M3#_=+CYZ'W8^+0,JQ#]#_9HW/I-R*M_3]/=RX]?#[6)=[I&.]+XHAPC,OQ=] MKZ.H',GLQW_J01?7G&5@\_/;Z'^M)F\F\SW(]7T:?0L/Q>EVX2_(03\%YZCX MDK[^HNL)B7*\?1KEU5_R6F/7"[(_YT4:U\%F#^(PN?P/_J@7HA%@QL$#:!U MNP&\)X#5 6QL!EX'\+$91!U037UUF7NU<-N@".YNLO259"7:C%9^J%:_BC;K M%2;E@?)89.;7T,05=U_TBT[.FOQ,?DN+(")OV]__) ]9>CCO"Q(DAW+SZR-Y MT5E^S@TF+TCZ1+ZE670@/VYU$811_I,9X^OCEOSXPT_D!Q(FY',81>98R&]6 MA=G1,MUJ7^_4I\M.T9Z=8N1SFA2GG.R2@SX@\5MWO'3$K\P"75>)OJW2)^H< M\&_G9$G8^B^$KJF'[,_]^/ U-IUIV7?OSMY:#'8]9%@U'NL9;QOFP?&8Z6-0 MG>KF0'@[:/[U=P,EOQ8ZSO_M2,2OB7B5B/JER8V-VK E;8.V-HA)NA1MU,Y&4:$:8[6F*:[3%,YI?ET^+AVK):_# MR'EI4==$:AHMEW"_28OD2[]#BXWRI46+#6+>QJ+%1E&V63*<%O\Z3=\YS2_I M-\=B;:ZC;.9EQ5N#DJ^G\5+'M]:)+V6'EQHE&BC5806!<-;A!$GFJ>4&Y\1K ME"O/.V0V"4L<;9VYXL:+GG%G,7<>2_9$ $/1!33\S,'PBN M)R?R)VW^!%]Z7?YLF)(V?S:*;H3-'P(SDMG''XB^YU;] ?[<:NF!Z'K^S/2! M,GN;B?1M1NGE9E@O;8BMES;&XSAI%$H"=9<$E+2?R2\ZTX>P,!>&Y#Y(]CIS MM<@@S=2;ESH*(DWI-.KJ^.9J^EWB:DQ+$#>-"E6WYC;*,YUAYQS>83 J&K#V M3*%&4'>-&,O@L(12D&K*9R82U)JZ>]]A(H6MC;*ORZ=0+JB[7/P?5+K5E()H4S4SDR#+@#BUFE$L8>^%.8.JP=Q58S2+;AUE(-UL9F^%@62S MB>X*0^P5SR8105D%$0,IJQXB*-ZGI SJ!7/7BQX.'S*=!&8%7&L):LUF-E\X MJ#6?:+YPQ'Q!O$K$-9'6R8>@!+-:4@3%9!]Q'(H%?X<# \0-:R<'M>8S>S$< M9)I/]&(XXHO8)1!!&?ZZ)1!!"=IM:G<(RO"G>OAKF.KO,&):_+E5DX-,\YFM M& X"S2=:,=RV1:RFXQX%>5WR,%"W\ VD:\\2:@,?Z\%L6]2=@BP.]NE1)VD< M[G/7BH(^\YF-& XRS2<:,1PQ8JAEQ" HWS[U;!"WNT\L8>_5@X B(<;:,4[^ MAB54@%J+F4T9 6HM)IHRPO9($!H1E$TC D)HQ!+VTPBU0HSU9(9H="NI ,T6 M,SLRHG$SV""@28JSSTL/[]'(8LAV&[)R0]NR@&LAW.2W_*$[.FT:R\=#*S,Z*!%66$YT5 MB7DFK,N5#;(]3G2D[O5=#6K=\>OA"\J!?)>K4O$U0B!!C>7,SHH"+583G15E M^QRV/J*@+FUC1MHI^^&7'MH4% 'U+D_EC3:W+"J08#6SGZ) @=5$/T4A3HGE M8M8@ES"BX\@N9ZYQVC,$X5=NX:_;?7TV7)FIED_)[@VFVLAU]A+NM>M*7($& MJYEM% 5JK";:* IYHF5M/9"$H.P;ZPBH=8>G9@Y!L67/@Q&J\0BCNQ:,(6]8 M+Q7HLIK935$@S6JBFZ)L

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�V$URROAWH@S+4I;1E MB*$3ZXLU+=C0AUVJ%W'>#!N$8K5+" M7&B-O>+!99_UQB=QAT_:]3PB>[T%(9L4;#NL2YZL; DV;*]W1X'Y._-T-):) M1UWUPVA5B"C127<6LO%'/+YL(1N?PVZ?>RKL:\0\O55)"Y5P86;FR4I.OJDD M#ER5;'P23[^_HU3*@C#M:87>&^H77W*JQI6RZ3?*PE/"_-:^. .QL[M_J>=K MP52Y1:ZOUE\8[LI]=3.\_#SQ2,2.ZM=T"EL=&O3&FER4._[R1/'<[K(W7.D] MNSU,@.A,S !]?\NY.IX8@OJ[R^)?4$L#!!0 ( ,6 !%/#_W.A00, ,$+ M 9 >&PO=V]R:W-H965T"<34-UEJ7;Z-(96LHB I%"=Q\60I9$&VFSB7MW*V<3L=&, M]+?R5II95'G):0%<4<&1A.4TN$K>SI.!-7 KOE/8JKTQLEM9"/%@)Y_R:1!; M(F"0:>N"F,'^^,7[![=YLYD%47 MV ^:Z_4T& 4H MAR79,'TGMA]AMZ&^]9<)IMPOVOJU0[,XVR@MBIVQ(2@H]T_RM$O$GD$:MQC@ MG0%VW#Z0HWQ'-)E-I-@B:5<;;W;@MNJL#1SE]E3NM31?J;'3LWLMLH?+N=E7 MCJY%80Y;$9>N2^0^H:^EFU[9[%']C%Z_ TTH4V^06A,)"E&.;BAC9I&:1-H@ M6<=1M@L_]^%Q2_@!NA%"7_?-SQ$:7R!<(R3 M5RC:4?K?(_[3*E^I\Y^V^/?I4!?HRZ98@$1BB?[INU?Y[CG?O>.^D2D>I0G/ M*5]=H 6L*.=FB%[[0&_0K\:0/CL^PLA%L!7Y..N'>!(]-F#U*ZQ^)ZR5)%R; M:]*)P[OL[W'$S12#BF+0B0*>0&94=>48'.3C$H=),\JP0AEV0LD(SXR\Y$A( M@U52V15J> @5MT&-*JC1Z9<'W+,;U.C@Q-)FHG%%-#[EQ,B" 2+:,MFJ*4%2 MT3%?XX-\X;#7#)?$M?#%W2KYAU-N!(82=[*IO\5VGG M@C$BE < M,A_$WHTZ;3@.&J1B:16\Z2;G#<*Q3F@_0;0 M-,1M!5H+?G*2XK?HQSG$@\/*&82X_Q=PM-=5%2!7KG8[TLA M],O$!JBZ]MEO4$L#!!0 ( ,6 !%,8*XZS$@, #P* 9 >&PO=V]R M:W-H965T9W02 G!2Z1]/D<,_UFRD6)E)Z*62#G J/<&I4TB,.P'92(,&_0L\^>Q:#' M%XH2AI\%R$59(O$QQ)2O^E[DK1^\D%FAS(-@T)NC&1YA]3I_%GH6U"HY*3&3 MA#,0>-KW[J.[8=0R!G;%3X)7Z$APA1/E)% ^K;$#YA2 MHZ0Y?E6B7KVG,=P>K]6_6.>U,V,D\0.G;R171=_+/,CQ%"VH>N&KK[AR*#5Z M$TZEO<+*K>VT/9@LI.)E9:P)2L+<'?VN K%ED(1[#.+*(+;<;B-+^8@4&O0$ M7X$PJ[6:&5A7K;6&(\Q\E9$2^BW1=FHP4GSR?CO4?N7PP$O]L26RX;J%E]$K MW)N@$?4!5X]8(4+EM7LA019(8 F$P1.A5%O(7J TD)$-)M7F0[=YO&?S-CQQ MI@H)GUF.\W_M ^U([4V\]F88'Q3\OF ^).$-Q&$Y 1'[:#-&N(=K'(998 MGLS0WF&X#?VH&:)30W2.0TP0F^AB-T:YSN"#@M:8J'KN#LQD".%88J(@"6B"WP@1:)P4ZK"RY,DYY0B M(6&N,],&P41C4P(:BY/;KKL5DCCTTSU?*=HJJ=$9B7,)6%6SPVVRKI]U]Y#% M&[+X]&RZ!"S>!8LR/\OV@&WJ:I2ZV;##0K=W6)@%^OV4<[6>F WJAG'P%U!+ P04 M " #%@ 13F@,V/(\# T#@ &0 'AL+W=O^>Z*DH@ M8ZHGMI#CS%K(C&GLRHVKMA)8;(VRU/4]+W0SQG-G.K9C#W(Z%CN=\AP>)%&[ M+&/RYPQ2<9@XU'D=>.2;1)L!=SK>L@VL0'_?/DCLN967F&>0*RYR(F$]<;[0 MNR4-C8%%_,7AH&IM8D)Y$N+9=+[&$\F(*Y2/_FL4XFSL@A,:S9+M6/XO [E $-C+](I,K^DD.) M]1P2[90666F,*\AX7GS92YF(F@'Z:3?P2P._:="_8!"4!L&U#/W2H'\MPZ T ML*&[1>PV<0NFV70LQ8%(@T9OIF&S;ZTQ7SPW&V6E)3YMJ*[?1==J7>\1KPW4K9T/*BG MNR%L"3E5A#:4O0:T; 7Y[=K2VAU*.X-_! 5,1HG5,X8]EE];+*9T>]BG)/Z1 MQ'\?38^G/0W>2M/@3%/:U#0X4X+6E"@U/0?YO4%3TS90<$'3X]5#N^^>%=:N M>,C>D WD(%EZ8\5E,=9@7&G)3'U[C;['$Y\.WD??X^%/P[?2-SR[\H9-7>8M MH//SN 5$^[VP*?$Y*CS[V[JU*C@#N;'/#X4Q[7)=U#C5:/7$^6(+^\;XC-[- M:<^\]NCFB M.-P)^4VM 33:)S%7(V^M]>;:]]5B#0E5+;$!;NXLA4RH-D.Y\M5& HTR4!+[ M) BZ?D(9]\;#;.Y!CH=BJV/&X4$BM4T2*I]O(1:[D8>]EXG/;+76Z80_'F[H M"N:@OVX>I!GY)4O$$N"*"8XD+$?>#;Z>A9T4D*WXA<%.5:Y16LJC$-_2P5TT M\H(T(XAAH5,*:OX\P03B.&4R>?Q9D'IES!18O7YA_S$KWA3S2!5,1/PKB_1Z MY/4]%,&2;F/]6>P^0%%0EN!"Q"K[C7;YVO; 0XNMTB(IP":#A/'\+]T70E0 MAJ<>0 H ^1[0?@40%H#PU CM M ^-4*G &2E^WGMF7!3JNEX*,4.R72U84LO M,O4SM-&+\;11YEJ:N\S@]/B.+T0"Z O=@T(74]"4Q>H27:&O\RFZ>'>)WB'& MT3V+8_-8U=#7)F:*]!<%_VW.3U[A#]&]X'JMT(Q'$-7@IVY\UX'W3:UEP>2E MX%OB)/RXY2T4!C\@$A!'#P!]G6 3-[+3PL%[QV/LEG5TG3QSG5;P-YK0F)GW$F?4 M#&94Q@R4SBI[!BH=@7IEH%[CO=@ON?O.(KX4::)'8'R%Z#9B&J+4V5BU2ZDQ M6)J^O^K^L=T12(![CD0'9:*#\]7^9.9.TQH'UO:#QM7&E9<*?G.]CX0P@O== MN1*;*SE)\I_-IN8C2 7/9S8XMFZ+F[=;;/T6NPVW$='=(8SHH2M7:X[8[4ZU MHI_1Y]:]<+=YR:UEX=[;2^X.<<18L+5 [':HJN2_F<6.,B MP9M+?B2$D;SKRM7:('%[5(WDI_2-P&5:?Y&5UN M_8OTFU?<7VS60L,W?YD%9_OF/X+9$QY=&:GA];$0MRX M[J'UKM"]^VI"]R,ACNE>^5AVV]1KNI_>[:%ULK#=O.K6O4+W]JL1U=TA7GN) M^I6SJ@3D*CLD5&@AMESG!Q?E;'D0>9,=OWTW?XNO)[AF?HJO9_DQHZ7/3SWO MJ5PQKE ,2Q,J:/5,!3(_2,P'6FRRD[)'H;5(LLLUT ADNL#<7PJA7P9I@/(X M=_P/4$L#!!0 ( ,6 !%,83A1>$@( &8$ 9 >&PO=V]R:W-H965T M]>3,>.QV4?C8- )*75DBSCAK$[I924S30 M,C-3'4B[4RG=,K2FKJGI-+#2@UI!DSB^H2WC,LI2[]OI+%4]"BYAIXGIVY;I M7UL0:EA'\^CDV/.Z0>>@6=JQ&@Z 7[J=MA:=6$K>@C1<2:*A6D>;^>UVZ>)] MP%<.@SE;$U=)KM2S,Q[*=10[02"@0,? [.\(=R"$([(R?HZ97W#%F6:C40[:(MFUOX4CW:BN/2'TN>F-;,M8Z\N@=D7)C7*46;VA'0 M8DRS#6F2"VENR*.2V!CR0990_HVG5O*D.SGIWB97"3_W(_[=A#IS1R69/OF]R@ML/SXPK]OKE!?JGOLU!$U79>78) M6"Z C.K-O[H:Z%:>SMVO8Y:D]'BN@)Z=?0NZ]A-N2*%ZB6$,)N]TB39A=OZ$ MAQOXR'3-I2$"*@N-9^]L7AVF.ABH.C])N4([EW[9V(< M NP^Y52>#)<@NEI MR7X#4$L#!!0 ( ,6 !%.@=D/?\ , .&PO=V]R:W-H965T MX8*>9@YTSAOK?+<7:L.;3P_I#C]A\?7PR.23UVC9 MY"4F/*<$,+R=.9_@[0I&2D C?LGQB;?60%%YIO2;>KC?S!Q?>80+G FE(I4_ M+WB!BT)IDG[\42MU&IM*L+T^:_]1DY=DGE..%[3X-=^(_5 M@^B*@P%XH$3L.5B1#=Y8Y)?#\M& O">#U40,G2-VAP85_GPD+@C\'P#R$;3X MLWB]N&^C\^^LK]YLO1.,H$F?0.L+_B%]UOA 69T0E^3Y[;.$@WN!2_[[@+%Q M8VRLC8VO&*LST)I$E62D)=7E^#*'R<0=3[V7]M'T49/ 15W0L@\*(N2&7=2J MCT)AW-+581@V#,-!ADLL;_LLKZ*G"BTM55C_TALVVI6ZI$T[JCT(!;)U?AQ_T+VW1?]]*K/5U>(=FE2ULJ*A7 MBQ94@$S4RH8*KC)O?1# ]Z['6F/'DUX-+2RHD70X,N^ M[Y)'%_)HD/P7L<=LH$#@I3'"_Z$SPDMKA&_OC;5H)^F0>1$N["BS.5I0,NZ1 M>3X65+L8NB0OW1&^110_JD[:!X!7.E^X(W[T]UAK; MWR:CL-?Y%C:8O&!#D[L%!N759K9(&RZ6ZB;M/R,:7FMP*3';Z8F1@XP>B:@^ M0IO=9BK]I&&@P%MIRG=C>7JLFBJK M!T$/>FQZID(.87JYEY,X9@H@WV\I%><'9:"9[>=_ U!+ P04 " #%@ 13 M]^9F:C,$ "L#P &0 'AL+W=O_V!8\LW MA-GF(=CR.4R-#D(^:*VC&GREJ5<37M;K7=7EJ6B+Q1$K7/,BI_W+!4'*8] MIW=L>$HV6YTW6+/)CF[8,]/?=X\2[JQ:)4XRQE4B.)%L/>U=.U=+Q\T)!>+/ MA!U4XYKD5E9"O.0W]_&T9^>5W;(TS95@'/]6HKVZSYS8O#ZJ M+PKS8&9%%;L5Z5])K+?37M@C,5O3?:J?Q.$75AGR<[U(I*KX3PX5UNZ1:*^T MR"HRC"!+>/E+WZI"- B@@Q/.<2AA5A>"[!KPC^N1Z"BA"< MV\.H(HR*R2JK6TS-G&HZFTAQ(#)'@UI^4Q6,QBA+\XS0].\"VH5ETR]UBR&_>DX*][/B">_96XMNL@X[D]37^@$NC. MA_3Y^;W;"/WN_-XQ^N+_>5_^].!;4^'5Z?4*/>^3])91S-/Y]_5*:0D+W#\G MY(>U_+"0'WX@7T9?U-%/C]&7[]%75?2Q8)?J0:&>?Q->9WW7'H03Z[4YWP@J M" =>&[7 4*.!WT8M2]2HW:-;@UI5\.LJ^">K<,\UDTQI>(TCD3',:"D0-KJU M!ZYA$\,8PU]@F*%AL8MQ&L5J.0QJA\%Y#MD;?.(5:K%4\%N5-1P&G9'UO8%C M6$1TS$E$=/Q&&5H61[7%T4F+W_262=J&(HKQ-6!.6$XT& &Q[7 MAL>?Y/5H\IA8[FTER"NC+]\< 9M_X,_P@%0C'& M[3OV^Z;%/EF WV&/GB_&Z&["[O8Y-',XQU"^WYEE5&QHKFU+#.:,[$:O;:.- MW9ESEE%"M9;):E]^<[0@7/!^!/L:*6!?!9^FI%K"T(HXG;FUS7(X70-V9^WZ M7&CYF5"[#NY['=R?J\/##YG0F"PA_3J)U%?8O$8# MOFZ&4KTIA)/"-N]VO: MR<@MAO+&9D;F&,SWS:7@#H,YCF]F:8&.#8D<)@>1,Y<6JW$VR)C<%,<^12*Q MY[K<:-6M]='RNCA0&>TWSM6=@[0O\J-H<19YER_/L;#7W"1&PO=V]R:W-H965TAP%I@L23+KX%M(+$=K 6"!0VZ?1CV@9;.%A=*5$G*3O_] MCI2B.K:BNEL^Q")US]USCX['FQVD>M(IHH'G3.1Z[J7&%->^K^,4,Z9[LL"< MWFRERIBAI=KYNE#($@?*A-\/@I&?,9Y[BYG;>U"+F2R-X#D^*-!EEC'U[1:% M/,R]T'O9^,QWJ;$;_F)6L!T^HOE2/"A:^8V7A&>8:RYS4+B=>S?A]3H,+,!9 M_,'QH(^>P::RD?+)+CXF?L,ZH:'U%TNAW7\XU+:!!W&IC%[]LN=:B", ^6D']&M _Q0P> ,0U8#HT@B#&C"X-,*P!KC4_2IW)]R* M&;:8*7D 9:W)FWUPZCLTZ<5S6RB/1M%;3CBS>"R+0B!]><,$+)E.X8YJ!S[F M50W:;_E^A89QH3_ %7QY7,'[=Q_@'? <[KD09*!GOB$FUI\?UU%OJZC]-Z)& M<"]SDVI8YPDF+?A5-W[4@?=)@4:&_HL,M_U.AY_*O =1\"OT@W[8PF=Y.3QH M2^?_15__Y^BOQ(B:FHB0E(KG.S I0H&*RP2H!JG.8IDA&/:,;86VJKR/G'?;%?>+L#>>^?MC^2J; M\;%-8_&*]+ A/;R0=$71H$)MVNA5?B:=],YM!KVHG>"H(3CZ,4&%,5(7/M6Q MWF<;T:[HZ(S.9-J;!D=_X4D"%6)XA C:Z8\;^N-.^G>,*]@S42*PY!_J@K;P M@'H1769/U(V(.B6TQ_J%QIAJQW#4-C>IJ"> D4#-,WY*I4A0Z5\ OY;.S$KH*>B>!76LK"==I M)=,6:(Y0U+SI- FD6Q24O2ZOY/:JI 73&ND4LSRIWPK.-EPX_3H.]+0A,^W\ M=K__.'9;U4W/#T'0&YYH-[VTT,+@^_T7_!3=-\6H[Z7@K X&H[,375N-.XCZ M1W=VAFKGAB4-L2QS4[7J9K<9R&[<&'*R?QM>+\.6_94=X-R,\-U]-?W=,[7C MN::$MQ2*JH\$5=5 52V,+-S$L)&&Y@_WF-(0BLH:T/NME.9E80,T8^WB7U!+ M P04 " #%@ 13/H?ZXNX# R#@ &0 'AL+W=O,T[5$ M*DL2(O/+(RT>6$O9BD)Z1/57].UA)%=60E80KEB@B-)MW/K M&K__B*<&D,_XQNA.-9Z1<64CQ$\SN OFEF,8T9CZVI@@\/-,ES2.C27@\:LT M:E5K&F#S^<7Z;>X\.+,ABBY%_)T%.II;$PL%=$NR6#^*W2=:.C0T]GP1J_P_ MVI5S'0OYF=(B*<' (&&\^"6_RT T -CK +@EP'T-&'0 O!+@G0H8E(#!J8!A M"1B^!HPZ *,2,#H5,"X!XSQ9173SU*R()HN9%#LDS6RP9A[R_.9HR CCIA2? MM(2O#'!ZL8)"4)KI3%*%+M$7(B4QQ8'>KJ@F+%;OX.W7IQ5Z^^;=S-:PHL'9 M?FG]IK#N=EA_('OD3BZ0Z[BX!;WL1W_.^!7RG$[XZN_@'TZ'.RWPVQ-=DN4?]_ 5W6F:J']Z;'N5;2^W/>BPO9;"IS10 M:"M%@A2)*1);1)2B6K4EK; VSJT9H7Q>>.[0,7\S^[F9GN.)]8P#IH.*Z:"7 MZ;U0"H'\<<$O?<)]&I,-L$TSZ4>@9L@72<(TZ*QNJ]7!$9WA])#V :EA16IX M$BG&GV%A(?=M:Q,A*@9+\F M.D+W]TL$L14@)4<.'9@?5^;'9Z_?265[$PK'M->'E^@[PBA M=S#%<,@"D>!?. EH@*#U0%H2KDAQD&\I;>4X/>:(W1Z.V*F/"Z>7Y2<:%S0, MQ9[HX\8!A,^>6UP+'W9[^=XE*6'2[&D3UYUDFJ) ['@CNE&W2^4IY9ZZ77 M MFKA?-0_BB/Y#3WESAJ#%-.G#\]M?CA?O5;$A6![D)G&^2."]YZ5A[K%2ZV M7&=!U\*%^Y7K=2+*F#[>/%R@.^Y?];E9RQ<^OW[A6L!POX*=%,1;?"Q<>#KI M#6(M7;A?NZ[#4-*0P-XJI,KL-Y5'U5Q$3#G[)&6:Q!=0S '=@):9*KW(R[LI M:+Y0K:I[BX\E[=)K/7_M1C-L;E,/1(:,*Q33+4"=JS$4DRPN*,5 BS3OCS=" M0[>=/T9PJ:/23(#O6R'TR\"TW-4U&PO=V]R:W-H965TW<1M+1R[LUT*_W[724@"34(G>&GCV.?<276OUY0:])ARH2?.VIC-F>?I>$U3HEVYH0)FEE*EQ,!0K3R]490D&2CE M7N#[ R\E3#C3+BB7NXF#G><7-VRU-O:%-QUO MR(K>4G.WN58P\DJ6A*54:"8%4G0Y<<[QV0R/+"!;\9O1G:X](YO*0LI[._B: M3!S?*J*,:8'UYV?VSUGRD,R":#J3_ ]+S'KB M1 Y*Z))LN;F1NTM:)-2W?+'D.OM%NV*M[Z!XJXU,"S H2)G(_\EC48@: /=: M $$!" X%A 4@S!+-E65IS8DAT[&2.Z3L:F"S#UEM,C1DPX3=QENC8)8!SDSG M4$1MF-DJJM$G=*XU-1H1D:#OC"P89X;!Q(P3K=F2T001C2XI3Q 4$=T23M'Q MG!K"N#X!^-WM'!T?G: CQ 2Z8IS#3NFQ9T"H#>?%A:B+7%30(NK;5K@H]$]1 MX >X 3[KAL]I#'"E ZBL"0*,Z)>"]%788A8 ML06G^A0):IHJDS,,,@9[!Q^F&(_EA'P/\E7#VBJ_662_%-GO+'/MP'74>E"R#0Y(F=<. M\9MY#_;RQH$;O$I[<&C:PU+HL%/H9;NL%WQ1R1>][[2.2J+1&Z?U@0HCU5-3 MK49[M0K=7G,AL%]YD?_N^U%01(==$%SS0=P9^XN4R0X5(N/)M_$6Z?3WTNF[44LRE=?@;K/Y(46\50JN"X(&2Q'#Q IQ"NW% MFWKV32=T<8N>RE)PMZ?D)^NMT,.&T&%+Z,I]%N_\J5 M@(TQ_? &[$;5B0L.&+P'GNT,X8RIO'_.!D9NL UM( M _U<]KB&EILJNP#FEU*:YX%MZLHF?OH/4$L#!!0 ( ,6 !%.C+"#RY , M +(0 9 >&PO=V]R:W-H965T( MD_D^CV?&GS-,]XQ_$UL B5[B*!$S:RME^L&VA;^%F(@>2R%13S:,QT2J(0]M MD7(@@0;%D>TZCF?'A";6?*KO/?+YE&4RH@D\>*+A M5N8W[/DT)2$\@_R7D'D$$OLPIB/K9P0*B*&=2?GPO2:UJSAQX?/W*?JL7KQ:S)@(6 M+/I" [F=66,+!; A622?V/X.R@4-ED22^92S/>*YO>+++W31:;PJ$YKD^^-9 M9U$/]?$5\@9M#K_5X?0.>VANS/#;V'=0VX[?-4Y<7C< +_O$'FWK^'>*=Q6E5F5IUN5 MIZOY^AW+$WW]I"S02D(L_C'P]RO^ON8?M/ _L+4X\'%0>#HP>/L&.13N:A,CG$%")-L2G$94' MP^J'%??P(M'U*G[/Z/L#>:%Q%B,2AAQ"(@&E5;Q]%L=4M@3\WCL+8]_Y.> G M+HTJET9OD?""9/CKA"]'71,^KCP<_U["T0]TK?P-(.A2 Y-JNLE%:@ []0GC M7*8*%B6QN0S* Z'!=-AH>M>===6)]30L1PHEK MP<1OH9@WN$$R'6]@BERMB-@LB:M$ @KIY MN$*K1+V?_$!+*E(F5%K8!JT/2) (3&&KM11?1DS=6DQ=LY@NB-BJ#*C^- !. M\A:SZ0VS)#DYOR9CDVZYM6ZY9MVZKDJ"!/^J%B7678/JU'4GK'GZONI,EW^ZCOR;OY!\)#F@@4P48A MG=Y(!8 7#7(QD"S5K=":2=5:Z6QEXO,7$*.T&&F\2[I1 M]SLU%R_:YG/[=-1AF]7)*%-RD]R(.(.-30L6/% Q)E,J^$QS\,IHP<7*F0=@ MF"NA=&!L5:V8/EBJ1P?WW0P*WO(47"K=Q'81W-]9NWP/6,] (!>B$S@@SC 9 ME=08IN65G32+&^,3*&C'=ZO2*LPU7?4'YV3CT-QLD)G2*=-=F#Y9FR8CP3*0 MHWF^@+M190B@,:JP@Y337$G::%A[M -+.V="W,+3\#W;X5YF6U7M04UE-[2" MVJ&C<1/@WV9SW-NTK^,-2OZ@S.?:;DRX*YS;\XX&1$UW[!0FG^:*-!J\RM@6D2/#!M^'S;\E/3\HXMS;J=EAFN M>7" FO]NGG,FF:9B6[3M_;>3FO\J^8*_&]HA[ZR+/#T%D? @B M#Z GH^1-:@S;HW'K_-TY?3MK &\Y8_(-WJC$)F@PJ[DP7+:S!4]3)I\ MT)E]T=WAM^M3EM%:F+L.')/-^)JEO"Z2;M4-)*)=M1E_A>WUX^X5R\;B,F5+ MED[;J_EWFB11%,=81J=3KX(IEK2>*O-A8'/+ J8+T#\?UQ MH*?\/E$$5<6T84\PCB0)AD O^GLTCI'LQ/#QUP=[2J(H2?P(8'X%480A\#3B M"*8 -&!(%#7GX-YY%*[/J7#SZ\_D%U!+ P04 " #%@ 13EXJ[', 3 M @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/ MV!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%" MKM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0 MT^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( ,6 !%.@ M/CQ3604 *4O / >&PO=V]R:V)O;VLN>&ULQ9I=;QHY%(;_BL555VH6 MYI,V"I':T'0CI6T4LKE=F9E#L#)C4]M#FO[ZM8>PL2D<[E'Z<*_7(?K2--)/!TMK5Z7!HJB6TW/RI5B#=E872+;?N4#\,S4H#K\T2 MP+;-,!V-RF'+A1R#*OU_TA6PLCYJ(1]GDR MZ+\W,&"MD*(5/Z&>#$8#9I;JZ2^EQ4\E+6]FE59-,QDDFPOWH*VH?CD]\Y!W M?&[Z,Y;/;[D#F0S*D7O@0FAC^SOZYW/'N 9W\^:HL^I2-!;TE%OXK%6W$O+! M/\:]Q3!XC;X3?KH(*2TJ?"7=!7=8]'B2)KD 9JYKX9U8C:<=3L(V^XK( % MD"D"F1X1\I\T@,P0R.PHD#./X_XT@,P1R/R(D%%)%@AD<4S(+( L$TD!^Y$8:I!;O18-RM_1T!VCL$[1TMVBVL0780P+Q'8-[3PGSA^A&< M3!I@5W(-QOK[V0RJ3@LK0LADA/75(UK,2RXTN^=-!^P+<--IW[%8$^*A*B%V MBHGT30]WY5K%/+! M$[ /QD!Y)9E<<"6:.A%@=5[)2+; [_B.N6DP@";%!?&6*7AOFI7*E M=<,+D%7\^TLQ?Z3$_IC!0R\V#WCK;P#? 6X>%==OBGDD)?;(K%NMFEYMO&$7 MW"S99:.>_B,-,=%!";%'IL(G!6&=AJ,:QJR1$EMCULT-?.]\)7]:[V2#%'-& M2NR,O4F4O;EQP7FWA6 228DE\I)*V9L['P;-'R$79HZ4V!QH0(W&;2EFCI38 M' <"ZK8X0TQ,("FQ0-"@&IQB)^Q.^6+<'L^?71Y2=8B) M"2H%9J""V$(X95GJ!6:@@MM#>(>0>HQ>8@PIB!^V, M(7?31XB).:CXK:LS#G/F'EIWKM)=BKM6(2:ZQG^\Y1I?G"$FYJ#BF$LV<3O' M'%20.PC#C-HYYJ""W$$89ACC"LQ!!;&#<,PRW("".:BD7LXY-,^QZ9I"3,Q! M)?5RSF%,?RG$Q!Q4$CL(P;R=_1V&XA*S4$F]PH.59I2/2LQ");&%PC7:O2HO M,?F41YUZBW:8H5O,J*?>4,RP5R\Q^934^P50S+!7+S'YE,3RP2:R/QUBBO<6(C)9TPLGQW,ES4I_Q/HDUR(B[QQYRO>5#>:^8_-SK:\\!M1%EW37+ASW^2UXO5VE_EV MA_SYOU!+ P04 " #%@ 13K&U05SP" "O*@ &@ 'AL+U]R96QS+W=O M0,UYOVR'IJO9=%MZ Y*>?- D MBL>A[=U/2!?)([.83?%9R5%\_8/P0]3'EWQHQWUW*KM]7Q:?Q\.IK*K=./:_ MZKJL=_G8EKNNSZ?SD4TW'-OQO!RV==^NW]MMKF6YC'JXG5$]/=[.7+Q^]?E_ M)G:;S7Z=?W?K/\=\&O\QN/[HAO>RRWFL%J_ML,WCJJH_#]?=I;YLTMUY"<"O07U%@*]!?46 KUE\K!-H+>@WD*@MZ#>0J"WH-Y"H+>@ MWD*@MZ#>0J"WH-Y"H+>@WD*@MZ+>2J"WHMY*H+>BWDJ@MTY>EA#HK:BW$NBM MJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AM MDY?=!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ[01Z M.^KM!'H[ZNT$>OOD8R6!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>@7H'@=Z!>@>! MWH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>,?G9A$#O0+V#0.] O8- [T"]@T#O!O5N M"/1N4.^&0.\&]6Y^4N\R?AURN?9\K_'Z/TGU>#XW7R]_67[OG-R7"\[U;45Y M^@M02P,$% @ Q8 $4T!K%[H @ QBD !, !;0V]N=&5N=%]4>7!E M&ULS=I-3L,P$ 7@JU39HL;U;P%1-L 66' !DTS;J$ELV0;*[7%20 )! M!2H2;].HM3UOXI&^5<_NGCW%R;9K^[@HUBGY4\9BM:;.QM)YZO/*TH7.IOPU MK)BWU<:NB(G9S+#*]8GZ-$U#C>+\[)*6]J%-DZMM_CDVKE\4@=I83"YV&X>L M16&];YO*IKS.'OOZ4\KT-:',)\<]<=WX>)0W%.S+A&'E^X#7/%$)3T^36 MAG1MN[R+;5L6TW-+L=Q?XHL>W7+95%2[ZJ'+1\KH ]DZKHE2UY:[HD?[DU.^ M8=I]\H/SQS+[ O/.V^!\S!,+]/NXMY$,IZ<^%Z*0FOVO^)Z82Q_\?C1,NZ;Z MA]GY>I]&UL4$L! A0#% @ MQ8 $4W(P@*&PO=V]R M:W-H965T&UL4$L! A0#% @ Q8 $4RPS"F\H!P K2 M !@ ("!1A< 'AL+W=O !X M;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4^]8E4RP" 828 !@ ("! M1RD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MQ8 $4_[L>T!C! DPL !D ("!C$L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4]_H).-D @ %@4 !D M ("!?F\ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ Q8 $4X9Z*D\)!0 &0P !D ("!.X 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $ M4SN1S2ST @ ; 8 !D ("!!(\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4^,GE%&PO=V]R:W-H965TVH !X;"]W;W)K&UL4$L! A0#% @ Q8 $4U,I3H$_! $0L !D M ("!>:T 'AL+W=O&PO=V]R:W-H965T MT !X;"]W;W)K&UL4$L! A0# M% @ Q8 $4Q3^BN&\ @ P@4 !D ("!P;D 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4[U M73#T P $@H !D ("!%\( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4ST2;-?C @ 7@8 !D M ("!3,\ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ Q8 $4UVSSRC& @ R@< !D ("! M MX 'AL+W=O&PO=V]R:W-H965T+ 4 %@; 9 M " @;'E !X;"]W;W)K&UL4$L! A0#% M @ Q8 $4P$-MZ?! P 4P\ !D ("!%.L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4P!66NET @ M@8 !D M ("!2 $! 'AL+W=O&UL M4$L! A0#% @ Q8 $4Y)T0(I] @ V@8 !D ("!^0L! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MQ8 $4]Z+Z6V! @ FP< !D ("!Z!8! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4Z*M,+CR @ MDP@ !D ("!^1\! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4ZXEM X>! @Q$ !D M ("!"BD! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ Q8 $4YH#-CR/ P - X !D ("!(#0! 'AL M+W=O&PO=V]R:W-H965T$@( &8$ 9 " M@3X\ 0!X;"]W;W)K&UL4$L! A0#% @ Q8 $ M4Z!V0]_P P YP\ !D ("!ASX! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4SZ'^N+N P ,@X M !D ("!T$H! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ Q8 $4P<"3I8: P "A( T M ( !E%8! 'AL+W-T>6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ Q8 $4ZQM4%<\ @ KRH !H ( ! M2& ! 'AL+U]R96QS+W=O XML 84 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 86 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 313 378 1 false 75 0 false 6 false false R1.htm 0001001 - Document - Cover Sheet http://www.myriad.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.myriad.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity Sheet http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders' Equity Statements 6 false false R7.htm 1006007 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation Sheet http://www.myriad.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 2103102 - Disclosure - Revenue Sheet http://www.myriad.com/role/Revenue Revenue Notes 9 false false R10.htm 2108103 - Disclosure - Marketable Investment Securities Sheet http://www.myriad.com/role/MarketableInvestmentSecurities Marketable Investment Securities Notes 10 false false R11.htm 2113104 - Disclosure - Fair Value Measurements Sheet http://www.myriad.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2118105 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.myriad.com/role/PropertyPlantandEquipmentNet Property, Plant and Equipment, Net Notes 12 false false R13.htm 2122106 - Disclosure - Goodwill and Intangible Assets Sheet http://www.myriad.com/role/GoodwillandIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 2127107 - Disclosure - Accrued Liabilities Sheet http://www.myriad.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 2130108 - Disclosure - Long-Term Debt Sheet http://www.myriad.com/role/LongTermDebt Long-Term Debt Notes 15 false false R16.htm 2134109 - Disclosure - Other Long-Term Liabilities Sheet http://www.myriad.com/role/OtherLongTermLiabilities Other Long-Term Liabilities Notes 16 false false R17.htm 2137110 - Disclosure - Preferred and Common Stockholders' Equity Sheet http://www.myriad.com/role/PreferredandCommonStockholdersEquity Preferred and Common Stockholders' Equity Notes 17 false false R18.htm 2143111 - Disclosure - Stock-Based Compensation Sheet http://www.myriad.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 2149112 - Disclosure - Income Taxes Sheet http://www.myriad.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 2151113 - Disclosure - Commitments and Contingencies Sheet http://www.myriad.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 2152114 - Disclosure - Segment and Related Information Sheet http://www.myriad.com/role/SegmentandRelatedInformation Segment and Related Information Notes 21 false false R22.htm 2157115 - Disclosure - Supplemental Cash Flow Information Sheet http://www.myriad.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 22 false false R23.htm 2160116 - Disclosure - Divestitures Sheet http://www.myriad.com/role/Divestitures Divestitures Notes 23 false false R24.htm 2164117 - Disclosure - Subsequent Events Sheet http://www.myriad.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 2202201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.myriad.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 25 false false R26.htm 2304301 - Disclosure - Revenue (Tables) Sheet http://www.myriad.com/role/RevenueTables Revenue (Tables) Tables http://www.myriad.com/role/Revenue 26 false false R27.htm 2309302 - Disclosure - Marketable Investment Securities (Tables) Sheet http://www.myriad.com/role/MarketableInvestmentSecuritiesTables Marketable Investment Securities (Tables) Tables http://www.myriad.com/role/MarketableInvestmentSecurities 27 false false R28.htm 2314303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.myriad.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.myriad.com/role/FairValueMeasurements 28 false false R29.htm 2319304 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.myriad.com/role/PropertyPlantandEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.myriad.com/role/PropertyPlantandEquipmentNet 29 false false R30.htm 2323305 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.myriad.com/role/GoodwillandIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.myriad.com/role/GoodwillandIntangibleAssets 30 false false R31.htm 2328306 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.myriad.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://www.myriad.com/role/AccruedLiabilities 31 false false R32.htm 2331307 - Disclosure - Long-Term Debt (Tables) Sheet http://www.myriad.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.myriad.com/role/LongTermDebt 32 false false R33.htm 2335308 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.myriad.com/role/OtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.myriad.com/role/OtherLongTermLiabilities 33 false false R34.htm 2338309 - Disclosure - Preferred and Common Stockholders' Equity (Tables) Sheet http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables Preferred and Common Stockholders' Equity (Tables) Tables http://www.myriad.com/role/PreferredandCommonStockholdersEquity 34 false false R35.htm 2344310 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.myriad.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.myriad.com/role/StockBasedCompensation 35 false false R36.htm 2353311 - Disclosure - Segment and Related Information (Tables) Sheet http://www.myriad.com/role/SegmentandRelatedInformationTables Segment and Related Information (Tables) Tables http://www.myriad.com/role/SegmentandRelatedInformation 36 false false R37.htm 2358312 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.myriad.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.myriad.com/role/SupplementalCashFlowInformation 37 false false R38.htm 2361313 - Disclosure - Divestitures (Tables) Sheet http://www.myriad.com/role/DivestituresTables Divestitures (Tables) Tables http://www.myriad.com/role/Divestitures 38 false false R39.htm 2405401 - Disclosure - Revenue - Total Revenue by Product and by US versus Rest of World (Details) Sheet http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails Revenue - Total Revenue by Product and by US versus Rest of World (Details) Details 39 false false R40.htm 2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details) Sheet http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails Revenue - Reconciliation of Deferred Revenue Balances (Details) Details 40 false false R41.htm 2407403 - Disclosure - Revenue - Narrative (Details) Sheet http://www.myriad.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 41 false false R42.htm 2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) Sheet http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) Details 42 false false R43.htm 2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) Sheet http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details) Details 43 false false R44.htm 2412406 - Disclosure - Marketable Investment Securities - Narrative (Details) Sheet http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails Marketable Investment Securities - Narrative (Details) Details 44 false false R45.htm 2415407 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 45 false false R46.htm 2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) Sheet http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details) Details 46 false false R47.htm 2417409 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details) Sheet http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details) Details 47 false false R48.htm 2420410 - Disclosure - Property, Plant and Equipment, Net - Balances (Details) Sheet http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails Property, Plant and Equipment, Net - Balances (Details) Details 48 false false R49.htm 2421411 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details) Sheet http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails Property, Plant and Equipment, Net - Depreciation Expense (Details) Details 49 false false R50.htm 2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) Sheet http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details) Details 50 false false R51.htm 2425413 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 51 false false R52.htm 2426414 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) Sheet http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails Goodwill and Intangible Assets - Amortization on Intangible Assets (Details) Details 52 false false R53.htm 2429415 - Disclosure - Accrued Liabilities (Details) Sheet http://www.myriad.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://www.myriad.com/role/AccruedLiabilitiesTables 53 false false R54.htm 2432416 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.myriad.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 54 false false R55.htm 2433417 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details) Sheet http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails Long-Term Debt - Schedule of Long-Term Debt (Details) Details 55 false false R56.htm 2436418 - Disclosure - Other Long-Term Liabilities (Details) Sheet http://www.myriad.com/role/OtherLongTermLiabilitiesDetails Other Long-Term Liabilities (Details) Details http://www.myriad.com/role/OtherLongTermLiabilitiesTables 56 false false R57.htm 2439419 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details) Sheet http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails Preferred and Common Stockholders' Equity - Narrative (Details) Details 57 false false R58.htm 2440420 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) Sheet http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details) Details 58 false false R59.htm 2441421 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) Sheet http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) Details 59 false false R60.htm 2442422 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details) Sheet http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details) Details 60 false false R61.htm 2445423 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.myriad.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 61 false false R62.htm 2446424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 62 false false R63.htm 2447425 - Disclosure - Stock-Based Compensation - RSU Activity (Details) Sheet http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails Stock-Based Compensation - RSU Activity (Details) Details 63 false false R64.htm 2448426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-Based Compensation - Stock-Based Compensation Expense (Details) Details 64 false false R65.htm 2450427 - Disclosure - Income Taxes (Details) Sheet http://www.myriad.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.myriad.com/role/IncomeTaxes 65 false false R66.htm 2454428 - Disclosure - Segment and Related Information - Narrative (Details) Sheet http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails Segment and Related Information - Narrative (Details) Details 66 false false R67.htm 2455429 - Disclosure - Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details) Sheet http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details) Details 67 false false R68.htm 2456430 - Disclosure - Segment and Related Information - Total Operating Loss for Reportable Segments (Details) Sheet http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails Segment and Related Information - Total Operating Loss for Reportable Segments (Details) Details 68 false false R69.htm 2459431 - Disclosure - Supplemental Cash Flow Information (Details) Sheet http://www.myriad.com/role/SupplementalCashFlowInformationDetails Supplemental Cash Flow Information (Details) Details http://www.myriad.com/role/SupplementalCashFlowInformationTables 69 false false R70.htm 2462432 - Disclosure - Divestitures - Narrative (Details) Sheet http://www.myriad.com/role/DivestituresNarrativeDetails Divestitures - Narrative (Details) Details 70 false false R71.htm 2463433 - Disclosure - Divestitures - Assets and Liabilities Classified as Held For Sale (Details) Sheet http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails Divestitures - Assets and Liabilities Classified as Held For Sale (Details) Details 71 false false R72.htm 2465434 - Disclosure - Subsequent Events (Details) Sheet http://www.myriad.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.myriad.com/role/SubsequentEvents 72 false false All Reports Book All Reports mygn-20210630.htm exhibit311-certificationof.htm exhibit312-certificationof.htm exhibit321-certificationpu.htm mygn-20210630.xsd mygn-20210630_cal.xml mygn-20210630_def.xml mygn-20210630_lab.xml mygn-20210630_pre.xml http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mygn-20210630.htm": { "axisCustom": 0, "axisStandard": 33, "contextCount": 313, "dts": { "calculationLink": { "local": [ "mygn-20210630_cal.xml" ] }, "definitionLink": { "local": [ "mygn-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "mygn-20210630.htm" ] }, "labelLink": { "local": [ "mygn-20210630_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mygn-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mygn-20210630.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 541, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 32, "keyStandard": 346, "memberCustom": 28, "memberStandard": 47, "nsprefix": "mygn", "nsuri": "http://www.myriad.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.myriad.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108103 - Disclosure - Marketable Investment Securities", "role": "http://www.myriad.com/role/MarketableInvestmentSecurities", "shortName": "Marketable Investment Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113104 - Disclosure - Fair Value Measurements", "role": "http://www.myriad.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118105 - Disclosure - Property, Plant and Equipment, Net", "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNet", "shortName": "Property, Plant and Equipment, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2122106 - Disclosure - Goodwill and Intangible Assets", "role": "http://www.myriad.com/role/GoodwillandIntangibleAssets", "shortName": "Goodwill and Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127107 - Disclosure - Accrued Liabilities", "role": "http://www.myriad.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130108 - Disclosure - Long-Term Debt", "role": "http://www.myriad.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134109 - Disclosure - Other Long-Term Liabilities", "role": "http://www.myriad.com/role/OtherLongTermLiabilities", "shortName": "Other Long-Term Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Preferred and Common Stockholders' Equity", "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquity", "shortName": "Preferred and Common Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2143111 - Disclosure - Stock-Based Compensation", "role": "http://www.myriad.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2149112 - Disclosure - Income Taxes", "role": "http://www.myriad.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151113 - Disclosure - Commitments and Contingencies", "role": "http://www.myriad.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152114 - Disclosure - Segment and Related Information", "role": "http://www.myriad.com/role/SegmentandRelatedInformation", "shortName": "Segment and Related Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157115 - Disclosure - Supplemental Cash Flow Information", "role": "http://www.myriad.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160116 - Disclosure - Divestitures", "role": "http://www.myriad.com/role/Divestitures", "shortName": "Divestitures", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164117 - Disclosure - Subsequent Events", "role": "http://www.myriad.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.myriad.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Revenue (Tables)", "role": "http://www.myriad.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Marketable Investment Securities (Tables)", "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables", "shortName": "Marketable Investment Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.myriad.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - Property, Plant and Equipment, Net (Tables)", "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables", "shortName": "Property, Plant and Equipment, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2323305 - Disclosure - Goodwill and Intangible Assets (Tables)", "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables", "shortName": "Goodwill and Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Accrued Liabilities (Tables)", "role": "http://www.myriad.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Long-Term Debt (Tables)", "role": "http://www.myriad.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335308 - Disclosure - Other Long-Term Liabilities (Tables)", "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesTables", "shortName": "Other Long-Term Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338309 - Disclosure - Preferred and Common Stockholders' Equity (Tables)", "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables", "shortName": "Preferred and Common Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2344310 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.myriad.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353311 - Disclosure - Segment and Related Information (Tables)", "role": "http://www.myriad.com/role/SegmentandRelatedInformationTables", "shortName": "Segment and Related Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2358312 - Disclosure - Supplemental Cash Flow Information (Tables)", "role": "http://www.myriad.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2361313 - Disclosure - Divestitures (Tables)", "role": "http://www.myriad.com/role/DivestituresTables", "shortName": "Divestitures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Revenue - Total Revenue by Product and by US versus Rest of World (Details)", "role": "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails", "shortName": "Revenue - Total Revenue by Product and by US versus Rest of World (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "id2115070195347a68a627af7acd57b0b_D20210401-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations", "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "shortName": "Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Revenue - Reconciliation of Deferred Revenue Balances (Details)", "role": "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails", "shortName": "Revenue - Reconciliation of Deferred Revenue Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4fe45116b79a4dbb9cf11cee4b523a2c_I20191231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i67fb6df203ec41aaaf1a18c0b9aa6c35_D20190701-20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "mygn:CARESActOf2020MedicarePaymentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.myriad.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i67fb6df203ec41aaaf1a18c0b9aa6c35_D20190701-20200630", "decimals": "-5", "first": true, "lang": "en-US", "name": "mygn:CARESActOf2020MedicarePaymentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)", "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails", "shortName": "Marketable Investment Securities - Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "lang": "en-US", "name": "mygn:InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)", "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "shortName": "Marketable Investment Securities - Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412406 - Disclosure - Marketable Investment Securities - Narrative (Details)", "role": "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails", "shortName": "Marketable Investment Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "reportCount": 1, "unique": true, "unitRef": "security", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i8dda836c6b8445b18c079262642bd769_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i8dda836c6b8445b18c079262642bd769_D20210401-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueNetAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416408 - Disclosure - Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)", "role": "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "shortName": "Fair Value Measurements - Fair Value of Financial Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueNetAssetLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417409 - Disclosure - Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)", "role": "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails", "shortName": "Fair Value Measurements - Change in Fair Value of Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Property, Plant and Equipment, Net - Balances (Details)", "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails", "shortName": "Property, Plant and Equipment, Net - Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Property, Plant and Equipment, Net - Depreciation Expense (Details)", "role": "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails", "shortName": "Property, Plant and Equipment, Net - Depreciation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424412 - Disclosure - Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)", "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails", "shortName": "Goodwill and Intangible Assets - Carrying Amount of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425413 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details)", "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426414 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)", "role": "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails", "shortName": "Goodwill and Intangible Assets - Amortization on Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429415 - Disclosure - Accrued Liabilities (Details)", "role": "http://www.myriad.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLinesOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432416 - Disclosure - Long-Term Debt - Narrative (Details)", "role": "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i13e33d35f2614d589162ff730275eafc_D20180731-20180731", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentMaturityDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "mygn:DebtInstrumentCarryingAmountNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433417 - Disclosure - Long-Term Debt - Schedule of Long-Term Debt (Details)", "role": "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails", "shortName": "Long-Term Debt - Schedule of Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "mygn:DebtInstrumentCarryingAmountNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436418 - Disclosure - Other Long-Term Liabilities (Details)", "role": "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails", "shortName": "Other Long-Term Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439419 - Disclosure - Preferred and Common Stockholders' Equity - Narrative (Details)", "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails", "shortName": "Preferred and Common Stockholders' Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2440420 - Disclosure - Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)", "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails", "shortName": "Preferred and Common Stockholders' Equity - Common Shares Issued and Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "lang": "en-US", "name": "mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441421 - Disclosure - Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)", "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails", "shortName": "Preferred and Common Stockholders' Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4fe45116b79a4dbb9cf11cee4b523a2c_I20191231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i984a5b804ec745648d10ca75e49d1e16_D20200101-20200331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442422 - Disclosure - Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)", "role": "http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails", "shortName": "Preferred and Common Stockholders' Equity - Potentially Dilutive Common Shares Excluded from EPS Computation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445423 - Disclosure - Stock-Based Compensation - Narrative (Details)", "role": "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446424 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "role": "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i10e0729335464f2d8a9f350663e7bc18_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i67db5d109a914ab49c4e1b973ba53f7c_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447425 - Disclosure - Stock-Based Compensation - RSU Activity (Details)", "role": "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails", "shortName": "Stock-Based Compensation - RSU Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i67db5d109a914ab49c4e1b973ba53f7c_I20201231", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448426 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "role": "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450427 - Disclosure - Income Taxes (Details)", "role": "http://www.myriad.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "3", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454428 - Disclosure - Segment and Related Information - Narrative (Details)", "role": "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails", "shortName": "Segment and Related Information - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455429 - Disclosure - Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)", "role": "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails", "shortName": "Segment and Related Information - Segment Revenue and Operating Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ibf535554519641d197de75221da2fce3_D20210401-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OperatingIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456430 - Disclosure - Segment and Related Information - Total Operating Loss for Reportable Segments (Details)", "role": "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails", "shortName": "Segment and Related Information - Total Operating Loss for Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459431 - Disclosure - Supplemental Cash Flow Information (Details)", "role": "http://www.myriad.com/role/SupplementalCashFlowInformationDetails", "shortName": "Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxesPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "lang": "en-US", "name": "mygn:NonCashInterestExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfProductiveAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462432 - Disclosure - Divestitures - Narrative (Details)", "role": "http://www.myriad.com/role/DivestituresNarrativeDetails", "shortName": "Divestitures - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i4a460f588c75492e96b2fe22abf44f65_D20210401-20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:InventoryFirmPurchaseCommitmentLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ib7a31e5e9455401dbbf9c735e5eb1211_I20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463433 - Disclosure - Divestitures - Assets and Liabilities Classified as Held For Sale (Details)", "role": "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "shortName": "Divestitures - Assets and Liabilities Classified as Held For Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i9a0be6a20fcc41a68d91acf6a8b0d4dd_I20210630", "decimals": "-5", "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RepaymentsOfLinesOfCredit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465434 - Disclosure - Subsequent Events (Details)", "role": "http://www.myriad.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "ic5a46c8b286a49fa9e3c1ced68c44161_D20210731-20210731", "decimals": "-5", "lang": "en-US", "name": "us-gaap:RepaymentsOfLinesOfCredit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation", "role": "http://www.myriad.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Revenue", "role": "http://www.myriad.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mygn-20210630.htm", "contextRef": "i1bca6ba907b04e88960c47fd15f20f68_D20210101-20210630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 75, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S." } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.myriad.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "mygn_AmendmentToCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amendment to Credit Agreement [Member].", "label": "Amendment To Credit Agreement [Member]", "terseLabel": "Amended facility" } } }, "localname": "AmendmentToCreditAgreementMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mygn_BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input, Term", "terseLabel": "Measurement period for earn out liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInputTerm", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "mygn_CARESActOf2020MedicarePaymentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "CARES Act of 2020 Medicare payment amount.", "label": "CARES Act Of 2020 Medicare Payment Amount", "terseLabel": "Advance Medicare payments to provide relief from economic impacts of COVID-19" } } }, "localname": "CARESActOf2020MedicarePaymentAmount", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mygn_ChangeInFairValueOfContingentConsideration": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of contingent consideration.", "label": "Change In Fair Value Of Contingent Consideration", "terseLabel": "Change in fair value of contingent consideration" } } }, "localname": "ChangeInFairValueOfContingentConsideration", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mygn_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contingent consideration.", "label": "Contingent Consideration [Member]", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "mygn_ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained", "label": "Contract With Customer, Asset, Adjustment To Revenue For Expanded Coverage, Previously Constrained", "terseLabel": "Revenue recognized due to expanded local coverage determination for which revenue was previously constrained" } } }, "localname": "ContractWithCustomerAssetAdjustmentToRevenueForExpandedCoveragePreviouslyConstrained", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mygn_ContractWithCustomerLiabilityHeldForSaleReclassification": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Held For Sale Reclassification", "label": "Contract With Customer, Liability, Held For Sale Reclassification", "negatedTerseLabel": "Held for sale reclassification" } } }, "localname": "ContractWithCustomerLiabilityHeldForSaleReclassification", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" ], "xbrltype": "monetaryItemType" }, "mygn_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract With Customer, Liability, Including New Contract, Revenue Recognized", "label": "Contract With Customer, Liability, Including New Contract, Revenue Recognized", "negatedLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" ], "xbrltype": "monetaryItemType" }, "mygn_ContractWithCustomerLiabilityPrepayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract with customer, liability, prepayments.", "label": "Contract With Customer, Liability, Prepayments", "terseLabel": "Prepayments" } } }, "localname": "ContractWithCustomerLiabilityPrepayments", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" ], "xbrltype": "monetaryItemType" }, "mygn_CostOfMolecularDiagnosticTestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included.", "label": "Cost Of Molecular Diagnostic Testing [Member]", "terseLabel": "Cost of molecular diagnostic testing" } } }, "localname": "CostOfMolecularDiagnosticTestingMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "mygn_CostOfPharmaceuticalAndClinicalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included.", "label": "Cost Of Pharmaceutical And Clinical Services [Member]", "terseLabel": "Cost of pharmaceutical and clinical services" } } }, "localname": "CostOfPharmaceuticalAndClinicalServicesMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "mygn_DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum", "label": "Debt Covenant, Unrestricted Cash And Cash Equivalents Threshold For Borrowing Restriction, Minimum", "terseLabel": "Minimum unrestricted cash and cash equivalents threshold per covenant" } } }, "localname": "DebtCovenantUnrestrictedCashAndCashEquivalentsThresholdForBorrowingRestrictionMinimum", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DebtInstrumentCarryingAmountCurrent": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of current portion of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument, Carrying Amount, Current", "terseLabel": "Current portion of long-term debt" } } }, "localname": "DebtInstrumentCarryingAmountCurrent", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DebtInstrumentCarryingAmountNoncurrent": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of noncurrent long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Debt Instrument, Carrying Amount, Noncurrent", "terseLabel": "Long-term debt" } } }, "localname": "DebtInstrumentCarryingAmountNoncurrent", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DebtInstrumentLIBORFloorPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, LIBOR Floor, Percentage", "label": "Debt Instrument, LIBOR Floor, Percentage", "terseLabel": "LIBOR floor (percent)" } } }, "localname": "DebtInstrumentLIBORFloorPercentage", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "mygn_DiagnosticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diagnostics.", "label": "Diagnostics [Member]", "terseLabel": "Diagnostics" } } }, "localname": "DiagnosticsMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "domainItemType" }, "mygn_DisposalGroupIncludingDiscontinuedOperationAggregateTransactionAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Aggregate Transaction Adjustment", "label": "Disposal Group, Including Discontinued Operation, Aggregate Transaction Adjustment", "negatedTerseLabel": "Aggregate adjustments for working capital, indebtedness, and transaction costs", "terseLabel": "Aggregate adjustments for working capital, indebtedness, and transaction costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAggregateTransactionAdjustment", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DisposalGroupIncludingDiscontinuedOperationAssetsNetOfLiabilities": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Assets, Net Of Liabilities", "label": "Disposal Group, Including Discontinued Operation, Assets, Net Of Liabilities", "totalLabel": "Total net assets held for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNetOfLiabilities", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Current", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Accumulated Amortization, Current", "terseLabel": "Less: intangible assets held for sale, accumulated amortization" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsAccumulatedAmortizationCurrent", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsGrossCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Intangible Assets, Gross, Current", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Gross, Current", "negatedTerseLabel": "Less: intangible assets held for sale, gross" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsGrossCurrent", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mygn_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liabilities, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesNoncurrent", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "mygn_EighthShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eighth share repurchase program.", "label": "Eighth Share Repurchase Program [Member]", "terseLabel": "Eighth Share Repurchase Program" } } }, "localname": "EighthShareRepurchaseProgramMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_EmployeeStockPurchasePlanTwentyTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan Twenty Twelve [Member]", "label": "Employee Stock Purchase Plan Twenty Twelve [Member]", "terseLabel": "2012 Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanTwentyTwelveMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_GainLossOnDispositionOfAssetsNetOfTransactionFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees", "label": "Gain (Loss) On Disposition of Assets, Net Of Transaction Fees", "terseLabel": "Net gain on sale of assets adjusted for transaction fees" } } }, "localname": "GainLossOnDispositionOfAssetsNetOfTransactionFees", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mygn_ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment Of Goodwill And Long-Lived Assets Held For Use", "label": "Impairment Of Goodwill And Long-Lived Assets Held For Use", "verboseLabel": "Impairment of goodwill and long-lived assets" } } }, "localname": "ImpairmentOfGoodwillAndLongLivedAssetsHeldForUse", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mygn_InProcessResearchAndDevelopmentWithIndefiniteLivesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process research and development with indefinite lives.", "label": "In Process Research And Development With Indefinite Lives [Member]", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentWithIndefiniteLivesMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mygn_IncreaseDecreaseInEarningsLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase decrease in earnings (loss) per share.", "label": "Increase Decrease In Earnings Loss Per Share", "terseLabel": "Change in earnings (loss) per share (dollars per share)" } } }, "localname": "IncreaseDecreaseInEarningsLossPerShare", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "perShareItemType" }, "mygn_IncreaseDecreaseInUnrecognizedTaxBenefits": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in unrecognized tax benefits.", "label": "Increase (Decrease) In Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "IncreaseDecreaseInUnrecognizedTaxBenefits", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mygn_IntangibleAssetsIncludingHeldForSaleAccumulatedAmortization": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Intangible Assets, Including Held For Sale, Accumulated Amortization", "label": "Intangible Assets, Including Held For Sale, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization, total" } } }, "localname": "IntangibleAssetsIncludingHeldForSaleAccumulatedAmortization", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "mygn_IntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets.", "label": "Intangible Assets [Line Items]", "terseLabel": "Intangible Assets [Line Items]" } } }, "localname": "IntangibleAssetsLineItems", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": 1.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax", "label": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Total, Gross unrealized holding gains" } } }, "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": 2.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax", "label": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Total, Gross unrealized holding losses" } } }, "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "mygn_InvestmentsAndCashAmortizedCost": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investments And Cash, Amortized Cost", "label": "Investments And Cash, Amortized Cost", "totalLabel": "Total, Amortized cost" } } }, "localname": "InvestmentsAndCashAmortizedCost", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "mygn_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "localname": "MedicareMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticAutoimmuneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular Diagnostic Autoimmune", "label": "Molecular Diagnostic Autoimmune [Member]", "terseLabel": "Molecular Diagnostic - Autoimmune" } } }, "localname": "MolecularDiagnosticAutoimmuneMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticHereditaryCancerTestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular diagnostic hereditary cancer testing.", "label": "Molecular Diagnostic Hereditary Cancer Testing [Member]", "terseLabel": "Molecular diagnostic - Hereditary Cancer" } } }, "localname": "MolecularDiagnosticHereditaryCancerTestingMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticOtherTestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular diagnostic other testing.", "label": "Molecular Diagnostic Other Testing [Member]", "terseLabel": "Molecular diagnostic - Other" } } }, "localname": "MolecularDiagnosticOtherTestingMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticPharmacogenomicsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular Diagnostic Pharmacogenomics", "label": "Molecular Diagnostic Pharmacogenomics [Member]", "terseLabel": "Molecular Diagnostic - Pharmacogenomics" } } }, "localname": "MolecularDiagnosticPharmacogenomicsMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticPrenatalTestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular diagnostic Prenatal testing.", "label": "Molecular Diagnostic Prenatal Testing [Member]", "terseLabel": "Molecular diagnostic - Prenatal" } } }, "localname": "MolecularDiagnosticPrenatalTestingMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticTestingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular diagnostic testing.", "label": "Molecular Diagnostic Testing [Member]", "terseLabel": "Molecular diagnostic testing" } } }, "localname": "MolecularDiagnosticTestingMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MolecularDiagnosticTumorProfilingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Molecular Diagnostic Tumor Profiling", "label": "Molecular Diagnostic Tumor Profiling [Member]", "terseLabel": "Molecular diagnostic - Tumor Profiling" } } }, "localname": "MolecularDiagnosticTumorProfilingMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_MyriadAutoimmuneAssetsAndMyriadRBMIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Myriad Autoimmune Assets And Myriad RBM, Inc", "label": "Myriad Autoimmune Assets And Myriad RBM, Inc [Member]", "terseLabel": "Select operating assets and intellectual property of Myriad Autoimmune business unit and Myriad RBM, Inc" } } }, "localname": "MyriadAutoimmuneAssetsAndMyriadRBMIncMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_MyriadAutoimmuneAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Myriad Autoimmune Assets", "label": "Myriad Autoimmune Assets [Member]", "terseLabel": "Select operating assets and intellectual property of Myriad Autoimmune business unit" } } }, "localname": "MyriadAutoimmuneAssetsMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_MyriadMyPathLLCLaboratoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Myriad My Path LLC Laboratory", "label": "Myriad My Path LLC Laboratory [Member]", "terseLabel": "Myriad myPath LLC laboratory" } } }, "localname": "MyriadMyPathLLCLaboratoryMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_MyriadRBMIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Myriad RBM, Inc", "label": "Myriad RBM, Inc [Member]", "terseLabel": "Myriad RBM, Inc." } } }, "localname": "MyriadRBMIncMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "mygn_NetAssetsHeldForSalePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net Assets Held For Sale", "label": "Net Assets Held For Sale [Policy Text Block]", "terseLabel": "Held for Sale Policy" } } }, "localname": "NetAssetsHeldForSalePolicyTextBlock", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "mygn_NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net Change In Cash And Cash Equivalents Classified As Held For Sale", "label": "Net Change In Cash And Cash Equivalents Classified As Held For Sale", "terseLabel": "Change in cash and cash equivalents classified as held for sale" } } }, "localname": "NetChangeInCashAndCashEquivalentsClassifiedAsHeldForSale", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mygn_NonCashInterestExpense": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash interest expense.", "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "mygn_NonEmployeeDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non employee director.", "label": "Non Employee Director [Member]", "terseLabel": "Non-employee director" } } }, "localname": "NonEmployeeDirectorMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_OperatingLeaseLiabilityEstablished": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Liability Established", "label": "Operating Lease Liability Established", "terseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityEstablished", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "mygn_OptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options and Restricted Stock Units.", "label": "Options And Restricted Stock Units [Member]", "terseLabel": "Options and RSUs" } } }, "localname": "OptionsAndRestrictedStockUnitsMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_OptionsGrantedAfterDecemberFiveTwentyTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options granted after December 5, 2012.", "label": "Options Granted After December Five Twenty Twelve [Member]", "terseLabel": "Awards granted after December 5, 2012" } } }, "localname": "OptionsGrantedAfterDecemberFiveTwentyTwelveMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_OptionsGrantedPriorToDecemberFiveTwentyTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options granted prior to December 5, 2012.", "label": "Options Granted Prior To December Five Twenty Twelve [Member]", "terseLabel": "Awards granted prior to December 5, 2012" } } }, "localname": "OptionsGrantedPriorToDecemberFiveTwentyTwelveMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_PaymentsOfInterestLinesOfCredit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Of Interest, Lines of Credit", "label": "Payments Of Interest, Lines of Credit", "terseLabel": "Interest payment" } } }, "localname": "PaymentsOfInterestLinesOfCredit", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "mygn_PerformanceObligationEstimatedTransactionPriceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Obligation Estimated Transaction Price", "label": "Performance Obligation Estimated Transaction Price [Member]", "terseLabel": "Performance obligation estimate" } } }, "localname": "PerformanceObligationEstimatedTransactionPriceMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "mygn_PharmaceuticalAndClinicalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical and clinical services.", "label": "Pharmaceutical And Clinical Services [Member]", "terseLabel": "Pharmaceutical and clinical services" } } }, "localname": "PharmaceuticalAndClinicalServicesMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "mygn_PurchasedLicensesAndTechnologiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchased licenses and technologies.", "label": "Purchased Licenses And Technologies [Member]", "terseLabel": "Purchased licenses and technologies" } } }, "localname": "PurchasedLicensesAndTechnologiesMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "mygn_ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary", "label": "Reclassification From Accumulated Other Comprehensive Loss, Deconsolidation Of Subsidiary", "terseLabel": "Reclassification out of accumulated other comprehensive loss upon the deconsolidation of a subsidiary" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveLossDeconsolidationOfSubsidiary", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "mygn_RecoupmentsPayableAndReserveCurrent": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Recoupments Payable And Reserve, Current", "label": "Recoupments Payable And Reserve, Current", "terseLabel": "Recoupments payable and reserves" } } }, "localname": "RecoupmentsPayableAndReserveCurrent", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "mygn_ScheduleOfIntangibleAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Intangible Assets [Table]", "label": "Schedule Of Intangible Assets [Table]", "terseLabel": "Schedule Of Intangible Assets [Table]" } } }, "localname": "ScheduleOfIntangibleAssetsTable", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans", "label": "Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans", "terseLabel": "Common stock issued upon exercise of options, vesting of restricted stock units and purchases under employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" ], "xbrltype": "sharesItemType" }, "mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan", "label": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member]", "terseLabel": "2017 Plan" } } }, "localname": "TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember", "nsuri": "http://www.myriad.com/20210630", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r194", "r296", "r301", "r509" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r317", "r320", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r506", "r510" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r317", "r320", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r506", "r510" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r194", "r296", "r301", "r509" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r190", "r296", "r299", "r457", "r505", "r507" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r190", "r296", "r299", "r457", "r505", "r507" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r307", "r317", "r320", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r506", "r510" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r307", "r317", "r320", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r506", "r510" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r191", "r192", "r296", "r300", "r508", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r191", "r192", "r296", "r300", "r508", "r535", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "U.S. [Member]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r267", "r318", "r445" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r196", "r442" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r20", "r38", "r197", "r198" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Trade accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails", "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r26", "r27", "r58" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Accrued royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r50", "r251" ], "calculation": { "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r41", "r74", "r75", "r76", "r491", "r515", "r516" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r76", "r77", "r126", "r127", "r128", "r399", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r39" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r126", "r127", "r128", "r351", "r352", "r353" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r321", "r323", "r356", "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based payment expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r159", "r177", "r178", "r179", "r180", "r182" ], "lang": { "en-us": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r323", "r347", "r355" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r114", "r234", "r241" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsAmortizationonIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive options and RSUs excluded from EPS computation" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityPotentiallyDilutiveCommonSharesExcludedfromEPSComputationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r122", "r172", "r179", "r186", "r218", "r393", "r401", "r424", "r463", "r488" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r23", "r25", "r70", "r122", "r218", "r393", "r401", "r424" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r407" ], "calculation": { "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Financial assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r10", "r12", "r15", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 1.0, "parentTag": "mygn_DisposalGroupIncludingDiscontinuedOperationAssetsNetOfLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Assets held for sale", "totalLabel": "Total assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r204" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Available-for-sale, Gross unrealized holding gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r205" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "terseLabel": "Available-for-sale, Gross unrealized holding losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r202", "r220" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Available-for-sale, Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "Available-for-sale:" } } }, "localname": "AvailableForSaleSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "auth_ref": [ "r210" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 4.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "Available-for-sale, Due after five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "auth_ref": [ "r206", "r210", "r484" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 4.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "terseLabel": "Available-for-sale, Due after five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "auth_ref": [ "r209" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 3.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Available-for-sale, Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "auth_ref": [ "r206", "r209", "r483" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "terseLabel": "Available-for-sale, Due after one year through five years" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Fair Value, Rolling Maturity [Abstract]", "terseLabel": "Estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]", "terseLabel": "Amortized cost" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "auth_ref": [ "r208" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 2.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Available-for-sale, Due within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "auth_ref": [ "r206", "r208", "r482" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "terseLabel": "Available-for-sale, Due within one year" } } }, "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r200", "r203", "r220", "r469" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Available-for-sale, Estimated fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r325", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]", "terseLabel": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]", "terseLabel": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r325", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails", "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r113", "r387" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in the fair value of contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r385", "r386" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Short-term contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r385", "r386" ], "calculation": { "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CaliforniaFranchiseTaxBoardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of California.", "label": "California Franchise Tax Board [Member]", "terseLabel": "California" } } }, "localname": "CaliforniaFranchiseTaxBoardMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedContractCostGross": { "auth_ref": [ "r226" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Gross", "terseLabel": "Capitalized costs incurred to obtain or fulfill contract" } } }, "localname": "CapitalizedContractCostGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r18", "r47", "r116" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents, Amortized cost" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash and cash equivalents:" } } }, "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash and cash equivalents, Estimated fair value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r109", "r116", "r118" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of the period", "periodStartLabel": "Cash and cash equivalents at beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r109", "r425" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsMember": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents [Member]", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Operating Activities, Lessee [Abstract]", "terseLabel": "Establishment of operating lease right-of-use assets and lease liabilities" } } }, "localname": "CashFlowOperatingActivitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]", "terseLabel": "Cash" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r134", "r150" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]", "terseLabel": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r134", "r150" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]", "terseLabel": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]", "terseLabel": "Reconciliation of Deferred Revenue" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r64", "r266", "r470", "r496" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r262", "r263", "r265", "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares available for issuance under the Plan" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r126", "r127" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Common stock issued at end of period", "periodStartLabel": "Beginning common stock issued", "terseLabel": "Common stock issued (shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails", "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r37", "r274" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common stock outstanding at end of period", "periodStartLabel": "Beginning common stock outstanding", "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Common stock outstanding (shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails", "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r37" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, 77.7 million and 75.4 million shares outstanding at June\u00a030, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r80", "r82", "r83", "r89", "r475", "r501" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to Myriad Genetics, Inc. stockholders" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r80", "r82", "r88", "r391", "r392", "r405", "r474", "r500" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedLabel": "Comprehensive loss attributable to non-controlling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r80", "r82", "r87", "r390", "r405", "r473", "r499" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r156", "r157", "r194", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r156", "r157", "r194", "r421", "r422", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r156", "r157", "r194", "r421", "r422", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Revenue and Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r156", "r157", "r194", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (percent)" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r154", "r156", "r157", "r158", "r421", "r423" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r156", "r157", "r194", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Reconciliation of Deferred Revenue Balances" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "auth_ref": [ "r285" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.", "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "terseLabel": "Revenue increase (decrease) due to changes in estimated transaction price due to contractual adjustments" } } }, "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r283", "r284", "r297" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "periodEndLabel": "Deferred revenue - ending balance", "periodStartLabel": "Deferred revenue - beginning balance", "terseLabel": "Deferred revenues" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/RevenueReconciliationofDeferredRevenueBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r308", "r315", "r517" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate bonds and notes" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r92", "r457" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r91" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r155", "r194" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the total principal payments made during the annual reporting period.", "label": "Debt Instrument, Annual Principal Payment", "terseLabel": "Scheduled principal payments prior to maturity date" } } }, "localname": "DebtInstrumentAnnualPrincipalPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r32", "r33", "r34", "r464", "r466", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r61", "r411" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r62" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r62", "r124", "r275", "r278", "r279", "r280", "r434", "r435", "r437", "r486" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r434", "r437" ], "calculation": { "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Current", "negatedTerseLabel": "Current portion of long-term debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r434", "r437" ], "calculation": { "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Debt Instrument, Unamortized Discount, Noncurrent", "negatedLabel": "Long-term debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "auth_ref": [ "r212", "r221" ], "lang": { "en-us": { "role": { "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions", "terseLabel": "Debt securities, available-for-sale, in unrealized loss position" } } }, "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_DeconsolidationGainOrLossAmount": { "auth_ref": [ "r400" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.", "label": "Deconsolidation, Gain (Loss), Amount", "negatedTerseLabel": "Gain on deconsolidation of subsidiary" } } }, "localname": "DeconsolidationGainOrLossAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r361", "r362" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Long-term deferred taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r114", "r249" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetDepreciationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r114", "r249" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r296", "r299", "r300", "r301", "r302", "r303", "r304", "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Total Revenue by Product and by U.S versus Rest of World" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r247", "r257" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposed of by sale" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r12", "r246", "r257" ], "lang": { "en-us": { "role": { "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]", "terseLabel": "Held for sale" } } }, "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "auth_ref": [ "r1", "r2", "r10", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Cash consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "auth_ref": [ "r1", "r2", "r10", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "terseLabel": "Goodwill" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "auth_ref": [ "r1", "r2", "r10", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "negatedTerseLabel": "Less: intangible assets held for sale, net", "terseLabel": "Intangibles, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r1", "r2", "r10", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "terseLabel": "Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r1", "r2", "r10", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "auth_ref": [ "r1", "r2", "r10", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "terseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "auth_ref": [ "r114", "r247", "r253" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "terseLabel": "Impairment on write down of assets held for sale", "verboseLabel": "Impairment on asset group held for sale" } } }, "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r16", "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Divestitures" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/Divestitures" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [ "r316", "r319" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarliestTaxYearMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Earliest identified tax year.", "label": "Earliest Tax Year [Member]", "terseLabel": "Earliest tax year" } } }, "localname": "EarliestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r90", "r131", "r132", "r133", "r134", "r135", "r139", "r141", "r143", "r144", "r145", "r148", "r149", "r476", "r502" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "terseLabel": "Weighted average shares outstanding:" } } }, "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r90", "r131", "r132", "r133", "r134", "r135", "r141", "r143", "r144", "r145", "r148", "r149", "r476", "r502" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r425" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of foreign exchange rates on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Approximate tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r58" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-Based Compensation Expense [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period for recognition of stock-based compensation expense (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r348" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r126", "r127", "r128", "r130", "r136", "r138", "r151", "r219", "r274", "r281", "r351", "r352", "r353", "r374", "r375", "r426", "r427", "r428", "r429", "r430", "r431", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r407", "r408", "r409", "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r407", "r408", "r409", "r417", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r407", "r419", "r420" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r408", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r308", "r309", "r314", "r315", "r408", "r447" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r308", "r309", "r314", "r315", "r408", "r448" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r408", "r449" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Reconciliation of change in fair value of contingent consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r412", "r418" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Change in Fair Value of Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "negatedTerseLabel": "Change in fair value recognized in the income statement" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "auth_ref": [ "r414" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)", "negatedTerseLabel": "Translation adjustments recognized in other comprehensive loss" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payment of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r412" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsChangeinFairValueofContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetAssetLiability": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of asset after deduction of liability.", "label": "Fair Value, Net Asset (Liability)", "totalLabel": "Total" } } }, "localname": "FairValueNetAssetLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FederalMinistryOfFinanceGermanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Germany.", "label": "Federal Ministry of Finance, Germany [Member]", "terseLabel": "Germany" } } }, "localname": "FederalMinistryOfFinanceGermanyMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r240" ], "calculation": { "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.", "label": "Finite-lived Intangible Assets Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Recorded Amortization Expense for Intangible Assets" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r235", "r237", "r240", "r243", "r458", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r240", "r459" ], "calculation": { "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount, amortizable" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r235", "r239" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r240", "r458" ], "calculation": { "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net, amortizable" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]", "terseLabel": "Foreign" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r114" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain (Loss) on Disposition of Assets", "negatedTerseLabel": "Gain on sale of assets" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r227", "r228", "r462" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Goodwill and long-lived asset impairment charges" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r230" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Translation adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill held for sale reclassification" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r85", "r172", "r178", "r182", "r185", "r188", "r460", "r471", "r478", "r503" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [ "r316", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails", "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Divestitures [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails", "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r367", "r369", "r371", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r365", "r370", "r372", "r376", "r378", "r380", "r381", "r382" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationYearUnderExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tax year being audited in the income tax examination, in CCYY format.", "label": "Income Tax Examination, Year under Examination", "terseLabel": "Tax year being audited in income tax examination" } } }, "localname": "IncomeTaxExaminationYearUnderExamination", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "gYearListItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r137", "r138", "r170", "r363", "r377", "r379", "r504" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/IncomeTaxesDetails", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r111", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid during the period for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Trade accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Deferred income taxes" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in receivables classified as other.", "label": "Increase (Decrease) in Other Receivables", "negatedLabel": "Other receivables" } } }, "localname": "IncreaseDecreaseInOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Expenses, Other", "negatedTerseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpensesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedLabel": "Prepaid taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Common shares issued and outstanding" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityCommonSharesIssuedandOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r236", "r242" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r242" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Non-amortizable" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r236", "r242" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Intangible Assets, Gross (Excluding Goodwill)", "terseLabel": "Gross Carrying Amount, total" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r233", "r238" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangibles, net", "totalLabel": "Net, total" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r84", "r166", "r433", "r436", "r477" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 }, "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r107", "r110", "r117" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFirmPurchaseCommitmentLoss": { "auth_ref": [ "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss recognized on firm purchase commitment for inventory.", "label": "Inventory, Firm Purchase Commitment, Loss", "terseLabel": "Loss on non-cancelable purchase commitment" } } }, "localname": "InventoryFirmPurchaseCommitmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r19", "r69" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r222" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Inventory Write-down", "terseLabel": "Loss on inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r94", "r165" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r497" ], "calculation": { "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "order": 3.0, "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "Investments and Cash", "terseLabel": "Total, Estimated fair value", "totalLabel": "Total, Estimated fair value" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAndCashAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments and Cash [Abstract]", "terseLabel": "Total:" } } }, "localname": "InvestmentsAndCashAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Schedule of Cash, Cash Equivalents, and Maturities of Debt Securities Classified as Available-For-Sale Securities" } } }, "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r217", "r461", "r485", "r534" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Investment Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LatestTaxYearMember": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Latest identified tax year.", "label": "Latest Tax Year [Member]", "terseLabel": "Latest tax year" } } }, "localname": "LatestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r56", "r122", "r180", "r218", "r394", "r401", "r402", "r424" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r44", "r122", "r218", "r424", "r468", "r494" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r60", "r122", "r218", "r394", "r401", "r402", "r424" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r407" ], "calculation": { "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "negatedTerseLabel": "Financial liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r1", "r2", "r10", "r12", "r15", "r248", "r255" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails": { "order": 2.0, "parentTag": "mygn_DisposalGroupIncludingDiscontinuedOperationAssetsNetOfLiabilities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Liabilities held for sale", "totalLabel": "Total liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresAssetsandLiabilitiesClassifiedasHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum aggregate principal commitment" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Undrawn fee (percent)" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r34", "r269", "r466", "r490" ], "calculation": { "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Debt, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Unclassified [Abstract]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-term Debt, Fair Value", "terseLabel": "Estimated fair value of long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "totalLabel": "Long-term debt, net" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/LongTermDebtScheduleofLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of long-term debt outstanding calculated at point in time.", "label": "Long-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Interest rate (percent)" } } }, "localname": "LongtermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r21", "r57" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable investment securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Long-term marketable investment securities" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Measurement input, expected term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r68", "r122", "r218", "r424", "r467", "r493" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestPeriodIncreaseDecrease": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.", "label": "Noncontrolling Interest, Period Increase (Decrease)", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterestPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Bonds [Member]", "terseLabel": "Municipal bonds" } } }, "localname": "MunicipalBondsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r109" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r109", "r112", "r115" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r15", "r78", "r81", "r86", "r115", "r122", "r129", "r131", "r132", "r133", "r134", "r137", "r138", "r142", "r172", "r178", "r182", "r185", "r188", "r218", "r424", "r472", "r498" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss attributable to Myriad Genetics, Inc. stockholders", "totalLabel": "Net loss attributable to Myriad Genetics, Inc. stockholders", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r78", "r81", "r137", "r138", "r396", "r404" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NewJerseyDivisionOfTaxationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of New Jersey.", "label": "New Jersey Division of Taxation [Member]", "terseLabel": "New Jersey" } } }, "localname": "NewJerseyDivisionOfTaxationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewYorkStateDivisionOfTaxationAndFinanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of the state of New York.", "label": "New York State Division of Taxation and Finance [Member]", "terseLabel": "New York" } } }, "localname": "NewYorkStateDivisionOfTaxationAndFinanceMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "RoW" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r126", "r127", "r128", "r281", "r388" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SegmentandRelatedInformationNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Costs and expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r172", "r178", "r182", "r185", "r188" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Segment operating income (loss)", "totalLabel": "Operating loss", "verboseLabel": "Total operating loss for reportable segments" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r439" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current maturities of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r439" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Noncurrent operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r438" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r114" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r17", "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r26", "r27", "r28", "r58" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r71" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Change in foreign currency translation adjustment, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r79", "r82", "r390", "r391", "r398" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss), net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r72", "r74" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized loss on available-for-sale debt securities, net of tax", "verboseLabel": "Fair value adjustment on marketable investment securities recorded to stockholders' equity" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Abstract]", "terseLabel": "Other Liabilities Disclosure [Abstract]" } } }, "localname": "OtherLiabilitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other liabilities.", "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Long-Term Liabilities" } } }, "localname": "OtherLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/OtherLongTermLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r63" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "terseLabel": "Schedule of Other Long-Term Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/OtherLongTermLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 }, "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "auth_ref": [ "r35", "r465", "r489" ], "calculation": { "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.", "label": "Other Sundry Liabilities, Noncurrent", "terseLabel": "Other" } } }, "localname": "OtherSundryLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/OtherLongTermLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedLabel": "Payment of contingent consideration recognized at acquisition" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r105" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedTerseLabel": "Fees associated with refinancing of revolving credit facility" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r103" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedTerseLabel": "Payment of tax withheld for common stock issued under stock-based compensation plans" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r97", "r100", "r201" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of marketable investment securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r101" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r325", "r349" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized (shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock outstanding (shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r23", "r45", "r46" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r22", "r24", "r224", "r225" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Taxes", "terseLabel": "Prepaid taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries": { "auth_ref": [ "r98" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or the sale of investment in consolidated subsidiaries (generally greater than 50 percent).", "label": "Proceeds from Divestiture of Interest in Consolidated Subsidiaries", "terseLabel": "Proceeds from sale of subsidiary" } } }, "localname": "ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIncomeTaxRefunds": { "auth_ref": [ "r112", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.", "label": "Proceeds from Income Tax Refunds", "terseLabel": "Cash received for income tax receivables" } } }, "localname": "ProceedsFromIncomeTaxRefunds", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r102", "r350" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from common stock issued under stock-based compensation plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from maturities and sales of marketable investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "auth_ref": [ "r99" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Proceeds from Sale of Productive Assets", "terseLabel": "Proceeds from sale of assets" } } }, "localname": "ProceedsFromSaleOfProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.myriad.com/role/DivestituresNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r15", "r78", "r81", "r108", "r122", "r129", "r137", "r138", "r172", "r178", "r182", "r185", "r188", "r218", "r390", "r395", "r397", "r404", "r405", "r424", "r478" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/SegmentandRelatedInformationTotalOperatingLossforReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r50", "r252" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r259", "r536", "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r49", "r250" ], "calculation": { "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r30", "r31", "r252", "r495" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant, and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r30", "r252" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r30", "r250" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RecordedUnconditionalPurchaseObligation": { "auth_ref": [ "r264" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the recorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).", "label": "Recorded Unconditional Purchase Obligation", "terseLabel": "Purchase commitment" } } }, "localname": "RecordedUnconditionalPurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r104", "r125" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayment of revolving credit facility", "terseLabel": "Principal repayment" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r359", "r548" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails", "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r40", "r281", "r354", "r492", "r514", "r516" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r126", "r127", "r128", "r130", "r136", "r138", "r219", "r351", "r352", "r353", "r374", "r375", "r511", "r513" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r163", "r164", "r177", "r183", "r184", "r190", "r191", "r194", "r295", "r296", "r457" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Total revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/RevenueTotalRevenuebyProductandbyUSversusRestofWorldDetails", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r156", "r194" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r298", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r292" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails", "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r440", "r441" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r146" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Dilutive Common Shares" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r207", "r211", "r213", "r214", "r215", "r216", "r480", "r481" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/MarketableInvestmentSecuritiesCashCashEquivalentsandMaturitiesofDebtSecuritiesClassifiedasAvailableForSaleSecuritiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of Supplemental Cash Flow Information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in common stock outstanding.", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "terseLabel": "Summary of Common Shares Issued and Outstanding" } } }, "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r62", "r124", "r275", "r278", "r279", "r280", "r434", "r435", "r437", "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Long-Term Debt" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r4", "r5", "r6", "r7", "r8", "r9", "r11", "r13", "r14", "r15", "r257", "r258" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Classified as Held For Sale" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/DivestituresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r323", "r346", "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r323", "r346", "r355" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r235", "r239" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Amortizable Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r242", "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Non-amortizable Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r50", "r252" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PropertyPlantandEquipmentNetBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r172", "r175", "r181", "r231" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r172", "r175", "r181", "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment Revenue and Operating Income (Loss)" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SegmentandRelatedInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r325", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails", "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "verboseLabel": "Schedule of Restricted Stock Unit Activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r330", "r342", "r344" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "verboseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r65", "r120", "r152", "r153", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r279", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r159", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r188", "r194", "r505" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r159", "r161", "r162", "r172", "r176", "r182", "r186", "r187", "r188", "r189", "r190", "r193", "r194", "r195" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment and Related Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SegmentandRelatedInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general, and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general, and administrative expense" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r113" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Service period for award vesting (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "RSUs canceled (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r341" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs canceled (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "RSUs granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs granted (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "RSUs outstanding, ending (shares)", "periodStartLabel": "RSUs outstanding, beginning (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "RSUs, Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r338" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "RSUs outstanding, ending (dollars per share)", "periodStartLabel": "RSUs outstanding, beginning (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "RSUs, Weighted average grant date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "RSUs vested (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "RSUs vested (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-Based Compensation [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails", "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable at end of period (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable at end of period (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options canceled or expired (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r337" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options canceled or expired (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r332", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options outstanding, ending (shares)", "periodStartLabel": "Options outstanding, beginning (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options, Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Options outstanding, beginning (dollars per share)", "periodStartLabel": "Options outstanding, ending (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Options, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r322", "r329" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails", "http://www.myriad.com/role/StockBasedCompensationRSUActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Award expiration period (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r3", "r159", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r177", "r178", "r179", "r180", "r182", "r183", "r184", "r185", "r186", "r188", "r194", "r231", "r256", "r260", "r261", "r505" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsCarryingAmountofGoodwillDetails", "http://www.myriad.com/role/SegmentandRelatedInformationSegmentRevenueandOperatingIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r67", "r126", "r127", "r128", "r130", "r136", "r138", "r151", "r219", "r274", "r281", "r351", "r352", "r353", "r374", "r375", "r426", "r427", "r428", "r429", "r430", "r431", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r126", "r127", "r128", "r151", "r457" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r36", "r37", "r274", "r281", "r335" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/StockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r36", "r37", "r281", "r324", "r343" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stock repurchase plan authorized.", "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Share repurchase program, authorized amount" } } }, "localname": "StockRepurchaseProgramAuthorizedAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Share repurchase program, remaining repurchase authorization" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "auth_ref": [ "r36", "r37", "r274", "r281" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased and retired during the period.", "label": "Stock Repurchased and Retired During Period, Shares", "terseLabel": "Shares repurchased" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r37", "r42", "r43", "r122", "r199", "r218", "r424" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Myriad Genetics, Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r122", "r126", "r127", "r128", "r130", "r136", "r218", "r219", "r281", "r351", "r352", "r353", "r374", "r375", "r388", "r389", "r403", "r424", "r426", "r427", "r431", "r512", "r513" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets", "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r121", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Preferred and Common Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r432", "r444" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r432", "r444" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r432", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r432", "r444" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r443", "r446" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SwissFederalTaxAdministrationFTAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Switzerland.", "label": "Swiss Federal Tax Administration (FTA) [Member]", "terseLabel": "Switzerland" } } }, "localname": "SwissFederalTaxAdministrationFTAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]", "terseLabel": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]", "terseLabel": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.myriad.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Accrued taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TrademarksMember": { "auth_ref": [ "r383" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.", "label": "Trademarks [Member]", "terseLabel": "Trademarks" } } }, "localname": "TrademarksMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/GoodwillandIntangibleAssetsIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r308", "r479" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "US government securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r308", "r479", "r517" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "Federal agency issues" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/FairValueMeasurementsFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MarketableInvestmentSecuritiesFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r360", "r368" ], "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r145" ], "calculation": { "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Effect of dilutive shares" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r140", "r145" ], "calculation": { "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (shares)", "totalLabel": "Weighted-average shares outstanding and dilutive securities used to compute diluted EPS" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r139", "r145" ], "calculation": { "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (shares)", "verboseLabel": "Weighted-average shares outstanding used to compute basic EPS" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperations", "http://www.myriad.com/role/PreferredandCommonStockholdersEquityReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r119": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r195": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4578-108314" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r259": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25383-109308" }, "r265": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r270": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r358": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r446": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r461": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803" }, "r485": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r534": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r549": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r551": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r552": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r553": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r554": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" } }, "version": "2.1" } ZIP 89 0000899923-21-000063-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899923-21-000063-xbrl.zip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િ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end